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Abstract
In the United States one person a second suffers a stroke. In England more than 110,000
will suffer a stroke each year and approximately one third of those will die within a year.
This costs the NHS over £2.8 billion. With an ageing population in the UK stroke will
be a major cause of death and disability for years to come. It is vital that stroke services
are improved to try and improve patient care and reduce the burden on an over stretched
NHS. Rapid access to brain imaging and expert stroke care in the acute stage is an
important part of that process.
Over the last ten years the availability of, and access to, CT imaging in particular, has
improved. The Royal College of Physicians now recommend that all stroke patients
should be imaged within 24 hours of symptom onset and early access to CT has been
shown to be cost effective. However, CT is not the only imaging modality available to
acute stroke patients. Advanced scanning with magnetic resonance imaging looks a
promising alternative to CT, particularly when selecting patients for thrombolysis, the
only currently available acute stroke treatment which has been shown to benefit patients.
The general aim ofmy period of research was to work on streamlining and improving a
few key areas in the care for patients with stroke, particularly those likely to be
candidates for thrombolysis. I focussed on: optimising the imaging method for patient
selection; assessing the availability of different imaging methods; and evaluating a range
of options for obtaining consent for treatment or research in this setting.
In the imaging work of this thesis I discuss some aspects of the two major imaging
modalities available to stroke patients - computerised tomography (CT) and magnetic
resonance imaging (MRI) and the evidence available for the treatment of acute stroke
with thrombolysis (Chapter 1). I then explore the evidence lying behind the use of some
of the advanced MR imaging modalities and how they may assist in the selection of
patients for thrombolysis. Using a systematic review, I pay particular attention to the
evidence behind the MR perfusion diffusion mismatch theory and the interaction with
thrombolysis (Chapter 2). Having analysed the evidence available on 'mismatch' and
thrombolysis I go on to compare the many techniques available for measuring the
perfusion lesion and the problems that arise as a result of this in Chapter 3. In Chapter 4
I move from the more complex details of specific MR techniques to the practicalities of
imaging acute stroke patients with MR, dealing with a UK survey on the actual
availability ofMR scanners. Finally, in Chapter 5,1 deal with patients who meet clinical
and imaging criteria for thrombolysis who require consent. This is an important part of
the process that each patient must undergo prior to treatment. This is a stage in the
pathway to treatment that can cause huge delays, particularly with an acutely ill patient.
The process of consent needs to begin before imaging. It is a vital first step in
thrombolysis because, without it, patients can not undergo the complex MR imaging
techniques that are discussed in earlier chapters of the thesis.
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In the United States one person suffers a stroke every second. In England more than
110,000 will suffer a stroke each year1 and approximately one third of those will die
within a year.2 This costs the National Health Service (NHS) over £2.8 billion per year.1
With an ageing population in the UK, stroke will be a major cause of death and
disability for years to come. It is vital that stroke services are improved to try and
improve patient care and reduce the burden on an over stretched NHS. Rapid access to
expert stroke care and brain imaging in the acute stage is an important part of
streamlining that process.
Over the last ten years the availability of, and access to, computerised tomography (CT)
imaging in particular, has improved. The Royal College of Physicians now recommend
that all stroke patients should be imaged within 24 hours of symptom onset and early
access to CT has been shown to be cost effective.4 However, CT is not the only imaging
modality available to acute stroke patients. Advanced scanning with magnetic
resonance imaging is suggested as a promising alternative to CT by some stroke experts,
particularly when selecting patients for thrombolysis, the only currently available acute
stroke treatment which has been shown to benefit patients.5
Much of the financial burden of stroke lies in providing care for those unfortunate
patients left with a major disability following their stroke. Acute treatments, such as
thrombolysis, decrease the number of patients dead and dependent as a result of their
stroke.5 It is therefore important that further studies are carried out into such treatments
(e.g. the Third International Stroke Trial, IST-36) to widen the number of people
potentially eligible to treatment and hopefully reduce the burden of stroke in the future.
The general aim ofmy period of research was to work on streamlining and improving a
few key areas in the care for patients with stroke, particularly those likely to be
candidates for thrombolysis. I focussed on: optimising the imaging method for patient
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selection; assessing the availability of different imaging methods; and evaluating a range
of options for obtaining consent for treatment or research in this setting.
Brain imaging forms a vital part of the assessment and management of patients with
acute stroke, but the choice of which of several brain imaging techniques requires
clarification. In ischaemic stroke it is well recognised that early imaging (to exclude
haemorrhage) and treatment with aspirin are beneficial. Over the last ten years or so
access to CT has improved dramatically and this is reflected in the Royal College of
Physicians guidelines which recommend a CT within 24 hours of stroke onset. My
survey of imaging facilities in the UK certainly suggests that the majority of acute
hospitals (97%) have on site CT. However, with acute treatments such as thrombolysis,
the key to success is to select those patients who will benefit most from thrombolysis
and avoid treating those in which it will cause harm. One of the ways to do this is to
look at imaging features, hence the interest in advanced imaging techniques such as
magnetic resonance imaging (MRI).
In the imaging work of this thesis I discuss some aspects of the two major imaging
modalities available to stroke patients - computerised tomography (CT) and magnetic
resonance imaging (MRI) and the evidence available for the treatment of acute stroke
with thrombolysis (Chapter 1). I then explore the evidence lying behind the use of some
of the advanced MR imaging modalities and how they may assist in the selection of
patients for thrombolysis. Using a systematic review, I pay particular attention to the
evidence behind the MR perfusion diffusion mismatch theory and the interaction with
thrombolysis (Chapter 2). Having analysed the evidence available on 'mismatch' and
thrombolysis I go on to compare the many techniques available for measuring the
perfusion lesion and the problems that arise as a result of this in Chapter 3. In Chapter 4
I move from the more complex details of specific MR techniques to the practicalities of
imaging acute stroke patients with MR, dealing with a UK survey on the actual
availability ofMR scanners. Finally, in Chapter 5,1 deal with patients who meet clinical
and imaging criteria for thrombolysis who require consent. This is an important part of
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the process that each patient must undergo prior to treatment. This is a stage in the
pathway to treatment that can cause huge delays, particularly with an acutely ill patient.
The process of consent needs to begin before imaging. It is a vital first step in
thrombolysis because, without it, patients can not undergo the complex MR imaging
techniques that are discussed in earlier chapters of the thesis.
As I demonstrate in this thesis there has been a great deal of interest in the MR perfusion
diffusion mismatch theory in acute stroke, but most of the studies are woefully small,
retrospective and do not provide enough evidence on which to base treatment decisions.
Perfusion imaging, if it is to be used requires clarification in larger studies to define
which post processing method and perfusion lesion should be used for treatment
decisions. In addition the substantial barriers to practical routine use of MR imaging in
acute stroke need to be addressed before it is advocated by experts more widely. It
simply creates false expectations and creates greater confusion when a clear message of
'1st line CT unless a very good reason' might help remove one barrier, some of the time
delay, to thrombolysis.
The broad aim of this thesis is expressed in the title. The answers to the question,
arising from the work in this thesis are summarised below under implications for clinical
practice and implications for research.
Implications of this thesis for clinical practice
1. CT is widely and rapidly available in the UK for patients with acute stroke, and
should therefore remain the 'work horse' imaging modality for these patients.
2. Advanced imaging with MR may provide us with more information on which
patients are likely to benefit from, and which are likely to be harmed by
thrombolysis. Since the current evidence base on MR is lacking, no clear
recommendations on the best approach is possible.
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3. There are many different MR methods to assess cerebral perfusion and perfusion
diffusion mismatch, and there is no consensus on which is best.
4. The perfusion measures which correlate best with baseline stroke severity are arterial
input function (ATF), peak time fitted (PTF), time to peak (TTP), full width half
maximum (FWHM) and first moment (rMTT); with clinical outcome, ATF and with
radiological outcome ATF, PTF, TTP, rMTT, FWHM, relative cerebral blood flow
(rCBF), quantitative cerebral blood flow (qCBF) and cerebral blood volume (CBV).
5. Simple techniques may be more practicable for use in routine clinical practice (i.e.
relative measures of MTT) and more complex and time consuming ones will have
greater application in research studies.
6. A feasibility study ofMR in acute stroke at WGH demonstrated that - despite access
to a research-dedicated MR scanner, with the resources available at the time - MR
was not a practicable tool for pre thrombolysis. Better and more rapidly responsive
clinical systems of care for patients with suspected acute stroke would be needed for
optimal use ofMR technology.
7. Although MR is more readily available than it used to be five years ago, rapid access
for stroke patients is still poor in the UK. Combined with the MR availability survey
data, this suggests MR will have very limited applicability in the UK NHS routine
acute stroke care for the next few years.
8. Flexible consent procedures are important so that a wide variety of patients have
access to trial treatments.
9. When considering the development of alternative forms of consent it is important to
include the public in discussions and to incorporate their views wherever possible.
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Implications of this thesis for research
1. There is an urgent need to standardise definitions of techniques used in advanced
MRI research in stroke, in particular the term 'mismatch' and the use of perfusion
imaging. If terms are standardised then different research groups can at least
combine results and analyse the data in meta analyses. The time has not yet arrived
for CT to be superseded and it should remain the 'work horse' for imaging patients
with acute stroke.
2. Although MR techniques are exciting and may offer a greater insight into the
pathophysiology of acute stroke, they are not ready to take over from CT yet. In
fact, in the UK, access to MR is so poor that we should be concentrating on research
studies involving more advanced CT methods in helping us to select patients for
thrombolysis.
3. Further research on MR is needed to determine if it is useful in assisting in the
selection of certain groups of patients with acute stroke, such as patients who present
later i.e. extending the time window for thrombolysis to be given.
4. Currently in the UK CT is the most accessible imaging technique for stroke
physicians. Therefore more work needs to be done on advanced CT techniques, such
as CT perfusion to see if this helps improve the selection of patients for
thrombolysis. However, CT perfusion techniques must also be standardised so that
similar problems that have affected some of the advanced MR techniques are not
repeated.
5. If advanced MR or CT perfusion techniques are to be useful, a large study of patients
with and without mismatch randomised to thrombolysis or control needs to be
undertaken.
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6. A study examining correlations between acute MR changes and corresponding
changes on CT may mean that early CT changes in stroke become more useful when
making treatment decisions.
7. The issue of consent is very important to consider in trials of acute medicine,
especially where there is little time available for people to consider treatment
options.
8. Restrictive consent procedures are a major obstacle to evaluating interventions that
could have substantial impact on mortality and disability. This must be remembered
and flexible consent procedures considered and incorporated into new trials where at
all possible.
Note: All identifiers have been removed from any images used in this thesis. The images are printed in
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The first possible reports of stroke were recorded in ancient Egypt on the Edwin Smith
Papyrus. This is a copy of an ancient manuscript which was thought to have been
written between 3000 and 2500 BC. It contains the first accounts of brain injuries,
which were noted to be associated with changes in the function of other parts of the
body and, in one case, hemiplegic contractures.1
Hippocrates (460-370 BC) described stroke as the sudden onset of paralysis with the
term 'apoplexy'. At that time apoplexy referred to anyone suddenly struck down with
paralysis and referred to a general disorder of the brain, rather than the focal pathology
which underlies the modem definition of stroke. Little was known about the complex
anatomy of the cerebral circulation and stroke was thought to be due to an imbalance in
the four humours: blood, phlegm, black bile and yellow bile.
The Swiss physician, Johann Jacob Wepfer (1620-95), identified signs of bleeding in the
brain at postmortem in patients who had died of apoplexy. He was also the first to
suggest that apoplexy could not only be caused by bleeding into the brain, but also by
blockage of an artery supplying the brain. Around the same time Thomas Willis (1641-
75) described the vascular connections at the base of the brain - now known as the
'Circle of Willis' (Figure 1) - a key advance in the understanding of the cerebral
circulation.
Leon Rostan (1790-1866), recognised that that lesions occurring in the brain were more
often due to softening of the cerebral tissue rather than haemorrhage, although there was
still no clear understanding of the causative lesion. It was not until Virchow (1821-
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Figure 1: The Circle ofWillis
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1902) that there was a general understanding that vascular disease was usually due to
atherosclerotic and not inflammatory disease of blood vessels.3
Since then our knowledge of the pathophysiology of stroke has increased further, aided
by new imaging techniques to investigate the pathological state of the blood vessels in
the brain, and the dynamics of the pathophysiology in the acute and recovery phase. X
rays were discovered in 1896, and although intracranial angiography was introduced in
the 1920's, it was really the advent of CT and then MR in the mid 1970's and 1980's
respectively that has made major recent progress possible. There are two main types of
stroke - infarct and haemorrhage - with ischaemic stroke being the main focus of this
thesis.
In an ischaemic stroke the blocked blood vessel causes a reduction in blood flow to the
area of brain it supplies. The extent of the reduction in flow is important since different
rates of flow equate to different degrees of tissue damage as demonstrated in Figure 2.
In normal conditions the cerebral blood flow is determined by the cerebral perfusion
pressure and the cerebrovascular resistance. In practical terms the measurement of
cerebral blood flow (CBF) provides a challenge. One way of ascertaining CBF is to
follow the concentration of an intravascular contrast agent within a given volume of
interest over time. Flowever, this is by no means straightforward. As contrast passes
through a region of interest a concentration time curve of contrast agent within the tissue
can be produced, C(t). Then, using principles of indicator dilution theory, C(t) within a
region of interest (ROI) can be expressed as a convolution:
C(t) = p/KH (CBF). (Ca(t) x R(t))
where Ca(t) is the arterial input function (AIF) i.e. the concentration of the tracer
entering the ROI, and R(t) is the residue function, which describes the fraction of
contrast agent remaining in the ROI at time t, following the injection of an ideal bolus at
t = 0. Cerebral blood flow is CBF, p is the density of brain tissue and kh accounts for
the difference in the haematocrit between capillaries and large vessels.4 There are
essentially two groups of methods to solve the above equation. One is by measurement
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Figure 2: Cerebral blood flow thresholds
CBF thresholds for preservation of function and structure
time
Diagram ofCBF thresholds requiredfor the preservation offunction and morphology of
brain tissue. The development ofsingle cell necrosis and infarction is dependent on the
duration of time for which CBF is impaired below a certain level. The solid line
separates structurally damaged from functionally impaired but morphologically intact
tissue (the 'penumbra'), and the dashed line distinguishes viable from functionally
impaired tissue.5
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of the AIF in order to perform the deconvolution of C(t), producing direct information
about CBF, cerebral blood volume (CBV) and mean transit time (MTT), but this
requires time consuming post processing of imaging data. The other group of methods
use summary parameters calculated directly from the concentration time curve e.g. time
to peak and full width half maximum (see Figure 2, Chapter 3, p.92 for more details).
However these parameters only provide indirect measures of perfusion, taking no
account of the variation in AIF and residue function (R(t) between individuals and
different areas of the brain. To date a number of summary parameters have been
calculated directly from the concentration time curve by various research groups and
include:
• Arrival time fitted (ATF) - estimated delay of contrast in a voxel obtained from
the curve fitting procedure
• Peak time fitted (PTF) - estimate of the time ofmaximum contrast concentration
obtained from the fitted parameters
• Time to peak (TTP) - peak time fitted minus arrival time fitted
• Full width half maximum (FWHM) - width of the concentration/time curve at
the point halfway to the peak concentration
• First moment (rMTT) - first moment of the concentration time curve
• Peak concentration (Cmax) - maximum value of the fitted concentration/time
curve
• Relative cerebral blood flow (rCBF) - rCBV/rMTT
The various perfusion parameters above will be discussed in more detail through the
thesis, with further explanation as to how the parameters are calculated. The details
above are simply an introduction to the concept. Using the central volume theorem
MTT = CBV/CBF. This is an important concept which will be picked up and expanded
on later in the thesis.
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As introduced above, as imaging techniques have developed it is possible to image, not
only the different pathological types of stroke, but also the stages of disease e.g. looking
at flow rates and perfusion in areas of ischaemic stroke.
1.2 Why is imaging so important in stroke medicine?
1.2.1 The burden ofdisease and the lack ofeffective treatments
Stroke is a major cause of death and morbidity throughout the world. Currently it is the
third most common cause of death. By 2020 it is estimated that stroke will not only
account for 6.2% of the total burden of illness in the developed world6 but will also be a
significant problem in the developing world. The tme global incidence of stroke is
difficult to establish due to lack of data from the developing world. As incidence rises
steeply with age, and as the number of people surviving in to old age increases, stroke
will remain a major health problem for the foreseeable future.
Though knowledge of the cerebral circulation and the physiology of the brain has
expanded enormously, it was only in 1997 that an effective treatment for acute stroke
was found (aspirin); though its benefits were modest, the treatment could at least be used
very widely.7 Admission to hospital and care within a stroke unit that offers
comprehensive care and multidisciplinary rehabilitation has more substantial benefits
O Q
(and benefits all stroke types). ' Thrombolytic therapy was first evaluated in stroke in
the late 1950's.10'11 However, since stroke was diagnosed clinically at that time, it was
not possible to reliably exclude haemorrhage as the cause of the stroke, and so many
patients with primary intracerebral haemorrhage died as a result of inappropriate
treatment with thrombolysis, and the treatment was abandoned as too risky.
Introduction of thrombolysis into acute stroke care had to await the development of CT
scanning. Even then, a thrombolytic agent was not licensed for use until 1996 in the
USA and in 2003 in Europe.
22
1.2.2 Different cerebralpathologies require different treatments
'Stroke' or 'non-stroke' pathologies
Imaging of the brain can determine both the pathological type of stroke and the territory
of brain affected, but can also reveal non-stroke lesions which can present in a stroke-
12like fashion (Figure 3). It is important to identify focal areas due to venous infarction
and other stroke mimics such as primary brain tumours and cerebral abscesses so that
appropriate treatment can be given as soon as possible.
Infarction or haemorrhage?
Over four fifths of strokes are ischaemic and are due to the blockage of extra- or
intracranial arteries by thrombus or embolic material. The remainder is caused by
haemorrhage, either primary intracerebral (around 10%) or subarachnoid (approximately
5%). Brain imaging with CT or MR is therefore essential to distinguish between the
main pathological causes of stroke, particularly when considering investigations and
treatments that may affect the different pathological types of stroke in different ways
(Table 1).
If stroke, brain scanning can determine the arterial territory
Location of arterial territory is important for a number of reasons. Knowledge of the
likely location of the cerebral lesion (and its arterial territory) enables the clinician to
assess the scan more critically to look for appropriate changes. If the clinical features do
not match the scan appearances, the diagnosis may need to be reviewed. Secondly, brain
imaging with CT or MR can help confirm the differentiation between carotid and
vertebrobasilar circulation ischaemic events. It is known that carotid endarterectomy is
beneficial for recently symptomatic severe carotid stenosis.13'14 However, in
asymptomatic patients up to 75 years of age, there is no net benefit of treating even a
severe carotid stenosis of greater than 70% with carotid endarterectomy.15 Follow up in
the Asymptomatic Carotid Surgery Trial (ACST) is ongoing and will be necessary to
establish whether the longer term benefits of treating asymptomatic patients are offset by
23
Figure 3: A stroke mimic
CTofa patient who presented with a history consistent with stroke. The image on the
left is the nnenhanced scan showing left temporal lobe hypoattenuation and sulcal
effacemet. The image on the right, with contrast, revealed a ring enhancing lesion
(arrow) consistent with an abscess.
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the immediate surgical risk. Hence if a patient is found to have a severe right carotid
stenosis, but the symptoms and brain imaging all point to an ischaemic event in the left
cerebral hemisphere, or either side of the brainstem, or cerebellum, surgery on the
asymptomatic right carotid is not needed. The third factor is that if the brain scan
reveals that multiple arterial territories are affected, as opposed to a single territory, it
may help reveal the cause of the stroke e.g. a cardio embolic source.
It is often possible to determine what arterial territory has been affected by the stroke
from the symptoms described by the patient and the physical signs elicited by the
clinician. Imaging can help confirm which territory of the brain is affected. Although
clinical classifications, such as that derived by Bamford,16 often correctly predict the
arterial territory affected, they are by no means perfect. When the Oxford Community
Stroke Project (OCSP) classification was first derived it was based on the clinical
examination of patients at a mean of four days post stroke.14 There are therefore
questions as to whether it is suitable for use in the assessment of patients in the
hyperacute stages of stroke. Several studies have shown that a patient's neurological
deficit in the hyperacute stages of stroke may well change over the next few hours to
days, suggesting that neurological deficit may not be fixed at the time of hypercute
assessment.17'18 However the OCSP is quick and simple to do and the combination of
clinical assessment and simple structural CT imaging of the brain often allows a rapid
and reasonably accurate localization of the arterial territory. The OCSP correlated well
with CT findings in patients recruited and scanned within 48 hours of onset into IST-119
and among patients recruited and scanned under 6 hours in IST-320. This is usually what
is required when considering further investigations or treatment in the acute stages of
stroke.
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1.3 Methods of imaging acute stroke patents
1.3.1 Computerised Tomography (CT)
CT is the most commonly used technique to scan acute stroke patients and is currently
the imaging method of choice recommended by the Royal College of Physicians.21 It
was developed by Godfrey Hounsfleld in 1972,22 and the first head CT scanners were
installed for clinical use in 1975. It is based on a narrow beam of x-rays being passed
through the area of interest from different angles around the circumference of an object.
It soon became apparent that this technique was useful in the diagnosis of stroke23 and
Hounsfield shared the Nobel Prize for medicine with Allan Cormack in 1979 in
recognition of this achievement and for such a step forward in medicine.
The single slice CT scanners, mostly operating in a slice by slice axial scanning mode,
have largely been replaced by multislice CT. This technique utilises multidetector rows
to allow fast helical scanning and rapid imaging of large volumes of the patient. The
data obtained from each set of exposures are reconstructed into an image by computer
manipulation.24,25 Contrast can also be injected to highlight certain lesions. With this
modern technology a standard head CT scan can be done rapidly, with image acquisition
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taking less than 2 minutes to perform."
A major disadvantage of CT is the dose of radiation that the patient receives. The dose
naturally depends on the inherent differences in CT equipment and variations in
scanning protocols.27 The mean radiation dose for an adult CT head is 1.5 millisieverts
(mSv),28 which is far smaller than for a CT of the abdomen. Therefore, the average CT




One of the most useful aspects of CT scanning is that, if it is done early on in the
presentation of acute stroke, then it is possible to distinguish haemorrhage immediately -
a tool that makes CT very useful in the selection of patients for thrombolysis. An acute
intracerebral haemorrhage shows up distinctly as an area of higher density than normal
brain tissue and looks 'whiter' on CT30 (Figure 4). As the parenchymal haematoma is
broken down over the days after the stroke, its CT attenuation (density) declines to a
level similar to the surrounding brain. Thus, for many small intracerebral haemorrhages,
after 7 to 10 days CT can no longer reliably differentiate haemorrhage from infarction.
Small haemorrhages become isodense with brain faster than large haemorrhages.
Eventually the haematoma site becomes hypodense and may be indistinguishable from
the cerebromalacia that follows cerebral infarction. Therefore stroke patients should be
scanned as soon as possible, and no more than seven days after stroke onset if using CT,
to differentiate infarct from haemorrhage reliably.31
'Early infarct' changes
32In the early stages of an acute ischaemic stroke, the CT scan may well be 'negative'.
Hence if a patient presents with stroke-like symptoms, and the CT is normal, the
question arises "are the symptoms described by the patient due to a stroke?" This is not
such a problem if the patient is to be given aspirin, but many physicians believe that
positive evidence of an infarct would make it easier to justify the risks of thrombolysis.
As technology has advanced, the diagnostic capabilities of CT images have improved,
enabling the detection of early ischaemic changes consistent with acute stroke within
just a few hours of onset in many patients with moderate to severe neurological deficits.
The 'early ischaemic signs' that have been reported include loss of the insular ribbon,
loss of grey-white matter differentiation (Figure 5) and the hyperattenuated artery sign
(Figure 6).30 However, small ischaemic lesions, such as might occur in patients with
mild stroke, may never become visible on CT.
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Figure 4a: Primary intracerebral haemorrhage on CT
Left parietal hyperattenuation extending to the cortex, consistent with a primary
intracranial haemorrhage due to amyloid angiopathy
Figure 4b: Subarachnoid haemorrhage
Subarachnoid haemorrhage showing blood in the anterior hemispheric fissure (a) and
left sylvian fissure (b)
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Figure 5: Early ischaemic change
Loss of the insular ribbon on the left (A) and loss of definition of the lentiform nucleus
(B), early CT signs suggesting ischaemia in the territory of the left middle cerebral
artery.
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Figure 6: Hyperattenuated artery sign
Left hyperattenuated middle cerabral artery sign, suggesting the presence of thrombus
in the left middle cerebral artery.
30
The artery appears 'hyperattenuated' (white) because of the high attenuation due to the
blood clot within it; the correlation of hyperdense artery with arterial occlusion has been
confirmed since the hyperattenuated artery sign is associated with occlusion of the
relevant artery on angiography33 and disappearance of the sign with reperfusion.34
However, calcified vessels or an increased haematocrit may also cause a similar
appearance, though usually bilaterally and symmetrically.35
Imaging the vascular pathology
CT of the brain has continued to evolve. A variety of methods are now available to
assess different aspects of vascular pathology: stable xenon-enhanced CT and dynamic
CT perfusion. CT perfusion (CTP) holds promise for permitting a positive diagnosis of
acute ischaemic stroke when the standard CT is normal by showing an area of reduced
cerebral perfusion.36 A plain CT is performed and shortly afterwards the patient's head
is positioned according to a predetermined clinically suspicious slice, and fast repeated
scans of the same slice are performed during the administration of a bolus of intravenous
contrast. The resulting images require complex processing to produce colour maps
representing parameters such as cerebral blood flow (see Figure 7).37 Although several
promising studies suggest that CTP may identify patients with perfusion deficits who
might benefit from thrombolysis, there are uncertainties about how best to process the
images to obtain this information, and more data are needed.
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Figure 7: An example of CT perfusion
A
The initial CT (A), the CT angiogram (B)
and the CT perfusion maps (C-E) were
obtained approximately one hour after
symptom onset in a 63 year old woman
who presented with right sided weakness.
A large perfusion deficit is visible in the
left middle cerebral artery territory on
the MTT (C), CBV (D) and CBF (E)
maps. The area of infarction follow up
37CT at 24 hours is shown in F.
C
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Computed tomographic angiography (CTA) is another useful technique which can be
used to study the cerebral arteries and veins. The arterial and venous system can be
imaged by giving a rapid intravenous injection of contrast and timing the images to
catch opacification in the vessels of interest. Although the base images are the most
useful, these can be reconstructed (Figure 8) to produce 3 dimensional images which can
38 39be helpful in acute stroke by demonstrating the site of arterial occlusion. ' When
considering patients for thrombolytic therapy, time is critical and although CTA is a
rapid procedure which may only require an extra five minutes scanning time and about
five minutes reconstructing the images, if used inappropriately, it could introduce an
unnecessary delay in treating the patient and exposes the patient to additional radiation.
There are also concerns about the safety of contrast agents. X Ray contrast agents can
cause allergic reactions and renal problems. More importantly, there is evidence that
contrast agents may reduce the efficiency of thrombolytic drugs and increase time to clot
lysis.40 However if extra information is needed in an individual case, e.g. if the routine
CT is normal and there is some doubt over the clinical history, then the time it takes to
do CTA may be time well spent. As always a quick assessment of the risk/benefit ratio
of the particular investigation must be made at the time. This will vary from patient to
patient depending on their clinical condition, co morbidities and time since onset of
stroke symptoms.
Cost effectiveness of CT
One of the most important issues regarding any form of imaging is cost. Funds within
the UK National Health Service are limited and therefore an awareness of cost
effectiveness is vital. A policy of 'CT all patients immediately' if they present with
suspected acute stroke has been shown to be cost-effective using all data available at the
time of the study.41 These data come from a deterministic model based on data from the
UK and therefore applicability to the rest of Europe may be questioned, but provide an
excellent basis on which to look at this complex area. This policy was dominant under a
variety of plausible scenarios examined in sensitivity analyses. The finding is robust.
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Figure 8: CT angiography
This image demonstrates right internal carotid artery occlusion with poor fdling of the
first part of the anterior cerebral artery (ACA, Al) and middle cerebral artery (MCA,
Ml) from posterior cerebral artery collaterals through the posterior communicating
artery (PCoA). The Al segment ofthe ACA also appears acutely blocked.
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Although implementing this strategy might mean higher initial costs, depending on
availability of staff and equipment at the point where the policy is implemented, these
are offset by savings in length of inpatient hospital stay as well as lower costs of
community care and better quality of life. As a result of these reliable results, this
approach is being adopted by NHS, European (2007) and USA (2007) policy makers.
1.3.2 Magnetic Resonance Imaging (MRI) to image the ischaemic brain
lesion
MR is more sensitive than CT for detecting the subtle early ischaemic changes in
patients with mild to moderate neurological deficits; hence the use of MRI for the
assessment of acute stroke patients has increased. A specific sequence, diffusion
weighted imaging (DWI), has been developed to detect the tissue changes of cerebral
ischaemia at a very early stage (Figure 9). Clinicians have encouraged the use of DWI
because of its apparent greater sensitivity and greater interobserver agreement for
detecting early ischaemic signs in some studies compared with CT.42 However this is a
simplistic view and fails to take into account the impracticalities of MR in acutely ill
patients with hyperacute stroke. In these patients CT is much more practical and nearly
as sensitive and specific as MR.
Improvements in MRI have made it potentially even more useful in the scanning of
acute stroke patients and some advocate its use for all stroke patients.43 The newer MRI
techniques with ultrafast imaging methods e.g. echoplanar imaging (EPI) have reduced
scanning times (useful for restless acute stroke patients). DWI using EPI sequences can
image the whole brain (20-30 slices) in a few minutes. During these sequences, strong
diffusion-sensitising gradients are used to make the MRI signal sensitive to the random
movement of water protons. In protons that are stationary, the symmetrical diffusion-
sensitising gradients will led to a dephasing and then exact rephasing of the water
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Figure 9: Diffusion weighted imaging (DWI)
Bilateral cerebellar infarcts. On the CT image on the left the changes are less obvious,
but are seen clearly on the DWI MR image on the right.
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protons in each voxel. However, if water protons move due to diffusion, phase shifts
occur and subsequently imperfect rephasing, which in turn leads to a smaller DWI
signal. In an area of acute cerebral ischaemia, intracellular water content increases and
cells swell (cytotoxic oedema), which reduces the extracellular space and hence restricts
diffusion of extracellular water protons. The resulting area of reduced diffusion appears
bright (white) on DWI images.44 The hyperintensity on DWI can appear within minutes
of an ischaemic event, as demonstrated in both experimental and human stroke.45'46
However, such changes on DWI are not specific for ischaemic stroke. Stroke mimics
such as encephalitis, hypoglycaemia, multiple sclerosos and brain abscesses can also
show as bright lesions on DWI.30 MR DWI may also fail to detect ischaemic lesions. In
one series of patients with definite ischaemic stroke, 20% had a negative DWI within 24
hours of stroke onset.47 When DWI was first introduced, it was thought increased signal
invariably represented irreversibly damaged tissue, but more recent studies have shown
that this is not always the case and that DWI abnormalities can resolve without
subsequent infarction developing.48'49
MR to image the vascular pathology
Perfusion imaging (PWI) is a method of assessing blood flow in the brain, introduced in
the late 1990s but still undergoing evolution. It is based on the same concept as the
more recently introduced CTP and many earlier brain perfusion imaging techniques.
There are two methods that can be used; contrast bolus tracking or arterial spin labelling.
In acute stroke patients, the method that has been most commonly used is contrast bolus
tracking, also known as dynamic susceptibility contrast imaging (DSC). A bolus of
exogenous contrast agent (gadolinium) is injected intravenously and a series of brain
scans then rapidly performed over the next couple of minutes as the contrast bolus
passes through the brain. This produces a signal-time curve from which information
about the amount of blood flowing through the brain per unit of tissue and time can be
derived. The details will be described in later chapters. Processing of these images can
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Figure 10: Mean transit time (MTT) perfusion map
Reduced bloodflow in the left MCA territory
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then reveal the areas with altered blood flow e.g. Figure 10. The chief problem with
PWI is that post processing of the images is required and the extent of this processing
and the time it takes depends on the perfusion method being used. Thus any gain in
diagnostic information with PWI must be balanced against the extra time required,
especially if thrombolysis is being considered. There are a number of perfusion
parameters that have been measured (e.g. time to peak, mean transit time), but as yet
there is no clear consensus on which method is best50 and this will be discussed later.
MR to select patients likely to respond to thrombolysis
In acute ischaemic stroke, if the perfusion lesion is larger than the diffusion lesion, a
PWI/DWI 'mismatch' is said to exist. This area of mismatch is thought to represent the
ischaemic penumbra i.e. the area of tissue that is under perfused but has the potential to
recover from the ischaemic insult if the affected area of brain is reperfused.51 Hence, it
has been suggested that patients with evidence of a significant degree of mismatch
would be ideal candidates for thrombolytic treatment. However the destiny of the tissue
in the area of PWI/DWI mismatch area has remained unpredictable and it is also
apparent that the DWI lesion may expand or shrink without treatment. The topic of
mismatch will be discussed in greater detail later in this thesis.
MR gradient echo imaging (GRE) is very sensitive at detecting the haemosiderin
deposits in the brain which are the residue of intracerebral haemorrhage and appear as
areas of signal loss (i.e. dark). These persist for months and years after a bleed. If the
lesions are very small and punctuate, they are referred to as 'microbleeds' (Figure 11).
There have been suggestions that microbleeds on MRI may be a marker of increased risk
of intracranial bleeding in patients receiving thrombolytic therapy for acute ischaemic
stroke.52 However, among patients whose presenting problem is an acute ischaemic
stroke, it is not yet clear whether the presence of microbleeds should be regarded as a
contraindication to thrombolytic therapy or not.53"56
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Figure 11: Microbleeds on GRE MR
Multiple areas ofsignal intensity loss i.e. microbleeds
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1.3.3 MR to detect acute intracranial bleeding
MR imaging is not reliable in the detection of acute subarachnoid haemorrhage and
hence CT is likely to remain the gold standard imaging tool for this condition for the
foreseeable future. With regards to acute intracerebral haemorrhage, CT has been the
investigation of choice, but with gradient echo MR sequences it has been suggested that
MRI may be as accurate as CT for the detection of acute parenchymal haemorrhage in
patients presenting with focal symptoms.57 However there is less experience with acute
cerebral haemorrhage than there is with acute ischaemic stroke, so the biggest problem
with the more specialised MR sequences for detecting intracerebral haemorrhages is that
the images may be difficult to interpret and require expert review.
1.3.4 Feasibility ofCT versusMRI in the acute stroke patient?
The question of which scanning method should be used in acute stroke patients is
contentious and a cause of much debate.58 CT has the advantage that it is quick,
accessible in most hospitals 24 hours a day and it reliably detects acute intracranial
haemorrhage, which is of paramount importance in cases where thrombolysis is being
considered. The main disadvantage of CT is that it uses ionising radiation, with one
brain CT exposing the patient to the equivalent of one year of background radiation.26 A
further disadvantage is that it may not enable a positive diagnosis of ischaemic stroke to
be made especially in patients with mild stroke.
Compared with CT, MRI has a large number of potential disadvantages. Firstly,
because it involves placing the patient in a strong magnetic field, it can cause
malfunction, movement and heating of any metal objects in the patient's body.59'60
Hence patients with cardiac pacemakers, intracranial aneurysm clips, metallic foreign
bodies in the eye or elsewhere should not be scanned. MRI scanners are also more
claustrophobic61 than CT scanners, although the modem designs have improved to some
extent on this problem. Due to the length of time needed to acquire images, patients
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have to lie supine for some time. This is not ideal in acutely ill stroke patients, many of
whom have impaired swallowing ability and hence are at risk of aspiration if laid flat for
too long. 2'6 In such unstable patients, there is the risk that they may not be able to
protect their airway safely and aspirate and because of ventilation/perfusion changes in
stroke may become hypoxic in the scanner.64 Finally, MRI scans are noisy and despite
providing patients with ear plugs they may not be able to tolerate the procedure, whilst
others may simply be too ill to be submitted for such an investigation. In some series,
between 20% and 40% of patients with acute stroke could not be scanned due to medical
reasons.62'63
The availability of CT and MR scanners is also an issue. Four successive audits by the
Royal College of Physicians Sentinel audit for stroke (last done in 2004) have shown
that CT has become increasingly available to stroke patients in the UK and the majority
of hospitals in the UK now have the facilities to CT scan a stroke patient acutely.15
However the availability ofMR scanners, although improving, appears relatively limited
outside large teaching hospitals.
As mentioned earlier CT scanning is cost effective in acute stroke, but the relative cost
effectiveness of CT and MR has not been determined. Hence, identifying effective and
widely practicable imaging strategies for the management of stroke and the selection of
patients for thrombolysis is a priority. In particular it is important to decide whether MR
should replace CT scanning for some - or for all - categories of patient with acute
stroke. This thesis will therefore examine several key aspects of imaging in acute stroke




Intravenous thrombolytic therapy with recombinant tissue plasminogen activator, rt-PA
has been licensed for use in selected patients with acute ischaemic stroke. The idea
behind thrombolytic therapy is that, by dissolving the clot occluding the cerebral artery,
ischaemic brain tissue is reperfused quickly. Reperfusion should decrease the volume of
brain tissue damaged by ischaemia, and hence lead to less neurological impairment and
less disability. Thrombolysis for acute stroke is not new. The first trial of thrombolysis
for acute stroke was published in 195810 and the first 'positive' trial was reported 10
years ago.65 However, even in countries such as the USA, where it has been licensed
since 1996, its use in routine clinical practice is limited and variable (an average of 4%
of all strokes, with a range from 0% to 12%).6 '67 Since then rt-PA has been licensed for
the treatment of acute ischaemic stroke in Europe and many other parts of the world.
Thrombolysis has the potential to benefit many more patients, if the ongoing trials show
which categories of patient outside the current licence benefit from treatment. One
theoretical model suggests that, if it could be used in 30% of patients in Europe, up to
14000 ischaemic stroke patients could avoid death or disability each year. A major
problem with the current approval is that patients must be treated within 3 hours of
symptom onset. At present this is a difficult target to achieve.69 There may be delays at
every stage: recognition of symptoms as stroke, calling emergency services, getting to
hospital, clinical examination, bedside investigations and brain imaging (which is
necessary to exclude intracranial haemorrhage and stroke mimics). Even in hospitals that
have a large throughput of stroke patients and well organised acute stroke services this is
a time consuming process. Some centres do not have acute stroke experts on site and
here processes such as telemedicine70 are being introduced to try and increase access to
the treatment and hence improve equity of care across different regions. Before this
drug can reach its full potential it is vital that hospitals have organised acute stroke care,
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to include streamlined imaging and a well organised acute stroke unit. This requires not
only reorganisation of existing services but also a large investment of time and money.
1.4.2 The evidencefor thrombolysis in acute ischaemic stroke
Thrombolytic therapy has now been evaluated in several randomised trials in acute
ischaemic stroke. The summary of the randomised trial evidence in the 2003 Cochrane
systematic review71 is being updated, but until the results of two large ongoing trials
(ECASS III and IST-3) are known, the conclusions of the 2003 review are unchanged.
By 2003 there had been 18 randomised trials including 5727 patients. The agents tested
include urokinase, streptokinase and recombinant pro-urokinase. About half the data
relates to recombinant tissue plasminogen activator (rt-PA, alteplase) and, as mentioned
before this is the only thrombolytic drug currently licensed for acute stroke treatment. In
an analysis of 'any thrombolytic agent versus control' given up to six hours after stroke
there was a significant reduction in death or dependency with thrombolysis; 53.3% of
those allocated to thrombolytic therapy compared to 58% of those allocated to control
(OR 0.84, 95% CI 0.75 to 0.95, p=0.004). This is the equivalent to 43 fewer patients
dead or dependent (Rankin 3-6) per 1000 patients treated.71 The review permitted an
indirect comparison of the effect of rt-PA with other thrombolytic agents. The authors
stated that 'Trials testing intravenous recombinant tissue plasminogen activator
suggested that it may be associated with slightly less hazard and more benefit than other
drugs when given up to six hours after stroke but these are non-random comparisons -
death within the first ten days OR 1.24, 95% CI 0.85 to 1.81, death at the end of follow-
up OR 1.17, 95% CI 0.95 to 1.45, dead or dependent at the end of follow-up OR 0.80,
95% CI 0.69 to 0.93. However, no trial has directly compared rt-PA with any other
thrombolytic agent.
72In 2003 a cumulative meta-analysis of all the rt-PA trials was published. Data on 2830
patients from 8 trials, since 1992, were included. The cumulative analysis confirmed
there were net benefits in treating patients with alteplase, despite the hazards. For every
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1000 patients treated with rt-PA up to 6 hours, approximately 55 more patients will be
independent at the end of follow-up, including the 'cost' of about 20 extra deaths.72
Individual data on 2775 patients from six trials (NINDS part 1 and 2, ECASS-I, ECASS-
73II and ATLANTIS part A and B) were pooled by the rt-PA study group. This analysis
has the advantage of enabling the effect in some specific subgroups to be explored.
Multivariate analysis showed that the main factor associated with a favourable outcome
(based on Rankin, Barthel and National Institutes of Health Stroke Survey (NIHSS)
stroke scores) was early onset of treatment. The analyses were consistent with the
Cochrane review and also suggested that there may be worthwhile benefit from
thrombolysis up to 6 hours from stroke onset for some patients. However, at all time
points the confidence intervals were wide and, hence the estimates of effect were
imprecise.
Overall there is good evidence to support the use of alteplase in highly selected patients
with ischaemic stroke, aged under 80 years, treated in well-organised centres within 3
hours of symptom onset. However the trial data suggest a wider variety of patients
might benefit from thrombolysis, though this hypothesis needs to be tested in further
larger scale trials. The most notable group is the elderly. To date the elderly have been
under represented in the trials of thrombolysis for stroke, despite the fact that stroke is a
disease of the elderly. In the UK, for example, about 20 000 patients aged over 80 have
an acute stroke each year. As a consequence of many of the trials setting an upper age
limit (only three of the recent trials have not had an upper age limit), only 42 patients
aged over 80 have been included in randomised controlled trials61 and hence alteplase is
only licensed - in Europe - for acute stroke in those patients under the age of 80.
More needs to be known about which factors really influence the benefit of treatment
e.g. age, concomitant aspirin use, blood pressure, the presence on the pre-treatment CT
scan of 'early infarct' signs, or the degree of diffusion/perfusion mismatch on MR
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scanning to name but a few. Once more is known about these factors we will be better
able to assess the balance of risk and benefit for each individual patient.
Another concern is the under-utilisation of rt-PA within the licence, and the wide
variation between centres and countries. The SITS MOST registry reported in March
2005 a fifty-fold variation between European countries in the use of rt-PA for stroke
between Finland (about 50 treatments per million population) and France and Portugal
(about 1 per million).74 This prospective observational study has now been published
7S
and suggests that rt-PA is safe and effective when given according to strict criteria.
However, data from those patients who did not fulfill all the prespecified eligibility
criteria were not reported. Therefore, figures relating to symptomatic intracranial
haemorrhage and outcome have to be interpreted with caution. At least part of the
explanation for the variation in the use of rt-PA must be the lack of really large-scale
randomised trial evidence. The example of the implementation of thrombolytic therapy
for acute myocardial infarction is illuminating. Before the late 1980's there was similar
under-utilisation of the treatment and enormous variation between centres. It was not
until randomised trial data were available on over 60000 patients that cardiologists
finally accepted the benefits of thrombolysis and then vigorously implemented it in
routine clinical practice, which changed extremely rapidly after he publication of the
large-scale trials (ISIS-2 and GISSI).76'77 In stroke, the evidence base is much smaller
(just 2800 patients), and I suggest this lack of large scale evidence must be contributing
to the poor uptake in routine practice. The ongoing randomised trials of alteplase in
acute stroke should help to improve the situation, though none are of 'cardiological'
scale (IST-3, ECASS-III, EPITHET).78
An economic analysis (based on the UK NHS) of thrombolysis with alteplase for acute
ischaemic stroke, found that the estimates of effectiveness and cost effectiveness were
imprecise. Although the benefits of treatment up to 6 hours appeared promising, the
data did not support the widespread use of thrombolytic therapy outside the terms of the
current restricted licence in routine clinical practice in the NHS.79
46
1.4.3 Can imaging help select patients for thrombolysis?
Since treatment of acute ischaemic stroke with thrombolysis is associated with a 3% risk
of fatal intracranial haemorrhage it would be of great benefit if there were imaging signs
that could help us select those patients who would benefit most from thrombolysis and,
just as importantly, help distinguish those who are most likely to be harmed by it.
Over the last decade various CT 'signs' have been proposed to identify the patients most
likely to respond poorly to thrombolysis. The European Stroke Initiative
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recommendations for stroke management, updated in 2003 advise caution before
giving rt-PA to a patient where the CT demonstrates extended early changes of a major
infarction, such as sulcal effacement, mass effect and oedema. The American Stroke
Association guidelines,81 also published in 2003, recommend that patients who have a
CT showing multilobular infarction (hypodensity greater than one third of the cerebral
hemisphere) should not be treated with rt-PA. These recommendations are based on
data from the ECASS trial.82 In that study, patients with CT evidence of low attenuation
involving more than one third of the territory of the middle cerebral artery (MCA) were
less likely to have a good outcome after treatment with rt-PA than those who received
placebo. However, the radiologists reading the scans were not blinded to follow up
scans, so this analysis may have been biased by prior knowledge of subsequent events.
Another study of thrombolysis with streptokinase for acute ischaemic stroke did not find
any association between early ischaemic changes (categorized into no signs, < l/3rd or
> l/3rd of the vascular territory) and major haemorrhage after thrombolytic therapy.83
However even if this ' l/3rd MCA rule' is to be advised (on the basis of little evidence)
the question of how easy it is to estimate greater or less than 1/3rd of the MCA territory
remains. An objective CT grading scheme, such as the Alberta Stroke Programme
Early CT Score (ASPECTS) may provide better inter rater agreement compared to the
1/3rd MCA rule and at least ensures that inexperienced CT readers carefully examine all
areas of the CT.84 The Third International Stroke Trial (IST-3) will provide further
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prospective data on whether CT features influence the response to rt-PA, and, if so,
which are the most important. To date a systematic review of early infarct signs and
interaction with thrombolysis did not find any association between early infarct signs
85and poor outcome. When examining the CT, clinicians should look for CT signs that
don't fit with the clinical history. For example, a patient with right hemisphere stroke
may have anosognosia and hence not realise when their stroke symptoms started. In the
example in Figure 12, the lesion on the CT scan looks more hypoattenuated than would
be expected for a stroke onset of just 2.5 hours. In this case, it was later established that
onset was probably 8 hours before the scan (hence indicating that the patient was
ineligible for thrombolysis). In general, if the clinical history and CT do not match, then
extreme caution should be advised in proceeding with thrombolytic therapy. It is often
advisable to revisit the history again if there is a clinical-CT mismatch.
1.5 Consent
It is important to evaluate new interventions for the treatment of medical emergencies
(such as acute stroke) by means of randomised controlled trials. Advanced MR imaging
may assist in the selection of patients for thrombolysis, and although limited availability
ofMR in the UK may limit its use, it may be valuable in other countries. After imaging,
the next step in the process of care is to streamline the process of consent.
The standard approach to recruitment in a randomised trial of a non-emergency
treatment is to require fully informed written consent after giving the patient sufficient
time to consider the matter. This is clearly not practicable in the emergency treatment of
acute stroke, where patients may have a variety of neurological deficits which either
impair effective spoken or written communication and/or writing (e.g. coma, confusion,
paralysis, aphasia).86,87 There is substantial variation between countries in the legal and
regulatory requirements for consent procedures for trials being conducted in such
patients. In Europe and the USA, such research can only be conducted if several
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Figure 12: CT scan showing changes which suggest apparent time of stroke onset may
be incorrect
This patient has a well defined, sharp edged, hypoattenuated wedge-shaped lesion in the
right posterior frontal region (A) and a smaller similar low density area in the right
posterior sylvian region (B). The patient's symptoms were initially said to have started
2.5 hours prior to the scan. However, this lesion is well and sharply demarcated and
very hypoattenuated suggesting that the onset of the infarct was more than 2.5 hours
previously. Further questioning revealed that the patient 's stroke symptoms had
probably started 8 hours earlier.
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stringent conditions are met, which may render some types of research impractical.
Further issues surrounding consent will be discussed later.
1.6 Conclusion
Advanced MRI techniques clearly have great potential for wider use in acute stroke. In
the imaging part of this thesis I will concentrate on what one particular MRI technique,
the 'perfusion diffusion mismatch concept', may add to CT in the diagnosis of acute
ischaemic stroke, and in particular how it might influence the selection of patients for
thrombolysis. MRI scan times have become shorter and the availability ofmultichannel
phased array brain coils and the development of parallel imaging techniques such as
sensitivity encoding (SENSE) allow comprehensive MR stroke imaging to be completed
oo
in under five minutes. However, these advantages may - for many acutely ill patients
- be offset by lack of access, contraindications to MR and the difficulty of ensuring
patient safety in the scanner. This thesis therefore focuses on three questions relevant to
selecting patients for thrombolysis: 1) Can MRI assist in the selection of patients with
acute ischaemic stroke for thrombolysis?; 2) If it does, is MR available to patients with
acute stroke in the UK? and 3) For patients who meet clinical and imaging criteria for
thrombolysis, what methods to obtain consent are most relevant?
1.7 Summary
• Stroke is a disorder which places a huge burden on medical resources and on
society and is likely to continue to do so for the foreseeable future.
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In combination with the history and clinical findings, imaging of acute stroke
patients has made it possible to make rapid and accurate diagnoses in patients
presenting early with stroke syndromes.
CT scanning is the standard technique for brain imaging in patients with
suspected acute stroke
- It excludes major stroke mimics (e.g. tumour)
- It identifies ICH and SAH rapidly and reliably (particularly important in
patients being considered for thrombolysis).
- If done within 7 days, is suitable for excluding haemorrhage among
patients being considered for treatment with antiplatelet, anticoagulation,
or carotid endarterectomy
- However, it does expose the patient to a dose of radiation (1,5mSv)
Expert clinical assessment and prompt CT scanning are often sufficient to
select patients for treatments such as thrombolysis.
If CT is normal in the context of a patient with a suspected acute ischaemic
stroke, there is no positive evidence of ischaemia to support a decision to use
thrombolysis (with its associated risks).
When CT scans are assessed by clinicians with specific scoring systems or
after training better detection of 'early ischaemic signs' is possible, which
may often be helpful when selecting patients for thrombolysis.
CT perfusion and CT angiography can demonstrate the underlying vascular
pathology, but require extra time and carry the associated risks from the use
of intravenous contrast.
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MR (DWI) may be more sensitive at detecting early ischaemia than CT.
MR GRE is able to provide evidence of previous intracerebral bleeding
which may represent a contraindication to thrombolysis.
MR PWI/DWI 'mismatch' potentially identifies tissue at risk of infarction
which may be 'rescued' by thrombolysis.
MR and CT have advantages and disadvantages in terms of feasibility, safety,
availability and cost effectiveness.
The process of consent should begin immediately and continue in parallel
with early clinical assessment and be completed after imaging.
Many patients suitable for thrombolysis are not competent to give fully
informed written consent; a range ofmethods are needed.
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Table 1: Interventions (specific investigations, procedures and treatments) commonly
used in patients with acute cerebrovascular disease, and the frequency with which they
are used in routine practice
INTERVENTION STROKE TYPE
Treatments Infarct ICH SAH
Aspirin Yes Avoid Avoid
Anticoagulants Sometimes Avoid Avoid
Thrombolysis Sometimes Avoid Avoid
Carotid endarterectomy Sometimes Avoid Avoid
Endovascular treatment Very rare Very rare Often
Investigations
Lumbar puncture Rarely Rarely If CT negative
Angiogram Rarely Sometimes Usually
ICH = intracerebral haemorrhage
SAH = subarachnoid haemorrhage
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2 MR Perfusion Diffusion Mismatch
2.1 Introduction
In the UK the most commonly used imaging modality in the assessment of acute stroke
patients is CT. The main reason being, as mentioned in chapter 1, that it is an excellent
technique to detect early haemorrhage and stroke mimics such as tumours. However,
MR imaging is constantly being refined and one form of MR imaging concept that has
been enthusiastically promoted is that of the 'perfusion-diffusion (PWI/DWI)
mismatch'.
The theory behind 'mismatch' came from studies of experimental large artery occlusion
stroke models in the 1970s. Following middle cerebral artery occlusion, microelectrode
studies in the baboon cortex demonstrated that some reduction in cerebral blood flow
(CBF) abolished evoked potentials, and further reduction abolished spontaneous activity
of cortical neurons.
The term 'ischaemic penumbra' was defined by Astrup and colleagues in 19811 and
referred to brain tissue which is perfused between the thresholds of functional
impairment (reduced or absent electrical activity) and loss ofmorphologic integrity (cell
disruption and death). This is illustrated in the image in the introduction (pi5). Cells
whose perfusion has been reduced to this level of functional impairment have the
capacity to recover if perfusion is improved.2 However the penumbra is not a static
entity, but a dynamic process, dependent on residual flow and the duration of flow
disturbance." In order to transfer this concept from animal experiments to man the
definition of three critical values are required (all of which are difficult to calculate in
the acute stages of an ischaemic stroke):
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• The flow threshold for functional impairment - to identify functionally impaired
tissue
• The flow threshold for morphologic damage - to identify irreversibly damaged
tissue
• The time period that a tissue tolerates decreased flow before it becomes
irreversible damaged - to predict recovery of function with reperfusion.2
In the 1980s and 1990s other experiments were performed in different animal models,
from gerbils and rats to cats and monkeys, which further explored the penumbra and
factors influencing it, including duration of ischaemia, cerebral blood flow levels and
metabolic changes.4"9 Similar critical blood flow levels were found in all species,
bearing out the penumbra concept, although the precise levels varied to some extent
between species and experiments.
Attempts to study the critical flow levels and penumbra in man started with a
radionuclide imaging technique called positron emission tomography (PET). PET has
been used to determine pathophysiological changes occurring shortly after ischaemic
stroke in man and animals. It permits major aspects of brain physiology to be
investigated, depending on the properties of the radiotracer used and biomathematical
models selected.10 PET provides a method for assessing physiological variables without
the need for invasive procedures that were used in the early animal experiments to
explore the penumbra. Although multitracer PET cannot accurately measure the
penumbra by its original definition, the use of this technique was an important step in
moving from investigating the penumbra in experimental animal models to evaluating
patients with acute stroke.
PET allows several variables to be mapped. These include regional cerebral blood flow
(rCBF), regional cerebral blood volume (rCBV), regional cerebral metabolic rate for
oxygen (rCMRCh) and regional cerebral metabolic rate for glucose (rCMRgic). CMRCE
and CMRgic are both useful values when looking at cell viability, since they indicate
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oxygen consumption and glucose consumption, respectively of the cells. Whilst cells
are still using oxygen and glucose they must still be viable.
Using advanced PET techniques, both baboon and cat models of stroke after middle
cerebral artery occlusion have been studied.11"13 In cats CBF decreases in the whole
vascular territory, possibly reflecting a model more akin to humans. One study of
middle cerebral artery occlusion in cats sequentially studied CBF, CMRO2 and CMRg|c
before, during, and up to 24 hours after vascular occlusion.14 This found that CBF
decreased to less than 30% compared to control in the middle cerebral artery territory on
arterial occlusion. CMRO2 was less diminished and was preserved at an intermediate
level. Consequently, oxygen extraction fraction (OEF) was increased indicating 'misery
perfusion'. The ischaemic penumbra spread from the core to the borders of the MCA
territory over time and was generally followed by a marked decrease in OEF, reflecting
impairment of metabolism and transition to necrotic tissue. The infarcts were generally
complete after 18-24 hours, although occasionally spontaneous collateral reperfusion
resolved the penumbra condition. However most animal experiments are small, PET is
expensive, labour intensive and technically quite difficult. Therefore the data are
helpful, but limited, in their generalisability to what might be happening in a broader
range of stroke patients.
Moving a step closer to the clinical situation, PET studies were carried out in humans
with the aim of identifying irreversibly damaged tissue and compromised, but viable
tissue. PET with l5oxygen tracers became regarded as the gold standard for the
pathophysiological changes in early stroke.15 The quantitative measurement of variables
such as CBF, OEF and CMRO2 allowed the independent assessment of perfusion and
energy metabolism. However, using such techniques is complicated and requires
multitracer application, limiting its use in the clinical setting. Numerous studies have
been performed in an attempt to identify values for the penumbra threshold and the
infarction threshold. In the late 1990s detailed PET studies in patients studied 5-18
hours after symptom onset reported a CBF penumbra threshold of around 17-22
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ml/lOOg/min, and an infarction threshold of about 7-10/ml/100g/min (although the
values quoted vary between studies) and 0.87mls/100g/min for CBF and oxygen
consumption, respectively.16"18 These analyses indicated that increased OEF is a poor
predictor of tissue viability, and that isolated flow measurements at a single time point
might be confusing if the pattern over time is unknown. Other markers of neuronal
integrity have been explored including flumazenil (a neuronal benzodiazepine/GABAA
receptor ligand). Flumazenil only binds to active GABA receptors and therefore areas
of cerebral tissue with reduced flumazenil binding may indicate areas of reduced cell
viability. In one study it was proposed that the penumbra threshold was best defined by
CBF, and the infarction threshold by flumazenil uptake.19
PET is never going to be a widely available technique suitable for stroke. Since
multitracer PET is not practical in the acutely ill and very rarely available in the clinical
setting, researchers moved on to test a potentially more widely available imaging
method of investigating the penumbra, with MRI. Initially, experimental models of
stroke using MRI suggested that DWI would be a useful marker of probably infarcted
tissue and perfusion imaging would show areas of reduced perfusion at critical levels
which would be at risk of infarction. This led to the concept, in the mid 1990s, that the
mismatch between the larger perfusion lesion and the smaller diffusion lesion would
indicate 'penumbra' tissue at risk. Diffusion weighted imaging was thought to provide a
measure of tissue bioenergetic compromise and perfusion weighted imaging a measure
of haemodynamic compromise.20 From early reports of DWI and PWI, the theory
developed that the difference between the two acute lesions (i.e. the mismatch - see
Figure 1) represented the ischaemic penumbra (i.e. hypoperfused tissue that has the
potential to be salvaged).21
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Figure 1: The initial diffusion perfusion model
DWI Abnormality: Bioenergetic Compromise = Core
M Perfusion Abnormality: Hemodynamic Compromise
Diffusion/Perfusion Mismatch = Penumbra
Schematic ofthe mismatch modelfor defining the ischaemic penumbra.'0
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This model has evolved further (Figure 2) and it is now thought that some of the DWI
lesion is not necessarily irreversibly damaged and so can be salvaged.22 Furthermore the
PWI abnormality includes tissue which is destined to have a relatively benign outcome.
The evolution of this theory is important, since it suggests that some patients who do not
have mismatch at baseline may still benefit from interventions such as thrombolysis.
The presence of 'mismatch' is increasingly being used as one of the selection criteria for
inclusion in clinical trials of reperfusion therapies23'24 and also in routine clinical
practice (where the equipment is available).
However, there are a number of inherent problems with what seems, at first glance, a
very attractive theory. There are no clear definitions of what constitutes mismatch and
no substantial randomised trial evidence to justify its use. As mentioned before, it is
now known that the DWI lesion is not irreversible (initial DWI lesions may disappear
spontaneously or following thrombolysis).25 Alternatively patients may have a scan
with no visible DWI lesion in the acute setting despite the clinical findings suggestive of
stroke. In around fifty percent of such patients ischaemic tissue will be found at follow
up.26 In such DWI negative cases the perfusion image is an important part of the acute
MR imaging sequence, since many patients will have a PWI deficit. Such a situation i.e.
PWI lesion with no DWI lesion may indicate ischaemic tissue which has not yet reached
the point of cell membrane compromise and so is still potentially viable at the time of
the scan. There have also been reported cases of DWI and PWI negative acute scans
which may go on to show evidence of ischaemic disease e.g. lacunes in the brain stem.27
In other cases a DWI negative scan may suggest that there is an alternative underlying
clinical diagnosis such as migraine or epilepsy. For the PWI lesion, it is increasingly
apparent that its appearance depends on which of the many methods available to
calculate it was used. Different perfusion parameters (e.g. mean transit time (MTT),
regional CBF),28 and arterial input function (AIF)29 have been used in different studies
but give different perfusion lesion volumes in the same patient, and it is unclear which
represents the 'at risk' tissue. For example, perfusion lesions calculated using MTT
28
were larger than CBF or CBV lesions.
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Figure 2: The modified diffusion perfusion model
■ Benign Oligemia | Core
■ Perfusion Abnormality Penumbra
■ Diffusion Abnormality
Modified view of MRI-defined ischaemic penumbra in which the penumbra equals not
only regions of diffusion-perfusion mismatch, but also a portion of the diffusion
abnormality itself.20
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In addition it appeared that different methods of measuring the same type of perfusion
lesion, and underlying vasculopathy have a direct impact on the size of the calculated
PWI.30 Thus it is unclear whether the presence (vs. absence) of mismatch affects
prognosis and how mismatch should be calculated. If mismatch is to be used to select
patients for acute stroke treatments such as thrombolysis, then the key point is to
determine whether thrombolysis has a greater prognostic effect in the presence, rather
than in the absence, of mismatch. This requires a randomised controlled trial in which
patients with and without mismatch are randomised to receive thrombolysis or control,
an expensive and difficult undertaking given that a large sample size would be needed to
account for any difference.31
As there was already considerable literature on the MR mismatch concept, I undertook a
systematic review to assess the evidence on the effect of MR PWI/DWI mismatch in
acute ischaemic stroke on outcome (clinical and radiological) and whether this was
modified by thrombolysis. I set rigorous pre-specified inclusion and exclusion criteria
based on scientific principles for observational studies and randomised trials to minimize
bias.
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2.2 Magnetic resonance perfusion diffusion mismatch and
thrombolysis in acute ischaemic stroke: a systematic review of
the evidence to date
2.2.1 Methods
Design
A systematic review of publications describing PWI/DWI mismatch in patients with
acute stroke and the relationship to outcome in the presence or absence of thrombolytic
treatment. A pre-specified aim of the review was to examine the technical detail of the
methods used, and to extract details of the results from the reports. Previous work on
systematic reviews of diagnostic tests by members of the Department has shown that, by
contrast with reports of randomised trials, abstracts reporting imaging studies do not
contain sufficient detail to permit meta analysis (Wardlaw, Sandercock, personal
communication). I therefore only included papers published in full in order to obtain
detailed methodological data and results.
Search strategy
I developed a search strategy with advice from the Cochrane Stroke Group to identify
potentially relevant articles published between January 1996 and May 2005. The search
started in 1996 as MR DWI was not available prior to that time. I searched Medline and
EMBASE (based on the terms 'diffusion weighted', 'perfusion weighted',
'thrombolysis', 'magnetic resonance imaging', exploded to maximise findings). I then
searched the reference lists in the identified articles for further relevant papers.
Abstracts from the major stroke meetings (European Stroke conference, World Stroke
Congress and American Heart Association stroke meeting) were also searched for
relevant studies (that might subsequently have been published in full) and to estimate
whether there were likely to be a large number of unpublished studies. Full details of
the strategy are given in Appendix 1.
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Inclusion criteria
I included prospective studies of human acute stroke, which had included at least twenty
patients, imaged at presentation with acute stroke with MR DWI and PWI, with clinical
assessment at baseline and follow up at least one month after stroke using a recognised
assessment scale, and - where possible - radiological follow up. I planned to include
studies irrespective of whether patients received thrombolysis, as long as it was possible
to tell which patients had received thrombolysis.
Exclusion criteria
I excluded articles published before 1996 (prior to that neither MR PWI/DWI or
thrombolysis were widely used in acute stroke), retrospective studies (because of the
potential for bias), studies with less than 20 patients (very small sample sizes are prone
to bias, are difficult to blind and provide little robust data to inform clinical practice),
and with functional and/or radiological outcome assessed at less than a month after
stroke (prior one month would be too early to assess functional outcome; radiologically,
ischaemic lesions may still be evolving,32 fogging may cause underestimation,33 and
oedema may cause overestimation of the final lesion volume34).
Data extraction
I extracted data on to a standardised assessment form (Appendix 2). Queries were
checked by another reviewer (Professor J Wardlaw) independently. I collected the
sample size, patient clinical characteristics, clinical scores (e.g. National Institutes of
Health Score, NIHSS), time from symptom onset to imaging, details of the MR
sequences performed and perfusion post processing techniques, definition of PWI/DWI
mismatch, evidence of infarct expansion (increase in the lesion volume from the acute
baseline DWI to final T2), whether interpretation of the MR images was blinded to
clinical details or imaging, details of patients excluded from analysis, whether
administration of thrombolysis was randomised or not and any information on functional
or radiological outcome (whether or not patients received thrombolysis or had PWI/DWI
mismatch). I compared imaging at presentation with final follow up performed at one
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month or more. I did not examine scan data from intermediary time points (if available)
because they are unreliable for estimation of final infarct extent (see above). I was
careful to avoid including duplicate publications derived from the same patients. I
defined poor functional outcome as modified Rankin score (mRS) > 1 or Barthel (BI)
<90. Details of all the clinical scores cited in the studies are listed in Appendices 3-6
(p 178-181).
Analysis
I summarised study population demographics, proportions with or without mismatch,
number treated with thrombolysis, with poor functional outcome or infarct expansion. I
used odds ratios (OR) and 95% confidence intervals (CI) to determine associations
between mismatch, infarct expansion, functional outcome and any influence of
thrombolysis. I aimed to compare functional and radiological outcomes in patients with
mismatch to those without mismatch, and to determine whether thrombolysis changed
the relationship between mismatch and functional or radiological outcome.
2.2.2 Results
The search identified 1652 papers on any aspect of DWI and PWI, of which 85 were
potentially relevant to DWI/PWI mismatch and outcome +/- thrombolysis. Eleven
papers (641 patients) fulfilled all pre-specified inclusion criteria (reasons for rejection,
often multiple, grouped by the primary reason are shown in Figure 1).
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Methodological details of included studies (Table 1)
Ten included reports34"43 were prospective observational studies and one23 was a placebo
controlled, double blind, randomised, dose finding phase II trial of desmoteplase. These
papers derived from six research groups. Median time to baseline MR imaging ranged
from 1.5 to 6 hours after stroke. Six papers had obtained radiological follow up at one
1 34-39 •
month or more in most patients.
The most common baseline clinical score was the NIHSS, used in all but two papers,42'43
by an individual explicitly stated to be trained in its use. In all but one paper,34 other
scores (e.g. BI and mRS) were recorded at follow-up. Eight papers gave incomplete
details of blinding of clinical and radiological assessors. Three papers (27%) ' ' 3 did
not mention blinding at all.
Measurement of perfusion lesion (Table 2)
All groups used gadolinium-based dynamic susceptibility contrast imaging to assess
perfusion, the dose varying from 0.l-0.2mmol/kg. The method for perfusion lesion
assessment varied: four papers calculated time to peak (ttp);34>39'41>43 the others used
35 37 38
some form ofmean transit time (MTT) measurement, quantitative in 3 cases. ' '
Assessment of perfusion/diffusion mismatch (Table 2)
There was no consistent definition of mismatch. Amongst the eleven papers from six
research groups, there were five different definitions of mismatch. Mismatch was
determined by 'visual inspection' in two studies,23'43 and by tracing the lesion volumes
on a workstation in the rest, using various lesion boundary definitions (e.g. visual lesion
edge estimation or specific perfusion thresholds e.g. MTT > 4s compared with the
contralateral side).
77
Overall assessment of PWI/DWI mismatch on outcome and effect of thrombolysis
Amongst the 11 studies initially included in the review, I was only able to extract data
regarding mismatch and outcome (without or with thrombolysis) from three.34'37'38
Although all of these studies recruited at least 20 patients, not all of the original sample
contributed to the data, mainly due to incomplete imaging (see Table 1). In the rest, it
was not possible to separate the results for 'thrombolysis' from 'no thrombolysis'
patients and for patients 'with' from 'without mismatch',35'39'41 even though some did
have outcome data. Some papers just reported recanalisation and outcome, not
mismatch.36'40
All three papers with usable data included patients with and without mismatch and
two34'38 examined the effects of thrombolysis. In total there were 61 patients with, and
18 without, mismatch. Final follow up scans were not available (patient died or scan not
done) for 7/61 patients, some with mismatch at baseline and some without. Only two
papers reported functional outcomes.37'38
PWI/DWImismatch and outcome: no thrombolysis (Table 3 andFigure 2)
Two papers37'38 provided data on mismatch and functional outcome and three34'37'38 on
infarct expansion at 1 month or more (total n=50 patients) in patients who did not
receive thrombolysis: 41/50 patients had mismatch (by any definition), of whom 33/41
(80%) had any infarct expansion and 6/41(20%) did not (two patients were missing
follow-up scans); 9/50 patients had no mismatch of whom 5/9(56%) developed infarct
expansion. Therefore mismatch was associated with a non-significant two-fold increase
in the odds of infarct expansion (OR 2.2, 95% CI 0.34-14.1). Note the wide confidence
intervals include the possibility of both a reduction and an increase in the odds. Data on
functional outcome were not presented in a way that allowed calculation of odds ratios.
However, the mean BI or mRS at final follow up was non-significantly worse in those
with mismatch at baseline than in those without mismatch.
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PWI/DWI mismatch and outcome: with thrombolysis (Table 4 and Figure 2)
Two studies provided data on mismatch, radiological outcome (but only one on
functional outcome38), and thrombolysis (total n=29).34,38 Note that in one34
thrombolysis was actually given immediately before the first MRI meaning that the
baseline scans may have already been affected by thrombolysis, thus making
interpretations about the effects of rt-PA in these patients difficult. However, we
included these data on the basis that the effects of rt-PA are not instantaneous. With this
in mind, 12/20(60%) with mismatch had infarct growth (data missing for 2 patients)
following thrombolysis, 8/20 did not: 4/9(44%) without mismatch had infarct expansion
(data missing for 1 patient) with thrombolysis, 5/9 did not. Thus there was a similar odds
ratio for infarct expansion in the presence of mismatch with thrombolysis (OR 2.0, 95%
CI 0.37-10.9) as without thrombolysis. The wide confidence intervals include the
possibility of either reduction or increase in the risk of infarct expansion. The one paper
with clinical outcome data17 compared mismatch patients who received thrombolysis
with 16 historical controls with mismatch who did not receive thrombolysis (Table 3),
but such historical comparisons are prone to bias and unreliable. There are therefore no
meaningful data on clinical outcomes in patients with or without mismatch in the
presence of thrombolysis.
To account for missing follow-up scans, I calculated 'best' (assuming all the patients
with missing data did not have infarct expansion) and 'worse' (assuming all the patients
with missing data did have infarct expansion) case scenarios (Tables 3&4). In the best
case scenario, mismatch without thrombolysis was associated with a 14-fold increase in
the odds of infarct expansion (OR 14.4, 95% CI 2.5-83.2), and with thrombolysis was
associated with a two-fold increase in the odds of infarct expansion (OR 2.5, 95% CI
0.48-12.9). In the worst case scenario, mismatch without thrombolysis was associated
with a seven-fold increase in the risk of infarct expansion (OR 7.3, 95% CI 1.5-35.2) and
with thrombolysis was associated with a two-fold increase in the odds of infarct
expansion (OR 1.86, 95% CI 0.37-9.49). However, note that the marked change in odds
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Figure 2: Fate of the acute MR DWI lesion in patients with or without mismatch with or
without thrombolysis
□ Infarct expansion
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ratio when outcome changed for only a few patients, combined with the wide CI's,
indicates that these data, though promising, are unreliable and highly unstable and
require confirmation in large, methodologically sound studies.
2.2.3 Discussion
This review highlights the need for more data to confirm (and refine) or refute the
mismatch concept, and for standardisation of methods to assess mismatch and PWI
lesions. Despite more than 1500 papers (primary studies and review papers) reporting
some aspect of PWI/DWI mismatch, many advocating its use to identify 'tissue at risk',
at the end of it all, there is very limited evidence even to say whether patients with
mismatch have a different outcome from those without mismatch, or crucially whether
the presence of mismatch modified the effect of rt-PA. These data were very fragmented
and difficult to summarise. Indeed some might argue that I should have excluded even
more data, such as the study which performed MR DWI/PWI just after rt-PA. However,
I reasoned that others may have adopted the same approach without explicitly
mentioning it (based on personal communications from various stroke research groups),
and that this was a relatively minor flaw amongst many more fundamental ones. I
searched conference abstracts for usable data (or at least to identify studies that might
later appear in full publications). However, I found, as others in the Department who
work on systematic reviews of diagnostic tests, that conference abstracts did not provide
any usable data, either because numbers included were small or the abstract contained
insufficient methodological details to decide if they were eligible. I did not seek
additional unpublished infonnation from authors because I anticipated very little useful
additional information would be gained, and information in personal communications is
not peer-reviewed. Experience of gathering such extra data for systematic reviews of
trials show that it is a time-consuming and costly way to obtain data, which is often of
poor quality. Furthermore, it would not have helped to overcome such basic flaws in
study design as lack of blinding, small sample size and differences in outcome time and
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measures. The published literature is the accessible knowledge base; current opinion
should not be based on information which is absent from the published literature,
because unpublished information is not accessible to all in order to evaluate and form
their own opinion. The fact that I decided not to seek unpublished data is a limitation of
the study which I acknowledge. On the other hand this is the first attempt that has been
made to summarise these important but difficult data. This systematic review, despite its
limitations, is an important step forward in studying this area of mismatch and defining
how the methodology of such studies should be improved. Groups are currently using
mismatch as a criteria for entry into some clinical trials with no good evidence on which
to base this practice: this study at least starts to explore the problems associated with that
practice.
The inclusion criteria for the review included studies with > 20 patients because of the
well known problem of bias in smaller studies. Other criteria such as type and site of
arterial occlusion were outside the scope of this systematic review and therefore not
included. It was not possible to extract reliably any information on these points, and the
small samples precluded any meaningful subgroup analyses.
There was no consistency in the DWI and PWI imaging methods. Perfusion imaging
used different doses of contrast, different processing techniques, and measured different
parameters in different ways. It is unclear whether one should use complex and time-
consuming methods of analysis of PWT data incorporating the AIF (and if so which29)
or, as suggested recently, simpler semi-quantitative methods like Tmax-44
There was no consistency in the definition or measurement of mismatch. The five
definitions from the six research groups ranged from a PWI lesion>acute DWI
lesion35'36'42 to a PWI lesion 50% > acute DWI lesion.43 Two papers specified visual
35 36 39
inspection but the others measured lesion volume on a workstation. Few studies ' '
commented on the observer reliability of any of these PWI/DWI assessments. The
reliability of assessing the percentage of diffusion perfusion mismatch has to be
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addressed. One study has suggested that quantifying mismatch by the human eye is
reproducible but not reliable amongst observers.45 This does raise serious doubts over
whether mismatch should be used for clinical decision making in the acute setting where
rapid assessments need to be made.
Nonetheless, the pattern suggested by Figure 2 does indeed, rather tantalisingly, suggest
that mismatch patients are more likely than non mismatch patients to have infarct
growth, and that the proportion of patients with mismatch and subsequent infarct growth
may be reduced by thrombolysis. However, there are no data on functional outcome
(more relevant than radiological outcomes), and these data are not from randomised
comparisons, but from rather small observational studies of different patients with
widely differing definitions, sometimes with historical controls. What is clear is that
some patients without mismatch definitely get infarct growth, so the absence of
mismatch does not mean that there is no 'tissue at risk' of infarct growth. This suggests
little justification for excluding patients without mismatch either from routine acute
stroke treatments or possibly from trials. If the mismatch theory is correct, then there is
a need to gather more robust evidence to support its application to patient selection.
Alternatively, if the mismatch theory is not correct, i.e. that it does not identify a
subgroup of patients at high risk of infarct growth and poor outcome, this might explain
the failure of the recent DIAS 246 trial to show any benefit with desmoteplase.
In order to move forward, common standards and definitions for mismatch are needed.
One of the biggest problems was the failure to include patients without mismatch in
previous studies. Therefore a large randomised trial of thrombolysis against control in
patients with and without mismatch is needed to reliably determine if the degree of
mismatch really does influence response to thrombolytic treatment. The Echoplanar
Imaging Thrombolysis Evaluation (EPITHET)24 study has this design, although patients
are recruited on the basis of their CT appearance and not on the presence or absence of
MR mismatch, which may lead to an imbalance of patients with and without mismatch
in the treatment and control groups. EPITHET recruitment is now complete and the
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results are due to be presented in 2008 (S Davis, personal communication). The fact that
it has taken the EPITHET group around six years to randomise 120 patients indicates
that MR DWI/PWI may not be easy to apply in practice. Certainly, until there is better
evidence, patients without mismatch should probably not be denied any routine acute
treatments, because on current evidence about 50% will get infarct expansion which
might be prevented by acute treatments like thrombolysis. The lack of data
underpinning the mismatch theory should also be acknowledged in the design of any
future trials of novel therapeutic agents (e.g. new thrombolytic or neuroprotective
agents). In other words, it would be more informative to design trials which included
patients with and without mismatch, rather than simply restrict trial entry to those with
mismatch. The former design then enables the interaction between mismatch and
response to treatment to be assessed.
2.3 Summary
• Diffusion perfusion MRI might help identify patients with cerebral tissue at
risk of infarction, (even beyond the current three hour time window), thereby
avoiding thrombolysis in those with little chance of benefit.
• However, the literature concerning perfusion diffusion mismatch and
thrombolysis is limited and numbers very small, as demonstrated in the
systematic review performed.
• There is no consistent definition of mismatch in the current literature. In the
systematic review I performed there were five different definitions in six
research groups. There is clearly a need to standardise the definition.
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The systematic review highlighted the lack of consistency with perfusion
measurements. At least seven different measurements were used in the
papers meeting the criteria for the review. There is clearly a need for a
standard measure to be defined and accepted.
Almost none of the studies provided information on inter- and intraobserver
reliability of the measurement ofmismatch.
The data from the review suggested that mismatch (versus no mismatch)
without thrombolysis was associated with a non-significant two-fold increase
in the odds of infarct expansion (OR 2.2, 95% CI 0.34-14.1), which did not
change with thrombolysis (OR 2.0, 95% CI 0.37-10.9).
Half the patients without mismatch also had infarct growth.
There were no extractable data on functional outcome in the patients. This is
of utmost importance when assessing the benefit of any treatment.
Although perfusion diffusion imaging remains a promising technique in
selecting patients for thrombolysis, it needs to be studied further in
randomised controlled trials to ascertain if the degree ofmismatch really does
identify a group of patients who will respond differently to thrombolytic
treatment.
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3 The MR perfusion lesion - a comparison of different processing
methods and parameters
3.1 Introduction
As highlighted in chapter 2, some of the advanced MR imaging techniques are
promising, but need more data to support their use in routine clinical practice. Methods
of calculating MR parameters need to be standardised across the research community in
order that concepts, such as mismatch, can be considered as useful clinical tools in the
treatment of patients with acute stroke.
As the previous systematic review suggested, there are several different methods for
measuring the perfusion lesion. Different studies used different parameters, but no study
to date has compared all of the most commonly used methods in the same group of
patients. A recent systematic review looking specifically at different methods of
imaging cerebral blood flow (CBF), did not identify any reliable threshold for infarcted
and salvageable brain tissue.1 I therefore investigated the different methods of
calculating the perfusion lesion in each one to see how this influenced the degree of
mismatch present and whether one method of calculation correlated best with the
patient's clinical and radiological outcome.
3.2 Measuring the MR perfusion lesion
3.2.1 Background
The term 'perfusion' normally refers to the delivery of blood at the level of the
capillaries, where exchange of oxygen and nutrients between blood and tissue takes
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place. As indicated earlier neurological dysfunction occurs when the cerebral blood
flow falls below about 18-20 ml/lOOg of cerebral tissue per minute.3 At levels of
cerebral blood flow less than 10 ml/lOOg of tissue per minute rapid cell death occurs, but
between cerebral blood flows of 10 and 20mL/100g of tissue per minute there is the
potential for this tissue to be salvaged.4 However, as mentioned in Chapter 2, there is
some imprecision around the levels. This has led to research in stroke patients to try and
investigate areas of potentially viable tissue within an area of acute ischaemia, so these
can be targeted with agents (e.g. thrombolytics) that may reverse ischaemia and so have
the potential to improve patient outcome.
3.2.2 Perfusion measurements researched to date
There are two types of perfusion MR: a) the first pass bolus tracking technique dynamic
susceptibility contrast (DSC) imaging and b) the arterial spin labelling technique
(ASL).5 The DSC method is generally used in acute stroke patients because imaging
time is shorter than with arterial spin labelling and ASL requires considerable patient
cooperation. To obtain the images a bolus of contrast (usually gadolinium based) is
injected by a power injector into the vein in the antecubital fossa. Once the contrast
reaches the brain the MRI signal drops, and then returns to normal as the contrast is
washed out. The raw signal-time curve6 (Figure 1) of perfusion data obtained from all
MRI machines is essentially the same but once these data have been obtained they may
then be analysed in several different ways to yield relative or quantitative values2'7
(Figure 2, Table 1). These post processed values vary markedly between imaging
centres because of the use of different processing methods. Relative values require less
complex data processing and are often immediately accessible from the scanner console
(e.g. time to peak, TTP, full width half maximum, FWHM). However, relative
measurements do not usually take account of the arterial input function (AIF), which
may introduce large errors.8"10 Quantitative perfusion parameters, which overcome some
but not all3'11 of the limitations of relative parameters, can be calculated (e.g.
12
quantitative cerebral blood flow, qCBF, or cerebral blood volume CBV) but this
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Figure 1: The raw signal time curve
►
time
An example of the raw signal-time curve perfusion data obtained when performing PWI
using the bolus tracking technique (DSC). A contrast is injected intravenously during
the acquisition ofseries of images, with the MR1 signal dropping as the contrast reaches
the brain. Once obtained, this data can be processed in a number ofways.6
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Figure 2: Contrast time curve
Time (s)
The raw signal-time curve data (Figure1) are converted to a contrast-time curve (Figure
2), with concentration in arbitrary units (AU). Different parameters are used to estimate
perfusion. Full width halfmaximum (FWHM); 1st Moment= 'Balancing point' of curve
along the time axis; Cmax=Maximum concentration value (also known as Peak Height);
Time to peak (TTP)=Time from arrival of contrast to Cmax (also known as Tmax after
deconvolution); BAT = bolus arrival time; AUC=Area under curve. (Figure prepared
by Dr T Carpenter, University ofEdinburgh).
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requires off line processing including deconvolution, and the perfusion image takes
longer to produce.3 In the case of quantitative perfusion measurements a measure of the
arterial input function (AIF) is necessary in order to perform the deconvolution of the
concentration time curve of contrast agent within the tissue, C(t) using the equation first
mentioned in the introduction i.e.
C(t) = p/KH (CBF) . (Ca(t) x R(t))
From a mathematical point of view deconvolution is an algorithm based process used to
reverse the effects of convolution on the recorded data. This is a concept widely used in
image processing. One approach uses the singular value decomposition method (SVD)
to perform the deconvolution but this does not account for the time delay between the
AIF and tissue concentration time curves. One way to overcome this is to fit gamma
variate functions which allows the arrival time of the bolus of contrast to be identified
and so the delay is removed prior to SVD deconvolution, giving more accurate perfusion
parameters.
A recent summary of the literature and survey of centres with an interest in stroke
imaging indicated that different PWI parameters were used in different centres,
underlying the problem of lack of standardisation identified in Chapter 2.13 PWI lesions
which reflect CBF are generally smaller than those which reflect mean transit time
(MTT),14-18 and even different ways of estimating a single PWI parameter like MTT
may yield different-sized PWI lesions.19 Some authors have compared the ability of
various different relative and/or quantitative PWI lesions to predict infarct growth but
with differing results,19-21 possibly due to differences in patient case mix, or timing of
scanning as well as to variations in the combinations of PWI processing methods used.
No studies have compared all the potential quantitative and relative PWI parameters.
Thus there is no clear consensus on which PWI parameter should be used; different PWI
lesions yield different estimates of the extent of DWI/PWI mismatch; and so variation in
estimates of potentially salvageable tissue. I therefore undertook this comparison.
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3.3 Comparison of ten different MR perfusion imaging processing
methods in acute ischaemic stroke: effect on lesion size and the
proportion of patients with diffusion perfusion mismatch
3.3.1 Methods
Patients
We recruited patients presenting with their first ever acute ischaemic stroke. Patients
were imaged as soon after stroke onset as possible, and within an absolute maximum of
twenty four hours. A trained stroke physician assessed all patients as soon as possible
and assigned a stroke subtype according to the Oxfordshire Community Stroke Project
(OCSP) classification.22 We included all ischaemic stroke subtypes.
Image acquisition
We performed all imaging on a GE Signa LX 1.5 T (General Electric, Milwaukee)
magnetic resonance imaging (MRI) scanner with a birdcage quadrature coil with a
standardised protocol for acute stroke previously described.16 The spin-echo echo-planar
imaging (EPI) diffusion-tensor axial sequences with six gradient directions and dynamic
susceptibility contrast EPI perfusion-weighted imaging both had 15 axial slices each of
5mm thickness with an interslice gap of 1mm, the imaging matrix was 128 x 128
encompassing a 240 x 240 mm field of view. Additionally for PWI, a gadolinium-based
contrast agent (Gadovist 1M solution 10 ml or Omniscan 0.5 M solution 20 ml) was
injected with imaging starting 10 seconds after the start of contrast injection, continuing
over a period of 85 seconds, collecting thirty four volumes of 15 axial slices with TE of
30 ms and TR of 2.5 s.
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Image processing
We performed all image processing blind to the clinical and any other imaging data. We
co-registered the individual DWI and PWI data using open access software FLIRT
(www.fmrib.ox.ac.uk/fsl). We obtained the volumes of the DWI lesions by manual
tracing round the edge of the hyperintense lesion on a workstation as described
previously.16 Note, as with PWI, the raw data obtained across different MRI machines
are similar assuming the same number of gradient directions (e.g. 6 in this case) are kept
the same. There is interest in testing different diffusion sensitisation values (Bo, Bioo)
but most centres use parameters as supplied by the manufacturer for clinical imaging.
The gradient directions would be the minimum. There is likely to be more variation in
the measurement of the DWI lesion itself depending on how this is performed in a
particular centre and whether the 'apparent diffusion coefficient' (ADC) map, and if so
what threshold, is used or the DWI lesion. We chose to use the DWI lesion as there is
no consensus on which ADC threshold should be used. All thresholds miss ischaemic
tissue and erroneously include normal brain in the lesion and it is hard to appreciate a
dark lesion on a dark background. In addition it is the DWI lesion that is routinely
looked at clinically.23
We produced the perfusion-weighted images as follows. The first acquisition volume
was discarded (as is standard), and the remaining signal time course in each voxel
(Figure 1) was converted to a concentration time curve (Figure 2). We fitted a gamma
variate function to the concentration data in every voxel which showed enhancement
greater than 3x above the standard deviation (SD) of the pre-contrast points. Voxels not
meeting the >3x SD criterion were given a negative value in the perfusion maps,
representing either CSF or other tissue not accessible to contrast (e.g. centre of infarct)
and were excluded unless a lesion volume completely encircled negative voxels, in
which case these voxels were included in the calculation of the lesion volume. The
anatomical distribution of negative voxels was visible to the observer so as to be able to
include/exclude those within the infarct and those in the CSF (e.g. ventricles)
respectively.
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We defined the arterial input function (AIF) from the fitted data by averaging the
concentration time data from voxels corresponding to the lumena of both internal carotid
arteries (ICA) on the first volume of the registered data (to limit effects of any carotid
stenosis). We chose this approach for several reasons: to be more relevant to an acute
situation where the only knowledge of infarct location (prior to DWI/PWI data
processing) may come from symptoms; to characterise brain blood supply as a global
'normalising' factor (the ICAs being prior to the Circle of Willis represent the available
blood supply less the contribution from the basilar artery); and lastly because the ICAs
are aligned perpendicular to the plane of imaging and hence avoid problems associated
with partial volume. Care was taken to ensure the regions drawn within the ICA
corresponded to the lumen (2 or 3 voxels per vessel).
We calculated maps of relative cerebral blood volume (rCBV), relative mean transit time
(rMTT), relative cerebral blood flow (rCBF), the arrival time fitted (ATF), peak time
fitted (PTF), and the time to peak (TTP), the full width half maximum (FWHM) of the
concentration time curve and the maximum value of the fitted concentration time curve
(Cmax). We normalized the parameter value in each voxel by the sample mean of the
parameter value in the voxels used to define the AIF. Normalising the rCBV value by
the rCBV sample mean of the voxels used to define the AIF results in the quantitative
CBV (qCBV) hence this parameter is not mentioned below. We produced maps of
quantitative cerebral blood flow and mean transit time (qCBF and qMTT respectively)
by deconvolving the peak voxel concentration time curves with the concentration time
curve of the AIF to obtain a scaled estimate of the voxel residue response.12,24 The
deconvolution was performed by singular value decomposition (SVD),11,23 with the
addition of a block-circulant discretion scheme to remove the dependency upon arrival
time in the calculated qMTT maps. We did not cross-calibrate the PWI data with an
assumed value for CBF for normal white matter, or use the patient's white matter to
provide an assumed normal value, as in this older patient population, the white matter is
unlikely to be standard. Note the routine use of an assumed normal CBF value for white
matter derived from young normal people is likely to be another source of variation and
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bias in previous studies. We then scaled the individual perfusion maps at a constant
level chosen to encompass the range of parameter values across all the subjects, to give a
consistent image presentation across all subjects. The thresholded maps (Figure 3) were
then converted to Analyze™ format for measurement of perfusion lesion volumes.
The flow diagram (Figure 4) shows the process by which the PWI images were
processed and analysed. We printed in colour each PWI parameter map (all 15 slices)
on a separate page. These images were presented to the neuroradiologist in batches i.e.
all MTT, followed by all ATF so that each PWI parameter for each patient was
interpreted blind to the appearance of the other PWI parameters for that patient. The
neuroradiologist, blind to all clinical, other imaging and other PWI data, provided an
initial rough outline of the lesion by identifying areas of altered signal from the
perfusion distribution, taking account particularly of any differences between the two
hemispheres. This was to guide the researcher (Dr I Kane, not a neuroradiologist) when
doing detailed tracing of the images in the Analyze™ software. The indication of the
lesion by the neuroradiologist was also included to mimic the process of identifying a
perfusion deficit in the acute situation where there would be little time for image
analysis. I then outlined the lesion outline on the electronic Analyze™ format images
using Analyze™ version 7.8 to derive PWI lesion volumes by counting the number of
voxels within the defined region on each slice on which the lesion was visible. The DWI
lesion volumes were traced separately using a similar approach whereby the
neuroradiologist outlined the lesion roughly on a printed image and an observer then did
detailed tracing of the image in Analyze™ on a workstation. We defined the DWI/PWI
mismatch as the acute PWI lesion volume minus the acute DWI lesion volume,
calculated from the DWI and PWI electronic values.
Statistical analysis
The data were not normally distributed (Kolmogorov-Smirnov test). I compared the
median PWI lesion volumes and the PWI/DWI mismatch volumes produced by the ten
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related measurements. I compared the proportion of patients with or without DWI/PWI
mismatch by each PWI processing method using the Chi-Square test. All analyses were
performed in SPSS version 13 for Windows.
3.3.2 Results
A total of 32 patients were recruited into the study (Table 2). Of those, 13 were female
and 19 male, with a mean age of 70 years (range 36-93). The median time to MR was
7.27 hours. The time to imaging was less than six hours from symptom onset in 12/32
(38%), 6-12 hours in 8 (25%) and between 12 and 24 hours in 12 (37%).
The PWI lesion size varied markedly with the method of calculating the PWI lesion
(Table 3, Figure 2). The median PWI lesion volume varied significantly from 0 voxels
(Cmax, rCBF, CBV) to 14,882 voxels (TTP) (Friedman test 121.5, p<0.0001). In
general, the measurements reflecting MTT (e.g. TTP and PTF) produced larger PWI
lesions whilst the measures of CBF gave smaller lesion volumes, with CBV giving the
smallest PWI lesions (Table 3). The number of patients with no PWI lesion by at least
one method (Table 3) varied from 7/32 (22%, rMTT, FWHM, PTF) to 19/32 (59%,
CBV) (Chi-Square p<0.001). As a consequence of the variation in PWI lesion size, the
median volume of mismatch tissue varied from zero (actually minus 1849 voxels, CBV)
to the smallest positive value of 715 voxels (ATF) to the largest of 9684 voxels (rMTT)
(Friedman test 123.8, p<0.0001). Four of the perfusion parameters (CBV, rCBF, qCBF
and Cmax ) had negative median mismatch values because the median DWI lesion was
larger than the PWI lesion. The proportion of patients with mismatch varied




Different PWI parameters produce very different estimates of the extent of abnormal
perfusion, and hence very different estimates of the volume of "tissue at risk". For
example, if only patients with DWI/PWI mismatch were to receive thrombolysis, then
selection based on time to peak (TTP) would result in 20/32 (63%) patients receiving
treatment, whereas selection on Cmax would result in only 7/32 (22%) patients being
treated. Such a variation is not acceptable if PWI is to be used to guide treatment in
routine clinical practice. However, despite this major limitation, both of these
parameters are commonly quoted in the literature, and separate experts have
recommended their use.
Non-quantitative PWI parameters have the advantage that they are quick to measure on
the scanner console, but may introduce unacceptable variability between patients.
Quantitative PWI parameters reduce the difference in lesion volume between the PWI
parameters, but would still result in discrepancies in the number of patients treated:
18/32 (56%) with qMTT, 13/32 (41%) with qCBF, and 3/32 (9%) with qCBV.
Furthermore, complex and time-consuming off-line processing is needed to produce
perfusion parameter maps. There were even differences between calculated parameters
which purport to reflect only MTT function or only CBF function. For example, with
relative CBF, 5/32 (16%) of patients had mismatch and with qCBF 13/32 (41%) patients
had mismatch; with any of the relative MTT measures, 18/32 to 23/32 (56-72%) had
mismatch and with qMTT 18/32 (56%) had mismatch.
These results are in agreement with other studies which compared fewer PWI lesions
derived by processing the raw data in different ways. We compared a wider range of
relative and quantitative parameters, and also determined the effect on PWI lesion
volume and mismatch. The maximum PWI parameters compared in previous studies
were nine,20 six,14 four19 21 and three,15'18 but these studies did not quantify the difference
in visible lesion volume or the impact of that difference on DWI/PWI mismatch. Instead,
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previous studies focussed predominantly on determining perfusion values in different
parts of the ischaemic lesion (e.g. in mismatch, DWI-abnormal, or final infarct tissue) in
an attempt to define thresholds for tissue recovery.
In this study we used visual assessment of the PWI lesions, where a focal abnormality
was carefully sought by the observer by comparing mirror image regions of the cerebral
hemispheres, because visual assessment is the fastest method for detecting the acute
lesion in the clinical setting. Cross calibration (scaling to a fixed value of presumed
normal white matter) was not used in this study so as to preserve information in the
perfusion maps about the underlying perfusion status of all tissues. While scaling to
white matter may allow the different PWI parameter images to be scaled directly into the
same windowing, in the population that is typically affected by stroke, the white matter
is often not normal, so applying an arbitrary scaling factor might not improve image
accuracy or interpretability. In addition, this may skew the scaling of some parameters
so as to actually reduce the visibility of some lesions. Instead, we normalised the
individual perfusion parameter maps to the average value of that parameter in the region
used to define the arterial input function (AIF). This approach was taken because the
underlying model commonly applied to perfusion (convolution of an AIF with a kernel,
the basis of the quantitative processing methodology) indicates that properties of the AIF
(e.g. maximum contrast value, area under curve) are linearly associated with the
corresponding quantities in the tissue, Cmax, rCBV, etc. Hence, normalisation by the
average parameter value within the AIF region of interest reduces variation in the
calculated relative perfusion parameters (resulting from the differing arrival rate of
contrast in the brain between patients), and hence is preferable to scaling to presumed
normal white matter.
I have not attempted to identify perfusion thresholds in the present work. The more
important first step was to define the visual differences resulting from applying different
PWI processing methods. I used manual tracing of the PWI lesion volume not
thresholding or automated lesion edge detection, because it is unclear what, if any,
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threshold should be used. None of the previous studies identified a consistent or reliable
threshold, nor was any consistent threshold identified in a recent systematic review of all
human perfusion imaging modalities.25 The failure thus far to identify a consistent
human threshold for salvageable/unsalvageable tissue may simply reflect, amongst other
factors, the wide variation in apparent perfusion abnormality produced simply by
processing the enhancement/time curve in different ways, as shown here. Individual
differences between patients e.g. due to age, time from stroke to imaging, may also be
major factors, though have yet to be fully explored. As large differences in perfusion
lesion volume can be produced when the same middle cerebral artery occlusion model is
applied under identical experimental conditions in two different genetic strains of
laboratory rat (Sprague-Dawley and Wistar-Kyoto),26 there is clearly a need for more
research into reasons or differences between individuals in their response to apparently
similar arterial occlusions.
Which perfusion data processing method is best? Some PWI lesions overestimate tissue
at risk and others probably underestimate it. The ideal test for detecting abnormal
perfusion should be: quick to acquire and process (necessary in an acute setting);
produce a reliable image of abnormal perfusion (i.e. the same image even when
processed by different operators); and show a clinically-relevant relationship with a
clinical outcome (and not merely some radiological surrogate). We have not evaluated
the effect of having different operators process the PWI data (all data were processed by
one observer to produce the PWI images); neither has anyone else. Nor have we, or
others, determined the inter- or intra-observer variability of measuring PWI lesion
volume (all PWI lesions were measured once by the same person). These would be other
factors that would need to be assessed if PWI were to become an essential tool on which
to base treatment decisions. In the next section I will discuss further aspects of the
above work, paying particular attention to the relationship between the perfusion lesion
and clinical scores and radiological outcome.
Ill
3.4 Comparison of ten different MR perfusion imaging processing
methods in acute ischaemic stroke: relationship between clinical
scores and radiological outcome
3.4.1 Background
The size of the PWI lesion depends on the method used for calculation. It therefore
seems likely that the method used will also affect the relationship between the PWI (or
DWI/PWI mismatch) lesion presence or size and the neurological severity of the stroke
at baseline. The penumbral tissue will contribute to the patient's neurological deficit (by
definition), so knowing which PWI baseline lesion is most closely associated with the
neurological score would be useful to identify which PWI lesion most closely identifies
the 'shut down' but potentially still viable tissue. Several studies have reported
correlations between perfusion parameters and stroke severity at presentation; two27'28
reported that time to peak (TTP, a relative measure of MTT), correlated with baseline
NIHSS; two17'29 suggested a correlation between qMTT (quantitative) and baseline
NIHSS; and one30 suggested a correlation between qMTT and the Scandinavian Stroke
Scale (SSS). No study examined the full range of PWI lesions and stroke severity.
If baseline imaging features are to guide the use of thrombolysis in practice or as a
research tool, then it is important to know which baseline PWI lesion(s) best relates to
final infarct extent and clinical functional outcome. The measures which predict these
two outcomes may be different and may be different to the PWI lesions that correlate
with the baseline neurological deficit. Although several studies have examined
relationships between PWI lesions in the acute phase and later radiological outcomes,
most have used very early timepoints (between 24hrs and about 1 week after stroke) to
70 3 1
determine the 'final' infarct extent, which is too early to be 'final'. ' Three studies
that examined later timepoints only compared perfusion values, not lesion extent, but
found associations between measures of MTT and 60 or 90 day infarct size measured
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with T2 MR.'7'28,32 A correlation between the acute PWI lesion and functional clinical
outcome was found between TTP and mRS,28 rMTT and mRS,33 and qMTT and Barthel
Index (BI).30 No studies examined a full range of PWI lesions.
I therefore explored the association between ten different MR PWI parameters and the
National Institutes of Neurological Disorders and Stroke (NIHSS) score on admission,
the Rankin score (mRS) at three months after stroke, the final infarct size on T2-
weighted imaging obtained at least one month after stroke, and infarct growth between
baseline and final T2-weighted imaging.
3.4.2 Methods
Patients
We recruited patients presenting with their first ever acute ischaemic stroke as detailed
in section 3.3 of this chapter. A trained stroke physician assessed all patients and
assigned a stroke subtype according to the Oxfordshire Community Stroke Project
(OCSP) classification,22 and determined the stroke severity using the NIHSS. We
measured functional outcome at three months using the mRS, assessed blind to baseline
features and imaging.
Image acquisition and processing
We performed diffusion and perfusion weighted imaging as soon as possible after
admission within a maximum of 24 hours of stroke onset (as detailed in section 3.3.1
p97), and final follow up T2-weighted imaging at > 1 month. The final T2-weighted
lesion volume was measured by the neuroradiologist on a workstation in Analyze™
blind to other imaging and clinical data. For the purpose of this study, we defined
infarct expansion as any increase in size from the acute DWI lesion to the final T2 lesion
and the degree of mismatch (DWI/PWI) as the baseline PWI lesion volume minus the
baseline DWI lesion volume.
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Statistical analysis
The data were not normally distributed (Kolmogorov-Smirnov test). Therefore to look
for any relationship between the various PWI methods, clinical scores and radiological
outcome, we compared the different PWI volumes with the DWI lesion volume, the
NIHSS at baseline, T2-weighted imaging final infarct volume and functional outcome
(mRS) at three months with linear regression. We took each PWI parameter in turn as
the dependent variable and the DWI lesion volume, NIHSS, T2-weighted final infarct
volume and mRS as the independent variables. We transformed the PWI lesion volume
data by taking the cube root to minimize the effect of outliers. We used Fisher's exact
test to investigate any correlation between the presence or absence of mismatch at
baseline and the presence or absence of infarct expansion on the final T2 image. All
analyses were performed in SPSS version 13 for Windows.
3.4.3 Results
There were 32 patients into the study as detailed in section 3.3.2 (p 100). Only one PWI
measure (Table 4) was associated with both baseline clinical severity (NIHSS) and
clinical outcome (mRS at 3 months); ATF regression slope 0.209 (p=0.006) and 0.049
(p=0.035) respectively. No other PWI measures were associated with clinical outcome
although p values for PTF, TTP and rMTT nearly reached significance.
Four other PWI measures (Table 4) were associated with baseline NIHSS (numbers
indicate slope of regression line): PTF 0.210 (p=0.005), TTP 0.193 (p=0.006), FWHM
0.180 (p=0.006), and rMTT 0.206 (p=0.005). All were relative measures ofMTT.
Eight PWI measures (Table 5) were associated with radiological outcome (final T2
infarct size), of which the four reflecting MTT reached greater significance (regression
slopes were: ATF 0.330 p=0.002, PTF 0.292 p=0.007, TTP 0.286 p=0.004, and rMTT
0.303 p=0.004). Four others, one which reflected MTT (FWHM 0.214 p=0.025), two
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reflecting CBF (rCBF 0.324 p=0.036, qCBF 0.236 p=0.025) and one which reflected
cerebral blood volume (CBV 0.392 p=0.032) achieved lesser significance.
Figure 3 shows the variation in the median PWI volumes and the median acute DWI and
final T2 lesion volumes.
There was no significant relationship between the presence or absence of mismatch at
baseline and infarct expansion at >1 month for any of the ten PWI parameters using
Fisher's exact test (all p values were greater than 0.183).
3.4.4 Discussion
Five MR perfusion parameters reflecting MTT were associated with clinical scores of
acute stroke severity and one, also reflecting MTT, with functional outcome. These
overlapped with perfusion parameters that were associated with final T2 lesion volume,
although the PWI lesions that reflected MTT in general produced stronger associations
than did those reflecting CBF or CBV. Our results are in agreement with previous work
that found both TTP and qMTT correlated with baseline NIHSS.15'25"27 However, we
also demonstrated that in this series ATF, PTF, FWHM, rMTT and rCBF were
associated with baseline stroke severity measured with NIHSS.
One of the perfusion parameters (ATF) was also associated with functional neurological
outcome at three months, although three other perfusion parameters achieved very weak
associations with p values bordering on significant (PTF, TTP, and rMTT). All four are
relative measures of MTT. These results differed from those of some28 and supported
others.33 In summary, the results suggest that, in general, relative measures of MTT
correlate with both baseline stroke severity and clinical functional outcome. These are
relatively quick to perform and easy to obtain (no deconvolution required) and therefore
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The variation in the median size (voxels) for all 32 patients of the perfusion lesion
measured by 10 different PWI processing methods. The median baseline DWI (DWI
acute) and final infarct extent (T2- final) lesion volumes are also indicated. Note the
median lesion volumes for Cmax, rCBF, qCBF and CBV were zero due to the large
proportion ofpatients with no visible PWI lesion.
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A wider range of acute PWI parameters were associated with the final T2 infarct extent
in this patient group, with ATF, PTF, TTP and rMTT being most closely associated and
FWHM, rCBF, qCBF and CBV achieving less strong significance. Note that these latter
(apart from FWHM) tend to produce smaller PWI lesions. However, how useful are the
acute PWI parameters that reflect final T2 lesion extent in clinical practice? The most
important outcomes are those that define the patient's functional status. Recent data
suggest that the final T2 lesion extent does not reflect the total damage within the brain
from the stroke. There may be histological evidence of damage outside the T2-visible
lesion, including tissue inflammation and selective neuronal damage.34'35 It may be that
the total area of damage is greater than just that in the T2-visible lesion and includes
tissue which fell within the acute MTT lesion. This might explain why, in this study, the
correlations between baseline PWI lesion and functional outcome were strongest for
relative MTT measures (i.e. large PWI lesions).
The present analysis included all patients, whether or not there was a detectable PWI
lesion present, so as to be able to determine the relative predictive values of the different
PWI processing methods, including those which less frequently produce a PWI lesion. I
did not use an explicit correction for multiple comparisons, but the effect of doing so can
be seen by ignoring any p values in Tables 3 and 4 which are larger than 0.01. It was not
clear in other publications whether or not all patients, or just those with visible PWI
lesions, had been included, which may explain some discrepancies between studies. The
considerable variation in the presence of a PWI lesion would cause substantial variation
in the recruitment to clinical trials if DWI/PWI mismatch were used as an entry
criterion. Excluding patients without PWI lesions would result in a very skewed
comparison - for example in our series, some PWI parameters (e.g. TTP) might
contribute 23/32 patients whereas others like rCBF or CBV might only contribute 15/32
or even 13/32 and this again might explain differences between studies. Excluding
patients without PWI lesions would provide no information on the clinical relevance of
an examination that did not show a PWI lesion. In the acute situation, with limited time
for multiple post processing attempts, one needs to use the PWI parameter which is most
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likely to inform decision-making - choosing a PWI parameter that has a high probability
of NOT producing a visible lesion combined with not knowing what the absence of a
lesion means, is unlikely to be a helpful test.
Note: At the time ofwriting, an attempt to establish a consortium to agree the minimum
standards for MR image acquisition and processing is being established - the group first
met in September 2007 and are due to meet again in February 2008. A paper describing
this process has been submitted to Stroke.
3.5 Summary
• There are a number of different ways of measuring the MR perfusion lesion;
all ofwhich require varying degrees of post processing.
• To date there is no consensus in the literature regarding the 'best' method for
measuring the perfusion lesion in the clinical setting.
• The data from our study confirm that the size of the perfusion lesion varies
markedly depending on the method used to measure it. This in turn impacts
on the size of the so called perfusion diffusion mismatch, resulting in
between 9% and 72% of patients having mismatch in our study.
• If treatment decisions for thrombolysis are based on a particular degree of
mismatch, the number of patients treated would vary by an unacceptable
level depending on the perfusion measurement.
• If trials recruited patients on the basis of mismatch then it could result in
substantial variation in treatment rates.
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Relative perfusion methods, although quick, may produce unacceptable
variability amongst patients.
Quantitative PWI measures require more time consuming post processing,
but reduce the difference in lesion volume between the PWI parameters.
In this study five measures of rMTT were associated with the baseline
NIHSS, one of which was also associated with clinical outcome.
Final infarct size was most strongly associated with measures of rMTT and
less strongly with CBF or CBV.
No relationship was demonstrated between the presence/absence of mismatch
at baseline and infarct expansion at > 1 month, in broad agreement with data
from the systematic review (Chapter 2).
In summary, relative measures of MTT, which are quick to perform and are
associated with stroke severity and functional outcome, may be more useful
than PWI parameters that relate closely to radiological surrogates.
There is an urgent need for standardisation of methods for processing
perfusion data across the research community and amongst any clinical users
of these techniques.
Inter- and intra-observer reliability needs to be investigated further if PWI
were to become an essential tool on which to base treatment decisions.
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Table 1: Ten different PWI parameters, relative and quantitative estimates of CBF,






MTT : relative Estimated delay in arrival of contrast in a voxel
obtained from the curve fitting procedure
Peak time fitted
(PTF)
MTT : relative Estimate of the time of maximum contrast
concentration obtained from the fitted
parameters
Time to peak (TTP) MTT : relative Peak time fitted minus arrival time fitted
Full width half
maximum (FWHM)
MTT : relative Width of the concentration/time curve at the
point halfway to the peak concentration
First moment
(rMTT)
MTT : relative First moment of the concentration time curve
Peak concentration
(Cmax)
CBF and MTT :
relative


















CBV : relative or
quantitative
Area under the concentration-time curve
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Table 2: Summary of characteristics of patients recruited
Men 19
Women 13
Mean age 70.4 years (range 36-93)
Mean time to MR 7.27 hours (range 1.36-23.34)
Mean baseline NIHSS 9 (range 0-25)
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Table 4: Association between perfusion method, baseline clinical score (NIHSS) and
functional outcome at 3 months (mRS). Significant associations highlighted in bold.
Perfusion method
Slope of linear regression







Arrival time fitted (ATF) 0.209 (0.006) 0.049 (0.035)
Peak time fitted (PTF) 0.210 (0.005) 0.042 (0.068)
Time to peak (TTP) 0.193 (0.006) 0.040 (0.066)
Full width half maximum (FWHM) 0.180 (0.006) 0.021 (0.313)
First moment (rMTT) 0.206 (0.005) 0.042 (0.067)
Peak concentration (Cmax) 0.147 (0.133) 0.018 (0.549)
Relative cerebral blood flow (rCBF) 0.206 (0.057) 0.035 (0.285)
Quantitative mean transit time (qMTT) 0.050 (0.456) 0.017 (0.407)
Quantitative cerebral blood flow (qCBF) 0.098 (0.195) 0.029 (0.202)
Cerebral blood volume (CBV) 0.236 (0.066) 0.042 (0.278)
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Table 5: Association between perfusion method and final infarct extent on T2-weighted
MR imaging (> 1 month after symptom onset). Significant associations highlighted in
bold.
Perfusion method
Slope of linear regression line
with final infarct size
> 1 month (p value)
Arrival time fitted (ATF) 0.330 (0.002)
Peak time fitted (PTF) 0.292 (0.007)
Time to peak (TTP) 0.286 (0.004)
Full width half maximum (FWHM) 0.214 (0.025)
First moment (rMTT) 0.303 (0.004)
Peak concentration (CMAX) 0.263 (0.059)
Relative cerebral blood flow (rCBF) 0.324 (0.036)
Quantitative mean transit time (qMTT) 0.162 (0.089)
Quantitative cerebral blood flow (qCBF) 0.236 (0.025)
Cerebral blood volume (CBV) 0.392 (0.032)
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4 The practicalities of MR as an imaging modality in acute stroke
4.1 Feasibility of a simplified MR imaging protocol for patients with
acute ischaemic stroke
4.1.1 Introduction
The most promising treatment for acute ischaemic stroke, in patients who present within
three hours, is thrombolysis with recombinant tissue plasminogen activator, rt-PA.
Currently rt-PA is licensed for use in patients with acute ischaemic stroke who meet
strict eligibility criteria. It is not known which brain imaging method best identifies the
patients that are most likely to benefit from (or be harmed by) thrombolysis, as has been
discussed in earlier chapters of this thesis. CT scanning is widely available and quick to
perform, but might not be sufficiently sensitive to tissue changes that could indicate
either a greater chance of benefit or greater susceptibility to haemorrhage.
MR DWI is very sensitive to early ischaemic damage.1 MR PWI demonstrates blood
flow in and around the infarct.2 Areas where there is 'mismatch' with evidence of
perfusion deficit without tissue damage may be the area of the brain (i.e. the
'penumbra') likely to be 'salvaged' by reperfusion therapy3'4 but as the systematic
review in Chapter 2 revealed there is a paucity of data supporting this theory. There was
no evidence that mismatch predicted clinical or tissue outcome or that it influenced the
response of an individual to thrombolysis.
Perhaps other features of the DWI lesion need to be considered, e.g. degree of
hyperintensity (whiteness) and 'haziness' of the lesion edge, might be important
determinants of tissue injury. Magnetic resonance angiography (MRA) may also help -
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perhaps patients with a still-occluded major artery without much evidence of tissue
damage on DWI will benefit most from rt-PA. MR imaging might help identify
potential hazards in other ways. Microhaemorrhages (tiny areas of old asymptomatic
haemorrhage) increase with age, are associated with periventricular white matter
hyperintensities on T2 MR and may5 or may not6 be associated with a higher risk of
bleeding with rt-PA.
The Third International Stroke Trial (IST-3) is evaluating the safety and efficacy of rt-
PA in a wider variety of patients than is covered by the current licence. To enable as
many centres as possible to randomise patients as quickly as possible, CT scanning is the
specified pre-randomisation imaging technique. However, many sites are interested in
evaluating MR PWI/DWI imaging for patient selection.
Thus, we needed to develop and test the methodology for a simple and efficient MR
PWI/DWI protocol that yields sufficient information to improve patient selection, yet is
not unduly time consuming or hazardous.7 This protocol could then be employed in
centres participating in IST-3 that have MR facilities. The MR would be performed
after CT scanning but before randomisation. The data would then allow an assessment
of the influence of mismatch and other MR features on the response to thrombolysis, in
a prospective study, with appropriate randomised controls. If the MR imaging protocol
we developed proved to be feasible in a multicentre study, and if the results were shown
to be useful in clinical practice, it could be adopted widely.
Prior to setting up the pilot study, 198 patients had been randomised into IST-3 (42 at
the Western General Hospital, Edinburgh). An interim analysis of 60 patients with
baseline PWI/DWI imaging in an observational study of the pathophysiological changes
following acute ischaemic stroke on PWI/DWI imaging at the Western General
Hospital, showed no association between the presence of a PWI/DWI mismatch (mean
transit time - MTT or cerebral blood flow - CBF) and 3 month clinical outcome in
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perfusion parameters had more rapid "normalization" of DWI changes.9 Previous work
in the Division of Clinical Neurosciences, Edinburgh and elsewhere, showed that
spontaneous reperfusion of the infarct is associated with improved clinical outcome.10
Whilst the influence these imaging features have on prognosis is of interest, the key
question is whether there is a significant interaction with the treatment effect of rt-PA.
This can only be studied in a randomised controlled trial, where the relevant MR
parameters are measured before randomisation.
We therefore aimed to develop and test a short, simple streamlined MR protocol that
could be widely adopted in centres participating in a randomised controlled trial of
thrombolysis (IST-3). These data would then provide reliable evidence about which MR
sequences were the most useful for identifying which patients were most likely to
benefit from or be harmed by thrombolysis.
Research questions to be asked and hypotheses to be tested
The key hypothesis for a large-scale study is that MR imaging will help select those
patients with acute ischaemic stroke who will benefit most from rt-PA. The ultimate
aim of a sub-study of IST-3 is to address the following questions:
• Can routine MR be made more rapid, practical and safe in acute stroke?
• Does ischaemic lesion appearance on DWI (extent, intensity, or clarity) predict
the amount of non-salvageable tissue?
• Is the benefit of rt-PA confined to those with a PWI lesion larger than the DWI
lesion (DWI/PWI mismatch) or do those without mismatch benefit as well?
• Are patients with white matter hyperintensities or microhaemorrhages at greater
risk of intracranial haemorrhage after rt-PA than those without?
• How do CT scan 'early infarct signs' and white matter hypodensities relate to
MR 'early infarct signs' and white matter hyperintensities?
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To answer these questions a multicentre study is required in order to attain a large
enough sample. Therefore the research question concerning the pilot study was, in the
context of IST-3, 'is it feasible to run an MR imaging sub-study at the Western General
Hospital aiming to improve the safety of thrombolysis?' As this was outside the funding
originally available for IST-3, I prepared and submitted a small project grant application
(£15,000) to the Chief Scientist's Office to obtain funding for scans and various
assessments of imaging (see Appendix 7).
4.1.2 Methods
Selection of MR sequences
We considered all of the MR sequences that might be included in the protocol,
information that might be gleaned from each, and the implications for scanning time,
requirement for post-processing, overall cost and feasibility. Then, by a process of
discussion, sought to select the best scanning sequence to: limit scanning time, ensure
that the sequences could be run on a wide variety of MR machines, ensure adequate data
were collected to investigate mismatch, without undue cost or risk to the patient. During
this process we also discussed potential MR sequences with IST-3 centres in Sweden
(including one visit from Stockholm by a radiologist) and in Belgium (including face to
face meetings, and communication by email and teleconference) to refine the protocol to
match what other centres could reasonably be expected to do.
Based on these discussions and data presented earlier in this thesis, the plan was for the
patients to have the following sequences: PWI/DWI, T2, gradient echo and 3D time-of-
flight MRA (TOF MRA):
• DWI (three gradient echo planar technique TR 10000ms, TE 98.8ms, 34 phases)
• PWI (intravenous gadolinium bolus tracking using various simple methods of
analysis of the signal time curve and more complicated methods such as the
modified Ostergaard technique to produce mean transit time (MTT), cerebral blood
7 11
flow (CBF) and cerebral blood volume) '
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• T2 weighted imaging (fast spin echo TR 6300ms, TE 102ms)
• Gradient echo imaging (TR 625ms, TE 15ms), and
• 3D time of flight MRA are all standard techniques, total acquisition time 12-15
minutes maximum (full details Appendix 8).
The MR protocol was to be repeated at 24-48 hours to identify haemorrhage, infarct
expansion and perfusion changes in place of the routine IST-3 follow-up CT at 24-48
hours. A final follow up scan at 3 months was proposed to determine the volume of the
late T2 lesion. This has similarities with the EPITHET protocol and other studies like the
recently completed DIAS 2.
There are no clearly defined validated guidelines equivalent to the "1/3 MCA rule for
CT", on whether the appearance of the infarct on PWI/DWI should alter treatment
decisions. Therefore we did not specify what PWI/DWI appearances should lead to
inclusion or exclusion of the patient from the study. The only major and absolute
exclusion was the presence of fresh intracranial haemorrhage. The justification for the
approach was that DWI lesions may resolve, that animal studies have shown severely
ischaemic tissue beyond the boundaries of the DWI-visible lesion, and that some
patients with severe strokes and poor outcome do not have a DWI visible lesion at
presentation. Even less is known about the PWI lesion.
Subject selection
All patients potentially eligible for IST-3 who presented at the Western General
Hospital, between 9am and 5pm, Monday to Friday, were assessed and recorded. Those
fitting the trial eligibility criteria (summary of IST-3 protocol Appendix 9), consenting
to IST-3 and safe to MR, were then examined, following the imaging protocol
mentioned above. Ethics approval had previously been sought for IST-3 (more detail in
chapter 5) and this was reviewed and granted for this MR sub-study with four methods
of consent possible - written, witnessed, assent and waiver of consent (see Appendices
10 & 11 for patient information leaflet and an example of a consent form).
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In the protocol it was proposed that patients should have a CT followed by MR as
outlined in the pathway (Appendix 12). This was specifically to test what additional
information MR could add to CT and to be able to translate MR results to CT. As part
of the protocol, coordination times and any delays were to be recorded (Appendix 13) as
part of the planning for a larger study in order to find the optimum way of organising a
comparative imaging study.
Clinical assessments
We planned detailed baseline clinical assessments of neurological deficit (National
Institutes of Health Scale - NIHSS), blind to imaging at baseline by the stroke
physician. Further clinical information was to be obtained at 7 days as per the IST-3 in-
hospital follow-up form and in addition we planned to record the NIHSS. Six month
final follow-up in IST-3 is by detailed postal questionnaire, mailed directly to the patient
and conducted independently of the treating physician.
Assessment of the scans
As part of IST-3 the CT scans were to be read centrally for lesion site and extent and
degree of hypodensity according to well-validated scoring methods by an expert panel as
already established for the main trial (see www.neuroimage.co.uk).12'13 The MR image
analysis for a main study would need to be established and streamlined, but would
include several methods, including comparing the MR read locally (i.e. by the attending
physician) with a reading centrally, blinded to treatment allocation. Central analysis
would be blinded to clinical details and would include simple subjective inspection of
12
the PWI/DWI mismatch (for example, by the same coding template as for CT, and
whether the DWI lesion involves more than 1/3 of the MCA territory),14 measurement of
the volume of the DWI and PWI lesions and mismatch, and voxel by voxel analysis of
subregions of the lesion on a workstation using co-registered images. The characteristics
of the DWI lesion appearance were to be recorded (e.g. signal intensity - bright/pale and
edge clarity - sharply defined/fuzzy edge) since these features may be the "DWI
equivalent" of CT early infarct signs. PWI processing was to include CBF, cerebral
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blood volume (CBV) and MTT." The PWI/DWI 'mismatch' was be defined as a
difference in the volume of the lesion of more than 20% between DWI and PWI (CBF
and MTT). We planned to compare estimation by visual inspection with measured
lesion volume analysis. On MRA, we aimed to compare the presence of major artery
occlusion with PWI/DWI appearance, degree of reperfusion, and clinical outcome.
Microhaemorrhages are round dots of low signal on gradient echo imaging usually less
than 2mm in diameter. Small asymmetric dots of low signal where the lenticulostriate
arteries perforate the brain substance in the inferior part of the basal ganglia are not
microhaemorrhages. The presence and extent of microhaemorrhages were to be
recorded. The proposal was that MRA be coded for vessel occlusion using the modified
TIMI classification.15
Statistical analysis plan for the main study and this pilot
When the main IST-3 study has finished statistical analysis will include univariate and
multivariate modelling to test for: a) independent associations between PWI/DWI lesion
volumes, other aspects of their appearance, the mismatch, time to treatment, final infarct
size and clinical outcome and the interaction with rt-PA; b) risk of intracerebral
haemorrhage with improved perfusion, and microhaemorrhages and the interaction with
rt-PA; and c) correlation between the CT appearance and PWI/DWI. Unblinding of
treatment allocation would not be appropriate prior to the final main study completion,
and at the time of planning, IST-3 was in the double blind phase with identical placebo
(although it subsequently became an open label study). We planned to evaluate how
each PWI parameter mapped to infarct extent at 24-48 hours16 and how initial DWI
lesion extent, perfusion changes, and rt-PA relate to infarct swelling. The primary
objective of the pilot was to assess feasibility, so although we aimed to analyse the
PWI/DWI data obtained as proposed, we have to accept the sample size is not large
enough to reliably answer the primary questions as put forward earlier in the
introduction.
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Sample size for the pilot study
A sample size of 20 subjects was chosen since it was thought this was a reasonable
number of patients to test feasibility and allow piloting of the analyses of the MR data,
given the limited time available. A smaller sample than this would be too small to draw
any meaningful conclusions. Although an ambitious target, it was felt that 20 patients
could be recruited in a 12 month period from the Western General Hospital based on
existing observational and trial data. Prior to starting this pilot study, around one patient
a month was being recruited into IST-3, but with increasing awareness of the trial and of
thrombolysis as a potential treatment for acute ischaemic stroke, it was felt that
recruitment should increase.
4.1.3 Results
The funding was finally approved in December 2004, leaving only 11 months for
recruitment. Over the study period, 68 patients with acute stroke were assessed for
consideration for thrombolysis. Of those, 57 were not suitable for thrombolysis. In the
majority of cases this was because they fell outside the 6 hour time window once a
detailed history was taken or they woke with their symptoms making the time of onset
impossible to ascertain. In a minority of cases there were specific contraindications to
thrombolysis e.g. rapidly resolving symptoms or recent treatment with heparin and a
clotting time exceeding that permitted for treatment. Eleven patients received
thrombolysis, one with intra-arterial rt-PA and balloon angioplasty, four under the
current licence and six were randomised in IST-3.
As it turned out, I was unable to recruit any of these patients into the proposed MR pilot
study. There were several reasons for this that were beyond my control. Firstly, re¬
organisation of stroke services in Lothian led to lack of clarity over whether the WGH
would continue as a hospital admitting acute medical emergencies and a reduction in the
number of acute stroke cases sent urgently to the WGH; this was further compounded by
a reduction in the capacity of the research team to assess those patients that did reach the
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WGH early enough to be considered for the study, (so some potentially suitable patients
may have been missed); and finally, by chance, most of the patients randomised into
IST-3 (or treated under the licence) in the last year arrived and were treated out of
normal working hours (when the research scanner does not operate).
Note: Further discussions about the Lothian-wide delivery of services for patients with
acute stroke, and an increase in the number of clinical research staff have led to nine of
the subjects for the pilot study being recruited at the time ofwriting. Of note five other
patients were excluded because of specific contraindications to MRI.
4.1.4 Discussion
This pilot was needed to see if MR is practicable in acute stroke, in patients treated in
the NHS, and to try to set up a streamlined way of investigating a larger group of
patients in the future. A much larger sample is needed to answer the questions about the
additional benefits (if any) of performing MR instead of CT in acute stroke patients
being considered for thrombolysis. It is important that any imaging sequences are
available in 'real time' if decisions have to be made regarding thrombolysis. Having
images which require complicated and timely post processing is useless in the acute
setting. The team worked very hard to establish this protocol and make sure that the
radiographers maintained training. We achieved this despite many changeovers - the
norm in the NHS. The simple fact was that there were not enough patients eligible for
recruitment into the study, and those that were eligible often presented outside working
hours. I was awarded a grant by the Chief Scientist Office (CSO), Scottish Executive, to
carry out this pilot study. The CSO have granted a 'no cost extension' to the grant so
that further patients can be recruited.
It is clear that, at the time this feasibility study was conducted, with the resources
available, acute MR was not practicable in this group of patients. The results of
previous, and subsequently published studies, suggest that similar problems are
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experienced elsewhere. For example the EPITHET study has been running since 2001
to recruit 120 patients in 10 centres in Australia and Europe. It has required several
extensions and struggled to reach its target. The DEFUSE study17 recruited 74 patients
in 7 centres over 4 years. If MR was easy, then more patients would be recruited more
rapidly.
The difficulties I have experienced in recruiting patients highlights a key problem in
acute stroke care in the UK. That is, that the majority of patients with stroke symptoms
still do not arrive at hospital early enough to permit assessment and treatment within 6
hours of symptom onset. There are factors operating at every point in the system that
handles patients with suspected acute stroke that hamper prompt treatment:7'1 the
patient and family do not recognise the symptoms of stroke; they fail to seek attention
urgently; the emergency transport system does not always recognise acute stroke as an
emergency condition, and there are major delays in triaging patients once they reach
hospital - although a quarter reach hospital in 3 hours and half within 6 hours (despite
referral by GP). There is then a median delay of 1 to 1.5 hours while the patient is
assessed by junior medical staff before any brain scan is even requested. A major
overhaul of the in-hospital system is needed to eliminate these avoidable delays. It
leaves the scanning element with little time before the six hour treatment deadline (for
IST-3) expires. The resource limitations are an additional factor, not enough medical
staff available for prompt expert assessment of acute stroke, and not enough radiography
and radiology staff to permit 24 hour use of MR. However, there would be little point in
providing 24 hour MR availability if serious efforts are not made to remove the barriers
that are apparent at earlier stages in the assessment process. Providing 24 hour MR now
would simply add to the already significant waste of resources due to inefficient stroke
assessment and treatment.
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4.2 Survey of the availability of CT and MR for assessing patients
with acute stroke in the UK
4.2.1 Introduction
As I have discussed throughout this thesis, brain imaging is one of the key elements in
selecting a patient with acute stroke for thrombolysis. Imaging needs to be accessible 24
hours a day, require a minimal amount of time to perform the necessary sequences, be
accurate in excluding stroke mimics and intracerebral haemorrhage, and ideally reliable
in identifying the acute ischaemic lesion.
In the UK, the most commonly used and cost effective method used for imaging acute
stroke patients is CT.19 Over recent years it has become widely available and is often
accessible 24 hours a day.20 It is known that with an experienced viewer CT will
21
identify all haemorrhages of sufficient volume to cause a clinically apparent stroke.
However, one of the problems for clinicians occurs when the patient presents with a
clinical stroke syndrome but a 'normal' CT scan. Clinicians find, when considering
patients for potentially risky treatments such as thrombolysis, that the absence of
positive evidence of ischaemia is a barrier to the use of rt-PA: 'positive signs of
infarction' add sufficient diagnostic information to the clinical features to help make a
confident diagnosis of ischaemic stroke and would help remove this barrier. However,
these CT signs e.g. loss of the insular ribbon and the hyperdense artery sign, are often
subtle in patients presenting within the first few hours of stroke onset,22 and hence easily
missed.
MRI can provide more information than CT about patients with acute stroke. For
example diffusion weighted imaging shows up more ischaemic stroke lesions than CT or
conventional T1 or T2 MR sequences. It may be that advanced MR techniques can help
us to select those patients who will do best with thrombolysis and other emerging
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treatments. In some centres (chiefly USA and Germany) MR is already regarded by
'experts' as the imaging method of choice to select stroke patients for thrombolysis23
and even in the UK, at least one centre has developed a policy of using MR as the first-
line imaging method in patients with clinically suspected acute stroke.24 However this
centre focuses primarily on minor stroke thus avoiding the 20-30% of patients with
moderate to severe stroke who are unable to tolerate MR.
As part of our assessment of the feasibility of MR to select patients for thrombolysis, I
sought to assess the availability ofMR for acute stroke in the UK. I therefore undertook
a survey of all acute hospitals in the UK in 2005 to assess how many had MR scanners
on site, and if they had one, to estimate how often (and how rapidly) patients with acute
stroke had an MR scan.
4.2.2 Methods
I assembled a database of all hospitals in the UK (England, Wales, Scotland and
Northern Ireland) that admitted acute stroke patients. The hospitals were identified from
the list of those trusts participating in the recent National Sentinel Stroke Audit20 and the
Scottish Stroke Audit. I included both teaching hospitals and district general hospitals.
At the time of the survey, some of the hospitals included had merged with others or had
closed since those lists had been assembled. Once the hospitals were located, I sought a
contact name for the lead stroke physician in each hospital. Where possible, this was the
named stroke physician, or in other cases it was the clinician with an interest in stroke,
who may have been a general physician, a geriatrician or a neurologist.
I developed a simple one page survey (Appendix 14) and sent it to the relevant clinician
at each acute hospital, with a covering letter detailing the survey, enclosing a stamped
addressed envelope for reply. The content and layout of the questionnaire, the covering
letter, the mailing and reply arrangements were designed to maximise response rates in
line with findings of a Cochrane systematic review.25 I sought details on the presence or
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absence of CT and MRI at each acute hospital. For centres with access to MR, I sought
further details on MR capacity to scan patients with acute stroke (i.e. within six hours of
symptom onset) within working hours and out of hours. The questionnaire included
visual analogue scales for the questions on ease of access to MR, which were measured
at equal intervals using a scale of 0 for 'impossible' to 12 for 'very easy'.
4.2.3 Quantitative results
Response rate
I sent the first mailing of the questionnaire to 268 hospitals. After the first posting, I
received 224 (84%). Of those, two reported that the hospitals concerned had closed or
were in the process of closing. One reported that it did not admit acute stroke patients.
After the second posting, a further 24 replies were received, bringing the total number of
responses to 248 (93%); this was very satisfactory.
Proportion with CT on site
Of the hospitals which responded to the survey, and were still admitting acute stroke
patients, 240 (97%) had a CT scanner on site. Only eight hospitals did not have a CT, of
which three were in remote areas of Scotland and required a journey of anything
between 108 to 250 miles (usually by air) to their nearest CT or MRI. The remaining
five hospitals with no CT or MRI were small units located, on average, 20 miles from
their nearest centre with CT or MRI. One of these hospitals was in Northern Ireland,
one in Wales and the remaining three in England.
Access to MR on site
Of the respondents, 245 hospitals admitted acute stroke patients. Of those, 192 (78%)
stated that they had MR facilities on site. Some hospitals reported that they had more
than one MR scanner, although this information was not specifically requested. Of the
hospitals which reported that they had MR, three had mobile units which were present at
certain times, but were not available 24 hours a day. Of the 56 (23%) without MRI
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facilities on site, one reported that it had a mobile unit visiting infrequently. The
availability of imaging facilities is summarised in Figure 2. There were no hospitals that
had an MRI scanner but no CT. As demonstrated, the majority of acute hospitals in the
UK (78%) had both CT and MRI on site. 48 hospitals had on site CT, but no MRI
facility. Of those, 46 gave details of the distance to their nearest MR. The average
distance was 22.9 miles with a range of 0.5 miles to 80 miles.
Although more than three quarters of hospitals had access to MR within their hospital,
availability of the scanner for patients with acute stroke was often problematic. Analysis
of the visual analogue scales (questions 3 and 4 of the survey) showed that for patients
presenting within 6 hours of stroke symptom onset, accessing MR at all times was far
from easy (Figure 3). I arbitrarily defined 'difficult' access to MR as a visual analogue
scale score of between 0 (impossible) and 5 (see Figure 3). With this definition, access
was difficult in 73% of hospitals during working hours and in 95% for 'out of hours'
access.
I wished to estimate how many acute stroke patients were being imaged with MR in the
UK at the time of the survey (question 7 of survey). The results (Table 1) suggest that
MR was rarely used as an imaging method in acute stroke patients. During the six
months before the survey date only 21 (11%) hospitals (out of 192 with MRI facilities)
reported that they had MR scanned any patients within 6 hours of stroke onset and 58
(30%) hospitals had scanned any patients within 12 hours of symptom onset. From the
survey responses, I estimated that, per year in the whole UK, about 150 patients with
acute stroke were scanned with MR within 6 hours of symptom onset, i.e. approximately
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Type of scanner and installation date
This question (question 5, Appendix 14) was the least well answered. Of the hospitals
with MR, 90 (47%) physicians did not know the make of the MR scanner or declined to
answer the question at all. Among those with known magnet strength, 75 (39%) had a
1.5T MR, 33 (17%) had <1.5T and 6 (3%) had 3.0T systems. Most of the more
advanced 3.0T scanners were in teaching hospitals and in a few cases the responding
physician commented that these were facilities specifically for research. The increasing
recognition ofMR as a scanning modality is reflected in the installation dates of the MR
scanners in the hospitals surveyed. Only 39 (20%) of the MR scanners were installed
before 2000; just over half, 103 (54%), of those acute hospitals with on site MR had
their machines fitted in the last 5 years. In 50 (26%) cases the responder was not aware
of the installation date of the MR at their hospital.
4.2.4 Qualitative results
The descriptive analysis of the comments from some of the physicians in response to the
survey were of interest and highlight the quite considerable hurdle that would have to be
overcome to introduce MR as a first line imaging technique in acute stroke. I have
grouped them in themes below.
Shortage of radiology and radiography staff, other staffing problems
'We don't have enough trained radiographers to operate the MRI scanner 24hrs a day.
CT however is available all the time at the discretion of the duty radiologist'
'In our hospital there are significant delays both at the scanning stage and then at the
reporting stage'
'Our main problem is that we have six vacant consultant radiologist posts and neuro¬
radiology is off site. Under the circumstances we do get good support from radiology'
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'Skilled staffing shortage'
'We have a fast MRI scanner - but poor access due to shortages of staff. Not available
after 5pm'
'Our MRI department is new. It lacks staffing (consultant support)'
'Radiology registrars often defer scans overnight till next morning'
'We have a very severe shortage of radiologists and no immediate prospect of
recruitment'
'We have neuroscience dept with neuroradiology and MRI scanner functional but only 2
of 3 neuroradiology posts filled'
'Radiology very reluctant [to adopt MR for stroke] as [they] argue that blood more
easily seen on CT'
'Restraints mainly due to manpower and funding shortages'
'Also issues of reporting, neuroradiology reporting although much improved recently is
still by no means perfect, but particularly out of hours is difficult'
'With sufficient funding to pay out of hours cover, staff are willing to come in but only
for RESEARCH scanner. The MRI scanner is hugely overburdened'
'Radiology won't do out of hours CT for stroke'
'Major funding and staffing issues - also pressure of other imaging needs'
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Pressure on scanner from other specialities; stroke not a priority
'Radiology service very over stretched. MRI seen as elective procedure. CT scanning
routinely within 24 hours only agreed 2 years ago'
'Our MRI was provided via a lottery grant, largely based on its potential use in acute
stroke and cardiology. Needless to say it is mostly used for knees and backs! Wouldn't
perfusion CT be more practical?'
'More delays recently due to pressures from 2 week cancer rule'
'MRI scanners in use most days for cancer planning. On some days there are slots where
it might be possible to slot stroke patients within 6 hours. However no out of hours MRI
service is funded'
Local protocols for acute stroke do not include MR
'The (unwritten) policy is CT as first line but radiologists happy to discuss doing MRI as
2nd line if clinically indicated. I think unlikely to ever be 1st line imaging'
'Our acute stroke protocol includes a section on neuro-imaging. CT scanning is
recommended in all acute cases. Indications for MRI scanning are included but not as an
emergency investigation'
'MR tends to be used for younger patients'
'Preferred option in our hospital is CT. MRI during working hours could be made
available assuming an appropriate case is made for an exception to CT'
'We routinely use CT structural and perfusion scans for acute stroke, and it is possible to
do an angiogram without excessive delays in thrombolysis'
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'We did previously use MRI on ALL patients, but waiting up to 10 days so reverted to
CT unless posterior circulation/?MS/further clarification of CT signs/>10 days after
onset, therefore by default most outpatients get MRI'
'CT access improving progressively over 10 years. Delayed formal reporting. CT is
investigation of choice. MR 1st line for posterior circulation strokes - [MR] increasing
for selected patients'
'24hr CT cover for acute stroke - if requested - otherwise next working day service'
'CT scanning is the first investigation and our X-ray dept provides an excellent service.
They don't provide MRI scanning for acute stroke unless there is some doubt on CT'
'CT is still the main imaging modality for acute stroke. Not yet providing thrombolysis.
CT usually available within 24 hours, though delays occur over weekends'
'CT scanning is used acutely with MR for uncertain images. MR used for O/P
especially if >7-19 days'
'Trust does not at present provide thrombolytic therapy. Not all our patients have CT
scanning within 6 hrs, 12 hrs. All patients have CT within 24 hours. Stroke
association/BASP should concentrate on improving acute stroke care in all hospitals
caring for stroke patients before addressing MRI provisions'
'New MRI installed mid 2004. No out of hours service. At present no coordinated
acute stroke care and thus no thrombolysis on site - but looking to change'
'The problem is that we don't have the software for DWI or PWI in our MRI scanner'
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General problems of access to scanning facilities
'We are not achieving CT scan within 24 hours. MR scanning within 6 hours would not
be feasible for us with the present setup'
'CT access and capability is good (new scanner). MRI access is limited, and always
delayed, impeding accurate assessment and impairing care'
'Very difficult to routinely get CT within 24 hours due to other pressures on scanners'
'No on site CT - this would be nice. I think it will be a long time before we have MRU'
'It is very difficult to get patients scanned within 24 hours as per RCP guidelines if it is
not urgent - this is for CT'
'We have access problems at the weekend which we are trying to resolve'
'Our MRI is PFI which makes it more complicated'
'We only scan about 60% of stroke patients within 48hrs (CT, that is), so are well off the
current RCP guidelines'
'Acute emergencies i.e. unconscious/suspected big bleeds/SAH can be done within
hours [using CT]. Routine strokes admitted via MAU daily take 24-48hrs [to get CT
scan]. Delay mainly due to workload for the scanner. No scans on weekend
'Re Q3 - I suspect that it would be very difficult to get acute MRI - but I am
unconvinced of the value and haven't requested them'
'No slots reserved for MRI scans for stroke patients'
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'Getting CT scan within time may be, at times, difficult'
'CT scanning is very accessible for inpatients and selected outpatients. 200 on waiting
list for O/P MRI, 24 weeks for routine CT'
'Have 2 MRI scanners but access, even to our neurologists, is poor and usually needs
consultant to radiologist verbal referral for urgent scan'
'Very limited access [to MRI] for stroke patients. Waiting time 20 weeks'
'CT easier to obtain and less contraindications'
'Getting a timely CT scan is difficult enough'
'Lucky to get a CT at weekends - no chance ofMRI!'
'We only have finance for three days of scanning/week. Within that limit our
radiologists are very helpful'
'We have difficulty at times getting CT let alone MR, although often this is due to poor
request mechanisms'
'Probably far more helpful to try and get a CT within 3 hours (of onset) before worrying
about additional, somewhat marginal benefits ofMRI within 3-6hours from onset. This,
to most of us in DGH's is difficult enough!!'
'Our main priority at present is to get carotid doppler examination without much delay'
'Access to carotid imaging also a problem. Techniques for rarer causes of stroke -
dissection, dural thrombosis - need to be incorporated into mainstream radiology'
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'Despite national sentinel audit x3 and agreement on need for an acute stroke unit we do
not yet have any stroke beds!! - PCT recognise the need but no funding available from
per
Specific comments on MR
'We have an extremely approachable MR service who have no problem doing urgent
MR's'
'Difficult to get patients on and off [MR] table. Scanning sequence takes a long time.
Some patients cannot lie still. Likely to cause disruption to service e.g. orthopaedic
cases'
'45% of our patients have MRI'
'I support the move towards MRI for acute stroke imaging'
'No difficulty getting MRI in working hours'
'Usually we can access MR DWI etc easily but if good reason'
The comments suggest that there is still a problem achieving current RCP guidelines for
CT scanning in much of the UK and there are obvious frustrations with the lack of
funding to staff 24 hour a day, seven day a week imaging services.
4.2.5 Discussion
The results of the survey confirm that CT is almost universally available to stroke
patients in the UK and must therefore - for now - remain the primary imaging method
for patients with acute stroke. Although just over three quarters ofUK hospitals have on
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site MR facilities, access to this imaging modality appears to be very poor for acute
stroke patients. This is probably due to a number of factors. Currently MR
appointments are usually fdled many weeks in advance and, with current work patterns,
it is difficult to fit in emergency cases, such as patients with acute stroke. There is a
huge demand from many other specialities for MR imaging, both medical and surgical.
Thus until there is very strong evidence that MR is a cost-effective way to provide
additional information to CT for the acute treatment of stroke patients, it will be difficult
to bring about a major change in the primary imaging methods for stroke. As mentioned
in Chapter 1 (section 1.3.4) there are practical difficulties with the MR imaging of 20-
30% of patients with moderate to severe strokes (i.e. patients likely to be considered for
thrombolysis) due to medical reasons (e.g. reduced conscious level, unable to lie flat,
unable to protect airway) or MR contraindications (e.g. the presence of a pacemaker).
This survey demonstrates that although the majority of hospitals have access to MR,
those in rural areas are still at a disadvantage. It also shows that access to MR is very
difficult for acute stroke patients. If on going trials were to show that MR was a useful
tool in selecting patients for acute treatments such as thrombolysis there would have to
be a massive investment in equipment and even more so in highly trained staff in order
to provide the service.
4.3 Summary
• Further data on MR imaging in acute stroke are needed so that we can
determine how features visible on MR may help to improve the use of
thrombolysis. Only by gathering such data in a randomised trial of
thrombolysis can we hope to identify features that may suggest that a patient
may benefit or be harmed by thrombolytic therapy.
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More data are needed on whether MR PWI/DWI mismatch influences
response to thrombolysis from randomised control trials and we hope the
protocol developed in the study in this chapter will prove feasible to be
undertaken as a multicentre sub-study within the MRC funded IST-3.
However, the experience at the WGH suggests that, even in a well-equipped
acute stroke centre with MR available to patients with acute stroke, many
factors act as barriers to the use ofMR in this situation.
Currently, in the UK, CT scanning is the primary imaging modality for acute
stroke patients.
The survey I performed has shown that, although many hospitals have on site
MR facilities, acute stroke patients are not commonly scanned within 6 hours
of symptom onset.
If ongoing studies show that MR is a useful tool in selecting patients for
thrombolytic therapy, a huge investment in staff, equipment and training will
be needed if it is to be implemented throughout the UK.
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Table 1: Summary of time taken to scan patients with MR (ifMR was undertaken at
all).
Approximate number of patients
scanned
Number of hospitals scanning within this time*
(time from symptom onset to MRI)
< 6 hours <12 hours At anytime after
stroke onset
None 137 117 8
1-5 17 29 34
6-10 3 3 40
>10 1 5 59
* Of the 192 hospitals with MRI, 158 gave useable responses to access < 6 hours, 154 to
access <12 hours and 141 to access at anytime
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5 Issues surrounding consent processes for thrombolysis and
related procedures
5.1 Consenting patients with acute ischaemic stroke for
thrombolysis
5.1.1 Introduction
As discussed in chapter 1, for patients with acute ischaemic stroke, thrombolysis with
recombinant tissue plasminogen activator (rt-PA), can reduce disability in survivors and
is of net benefit, despite a 3% risk of fatal intracranial bleeding.3 As mentioned
previously in the USA and Europe, rt-PA is approved for use in acute ischaemic stroke
in highly selected patients who present very early and can be assessed and treated within
three hours of symptom onset. The American Heart Association (AHA) guidelines state
that, when considering treatment in routine clinical practice with intravenous rt-PA,
written consent is not a necessity, but patients and their relatives should be informed
about the potential risks and benefits.4 Ciccone has proposed a practical approach to
consent in this setting.5 A recent study by Rosenbaum et al highlighted that while such
consent was often not documented, patients with diminished capacity seemed to have
given consent.6 A systematic review also highlighted difficulties in obtaining informed
consent as a barrier to effective delivery of thrombolytic treatment.7
To investigate which forms of consent could be used I looked at data from IST-3. IST-3
is a large-scale trial (aiming to recruit up to 6000 patients) which seeks to determine
whether a wider variety of patients might benefit from thrombolytic therapy, beyond the
very restricted group defined by the current approval. In order to achieve this sample
size, the trial methods had to be simple, flexible, yet ethically acceptable. The trial team
therefore developed,8 and obtained ethical approval for, a set of flexible consent
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procedures that allowed patients with different types of stroke and different degrees of
neurological impairment to be included. In this analysis, I aimed to examine how often
each method of consent was employed and to explore the impact of the patient's initial
neurological deficit on the method of consent employed. This analysis sought to
identify ways to reduce the 'consent barrier' for use of thrombolysis both in trials and in
routine clinical practice.
5.1.2 Methods
IST-3 is a multicentre randomised controlled trial of intravenous recombinant tissue
plasminogen activator (rt-PA) in patients with acute ischaemic stroke. Patients, aged
over 18, who can be assessed and have treatment started within six hours of symptom
onset, are eligible for the trial. Consent or assent must be obtained before
randomisation. The full trial protocol can be found at www.ist3.com.
We developed draft patient information leaflets and consent forms. To improve the
quality of the informed consent process, we then subjected the draft forms to an iterative
process of testing and further development that closely involved patients and potential
o
patients. The trial information leaflets include approximate percentage benefits and
risks derived from the latest Cochrane review.3 There are three methods of
consent/assent, which may be employed to recruit patients into the trial. The UK
multicentre research ethics committee has approved these. The first, and the ideal, is
written consent from the patient themselves. However, if the patient is unable to write,
for example if the dominant hand is affected, they are able to give witnessed consent if
they have no problems with communication. If the patient is unable to give informed
consent as a consequence of their stroke (e.g. due to aphasia), assent can be sought from
the patient's relatives (in North America, this is known as surrogate consent). In some
countries, under exceptional circumstances, a fourth method, waiver of consent is also
permitted, usually on condition that an independent physician agrees that recruitment of
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that individual into the trial is appropriate and that if the patient recovers, the option to
withdraw consent may be offered (this is not exactly comparable to what is referred to as
'deferred consent'). When obtaining consent to enter a patient in the trial, the
randomising clinician has a discussion with the patient and the family and the trial
information leaflets are used as a guide to the conversation, employing simple language
that is easy to understand. The method of consent is recorded in the hospital records and
on the trial seven day follow up form. The presence or absence of the key neurological
deficits is recorded at randomisation. A computer algorithm uses these data to assign a
stroke syndrome to each patient: total anterior circulation (TACS), partial anterior
circulation (PACS), lacunar (LACS) or posterior stroke syndrome (POCS). A separate
algorithm, based on a validated prognostic model,9 uses the baseline clinical data to
calculate a predicted probability that the patient will be alive and independent at six
months after the stroke.
Note: The introduction of the European Union directive on clinical trials, and its
enactment in UK law led to some changes in terminology and minor changes to the
documentation. These changes came into force after the patients included in this
analysis were recruited. The term 'assent by relatives' has been replaced by 'consent by
personal legal representative'. For simplicity, we have retained the term 'assent', for
these analyses.
5.1.3 Results
We analysed data for the first 300 patients randomised in the trial. The method of
consent employed was: written consent in 71 patients (24%), witnessed verbal consent in
30 (10%), assent by relative in 197 (66%) and waiver of consent in 2 (1%).
Table 1 shows the impact of individual neurological deficits on the method of consent.
In patients with dysphasia, 92% were randomised into the trial with assent of a relative
or by witnessed verbal consent. In patients with visuospatial disorders, most commonly
164
due to a non-dominant hemisphere stroke, the majority of patients were recruited by
relatives assent (76%) or witnessed verbal consent (10%). Those without such a deficit
were more likely to be able to give written consent. As expected, the hemisphere
affected by the stroke has a clear influence: patients with left hemisphere lesions were
less likely to be able to give written consent than patients with right hemisphere lesions
14% vs 36% respectively (difference 22%, 95% confidence interval 13 to 32%).
As demonstrated in Figure 1, those patients with most severe strokes (i.e. TACS) were
consented with either relatives assent or witnessed verbal consent in the majority of
cases. In patients with the milder PACS syndrome, about a third of patients were able to
give written consent. The numbers in the LACS and POCS subtypes were small but
written consent in these groups was common.
Figure 2 confirms the observations from Figure 1, that demonstrates a trend, that patients
randomised into the trial with written consent, have less severe strokes and those
consented with assent or waiver of consent had, on average, more severe strokes.
5.1.4 Discussion
These analyses confirm that the consent procedures we developed were feasible and
permitted patients with a range of neurological deficits to be recruited. In general, the
more the severe the stroke (either determined by clinical stroke syndrome or predicted
outcome), the less likely was written informed consent to be employed, as one would
expect. The proportion of patients with TACS syndrome was greater in the assent group
compared with the written consent group (Figure 1). When stroke severity was assessed
by the predicted probability of outcome, patients giving written consent were judged to
have milder strokes (Figure 2).
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The percentage ofpatients within each stroke subtype and the type of consent used to
recruit them into the trial depending on their stroke subtype: Total anterior circulation
stroke (TACS), partial anterior circulation stroke (PACS), lacunar stroke (LACS) and
posterior circulation stroke (PACS). Note: Only 2 cases had waiver of consent, both of
which have been omittedfrom this figure. Both had TACS type strokes.
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Figure 2: Effect of stroke severity on method of consent
Stroke severity is assessed by the predicted probability of the patient being alive and
independent 6 months after their stroke. The predicted probability is calculatedfrom
their pre-treatment neurological deficit with a validated prognostic model. Hence, a
probability of zero represents a very severe stroke with a low probability of good
outcome and 1.0 a very mild stroke, with a very high probability of a good outcome.
The patients have been grouped according to the method ofconsent used to recruit them
into IST-3. It does not take into account the effect ofpost-randomisation treatment. In
this plot, the box represents the interquartile range. The whiskers extendfrom the box to
the highest and lowest values. The line across each box indicates the median. If it is
assumed that the method ofconsent is an ordered categorical variable and a Jonckheere
test is performed, then the trend is significant (p<0.001) with those giving written
consent having a less severe stroke, as assessed by this measure.
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The data also suggested that, the more severe the stroke deficit, the more likely it is that
assent will be needed as the method of consent (Table 1). In particular, the data show
that those with any type of higher cerebral dysfunction such as TACS patients e.g.
dysphasia or a visuospatial disorder, could not take part in a trial such as IST-3, without
the option of a flexible consent procedure. If the left hemisphere is affected by the
stroke, then assent is more likely since patients are more likely to be dysphasic or - even
if they do not have such a higher cerebral dysfunction - their dominant (writing) arm is
likely to be affected making writing difficult or impossible.
If only the patients who are able to provide written informed consent were included in
acute stroke trials, they would generate estimates of treatment effect applicable to a
group with a good prognosis (irrespective of treatment allocation). The IST-3 consent
procedures conform to legal requirements and allow a wider variety of patients to be
included in the trial. These patients may have as much to benefit from thrombolysis
treatment as patients with milder strokes. Indeed, previously fit and active elderly
people who are affected by a severe stroke should surely have the opportunity to
participate in research. According to the World Medical Association Declaration of
Helsinki policy on the ethics of medical research involving human subjects it is stated
"for a research subject who is legally incompetent, physically or mentally incapable of
giving consent, or is a legally incompetent minor, the investigator must obtain informed
consent from the legally authorised representative in accordance with applicable law.
These groups should not be included in research unless the research is necessary to
promote the health of the population represented and this research cannot instead be
performed on legally competent persons".10 Research on emergency medical treatments
is necessary on stroke patients who are unable to give consent due to the nature of their
stroke. Without studying them, we would be unable to move forward and provide an
evidence base for giving these groups of people such acute treatments in emergency
settings, when time is limited and decisions have to be made very quickly.
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When considering treatments whose benefits decline with increasing time from onset of
symptoms, the need to avoid delay, reduces the time available to the patient and the
family and the doctor for discussion and weighing up risks and benefits. Data from the
recent MRC CRASH trial showed there were significant reductions in time to
randomisation when waiver of consent was used compared with assent by relatives.11
This reduction in time delay may be crucial in acute brain disorders to maximise the
benefit from treatment and hence the likelihood of the trial producing a clear and
positive result, if treatment is clearly effective. One way to do this may be to increase
public understanding and awareness of conditions like acute stroke by improving public
education in groups at risk of stroke. At least then people have a chance to think about
potential situations that may arise in the future and what sort of risks of treatment they
may find acceptable.
The requirements of the EU directive makes consent for trials in emergency situations
possible under some circumstances. A relative or spouse may act as the patient's
'personal legal representative' and can give consent on their behalf. A 'professional
legal representative' can also give consent, but it is not rapidly available at the moment
when consent is required. This will be a major obstacle to evaluating interventions that
could have substantial impact on mortality and disability.
These data confirm that the consent procedures developed for IST-3 have proved
feasible and have enabled the balance of risk and benefit of thrombolytic therapy to be
assessed in a randomised trial in a wider variety of patients than previously. This is an
area where there is scope to develop still better tools to improve the process of informed
consent in acutely ill people. A wider public debate to secure acceptance of waiver of
consent in trials in emergency situations would also be appropriate.
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Summary
• The issue of consent is very important to consider in trials of acute medicine,
especially where there is little time available for people to consider treatment
options.
• Data from this study show that different methods of consent are feasible in an
acute stroke trial. This is important to allow a wide variety of patients with
stroke to be recruited, who otherwise may not be eligible.
• Without flexible consent procedures, those with the most severe neurological
deficit (who potentially have the most to gain), would be excluded from trial
treatments.
• When considering the development of alternative forms of consent it is
important to include the public in discussions and to incorporate their views
as much as possible.
• Restrictive consent procedures are a major obstacle to evaluating
interventions that could have substantial impact on mortality and disability.
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Table 1
Method of consent and neurological deficit.
Method of consent
















Motor deficit only 18(69) 2(8) 6(23) 0(0)
Dysphasia 13(7) 14(8) 145 (83) 2(1)
Visuospatial disorder 26(14) 20(10) 145(76) Kl)
Lesion location (final diagnosis)*
Right hemisphere 45 (36) 13 (10) 66 (54) 0(0)
Left hemisphere 23(14) 15(9) 128(76) 2(1)
Cerebellar or brainstem 2(67) 1(33) 0(0) 0(0)
Not localisable* 1(20) 1(20) 3(60) 0(0)
Total 71(24) 30 (10) 197 (66) 2(1)
*
Percentages are of row totals
^Final diagnosis is determined at 7 days on the basis of all the neuroimaging data,
ancillary investigations and the patients clinical course
""Some patients had a clinical syndrome consistent with localisation in either hemisphere
or the posterior fossa, but had no relevant visible lesion on brain imaging
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My contribution to this thesis
I applied for, and was awarded, a grant from the Chief Scientist Office (£15,000) to fund
the IST-3 MR imaging sub-study and the UK MRI survey, outlined in chapter 4.
I performed the systematic review that fonned the basis of chapter 2. I developed the
rationale for the perfusion MRI study (chapter 3), coordinated the analysis and processed
all the PWI lesions by drawing around the individual perfusion lesions for each patient
in the study and collated the baseline details of the patients along with their clinical and
imaging results. I entered the data into Excel and SPSS and analysed the data.
For the MRI pilot study (chapter 4) I coordinated discussions between interested centres
to develop a suitable protocol, obtained ethical approval for the study and designed the
information and consent forms for potentially eligible patients. I also designed the data
collection forms. I reviewed suitable patients in the hospital and where possible
recruited them into the study. I performed all the work for the survey of imaging
facilities, including creating a comprehensive database of all acute hospitals in the UK.
I was involved in recruiting a large number of acute stroke patients during my time in
Edinburgh, including into IST-3, to both the studies mentioned and several others. I was
the IST-3 trial research fellow. As IST-3 research fellow I also produced several trial
items not explicitly recorded in this thesis but all designed to streamline thrombolysis
trial processes. This included the design and production of the image training set for the
British Association of Stroke Physicians (http://www.dcn.ed.ac.uk/ist3/) now available
to all IST-3 centres during start up, and a simple 'thrombolysis trolley' with all
necessary materials easily available for use in IST-3 centres.
Work from chapters 2 and 3 formed the basis of platform presentations at the European
Stroke Conference 2006 and the Joint World Congress on Stroke in 2006. The
systematic review from chapter 2 and the comparison of PWI processing have been fully
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published in the Journal of Neurology, Neurosurgery and Psychiatry and Stroke; and the
study in chapter 5 has been published by Cerebrovascular Diseases (2006). The results
of the MRI survey have been presented in poster format at the British Association of
Stroke Physicians Meeting 2006 and the British Geriatrics Society Meeting in 2006 and
accepted for publication in Cerebrovascular Diseases.
During my time in research I was a member of the group developing the programme for
the European Stroke MSc; this involved attending meetings in Austria as well as in the
UK.
This thesis was composed by myself, the research undertaken in Edinburgh, and has not
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Appendix 1: Electronic search strategies
Glossary of search terms
/ MEDLINE subject heading (MESH)
mp. Title, abstract, heading word, trade name, manufacturer name
.tw Identifies the word specified in the title or abstract
ti. Identifies word specified in title
$ Identifies any word beginning with the text preceding it
or In the search parameter specified, the article only has to be found in one of the search terms
and In the search specified, the article must be found in all search terms















































exp occlusive cerebrovascular disease/
(stroke$ or apoplexyS or cerebral vasc$ or cerebrovascS or cva or transient ischS or tia$).tw
(brain or cerebrS or cerebellS or verebrobasilS or hemispheres or intracranS or intracerebral or
infratentorial or supratentorial or middle cerebrS or mca$ or anterior circulation).tw.







plasmin/ or plasminogen/ or exp plasminogen activator/
exp thromboembolism/dt
recanalization/ or recanali#ation.tw.
(thrombolyS or fibrinolyS or clot lysis).tw.
(plasminogen or plasmin or tpa or t-pa or rtpa or rt-pa).tw.
(anistreplase or streptodornase or streptokinase or urokinase or pro?urokinase or rpro?uk or
lumbrokinase or duteplase or lanoteplase or pamiteplase or reteplase or saruplase or
staphylokinase or streptase or alteplase or tenecteplase or TNK).tw.
18 or 19 or 21 or 22 or 23 or 24 or 25 or 26 or 27
17 and 28
*nuclear magnetic resonance imaging/
29 and 30
nuclear magnetic resonance imaging/
(magnetic resonance imaging or mri).tw.
32 or 33
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35 29 and 34
36 35 not 31
37 diagnostic imaging/ or diffusion tensor imaging/ or diffusion weighted imaging/
38 29 and 37
39 38 not (31 or 36)
40 (1994$ or 1995$ or 1996$ or 1997$ or 1998$ or 1999$ or 200$).em.
41 31 and 40
42 36 and 40




2 exp brain ischemia/
3 carotid artery diseases/ or carotid artery thrombosis/
4 exp cerebrovascular accident/
5 exp hypoxia-ischemia, brain/
6 cerebral arterial diseases/ or intracranial arterial diseases/
7 exp "intracranial embolism and thrombosis"/
8 (stroke$ or apoplexy$ or cerebral vasc$ or cerebrovasc$ or cva or transient isch$emic attack$
or tia$).tw.
9 (brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or
infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation).tw.
10 (isch?emi$ or infarcts or thromboS or emboli$ or occlusS or hypoxi$).tw.
11 9 and 10
12 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 11
13 thrombolytic therapy/
14 fibrinolysis/
15 exp plasminogen activators/
16 fibrinolytic agents/ or plasmin/ or plasminogen/
17 (thrombolyS or fibrinolyS or clot lysis).tw.
18 (plasminogen or plasmin or tPA or t-PA or rtPA or rt-PA).tw.
19 (anistreplase or streptodornase or streptokinase or urokinase or pro?urokinase or rpro?uk or
lumbrokinase or duteplase or lanoteplase or pamiteplase or reteplase or saruplase or
staphylokinase or streptase or alteplase).tw.
20 exp "intracranial embolism and thrombosis'Vdt or thromboembolism/dt
21 thrombosis/dt [drug therapy]
22 or/13-21
23 12 and 22
24 *magnetic resonance imaging/
25 23 and 24
26 magnetic resonance imaging/
27 mri.tw.
28 26 or 27
29 23 and 28
30 29 not 25
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Appendix 2
Systematic review data collection form
• Author Publication date
• Ref ID Study design
• Sample size Univariate / multivariate analysis
• What MR lesions measured
• How? a) workstation
b) quantification
States patients attempted to image but not able to complete or imaged but discarded:
incomplete / not analysed / not a stroke
• Number who died or not followed up. Stated n= ; Not stated
• Thrombolysis given? Agent and route:
• Proportion getting thrombolysis
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MR DETAILS
• Onset to MR scan
• Time to perform sequences
• Magnet Strength
• Was DWI/PWI mismatch defined and how
• What proportion of patients had mismatch or not?
• Where the radiologists blind to clinical and previous imaging data Y / N
Explicit / implied / not
• Was IOV given Y / N
CLINICAL DATA
• At baseline
• At follow up
• Who saw patient?
• Were they blind to other info at baseline? Explicit /implied /not
• Were they blind to baseline clinical details and imaging at follow up?
Explicit /implied /not
Did they give IOV? Y / N
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Appendix 3: NIHSS
NIHStroke Scale (Please circle the most appropriate response for each section. See supplementary notes attached.





Alert — keenly responsive
Drowsy — arousable by minor stimulation to obey, answer, or respond
Stuporous — requires repeated stimulation to attend, or is obtunded and requires strong orpainful
stimulation to make movements (not stereotyped)
















Partial gaze palsy — gaze is abnormal in one or both eyes, no forced deviation/total gaze paresis




Partial hemianopia or visual inattention
Complete hemianopia




Minor - flattened nasolabialfold, asymmetry on smiling
Partial — total or near totalparalysis oflowerface





No drift - holds limb at 90 degreesforfull 10 seconds
Drift - drifts down but does not hit bed
Some effort against gravity
No effort against gravity
No movement





No drift - holds limb at 90 degreesforfull 10 seconds
Drift - drifts down but does not hit bed
Some effort against gravity
No effort against gravity
No movement





No drift — holds limb at 45 degreesforfull 5 seconds
Drift - drifts down but does not hit bed
Some effort against gravity
No effort against gravity
No movement




No drift - holds limb at 45 degreesforfull 5 seconds
Drift - drifts down but does not hit bed
Some effort against gravity
No effort against gravity
No movement




Present in 1 limb
Present in 2 or more limbs
Untestable (only for amputation or joint fusion - please state which)
10. Sensory
Normal
Partial loss - patientfeels pinprick is less sharp or is dull on affected side







Mild to moderate dysphasia - obvious loss offluency or comprehension, without significant limitation in
ideas expressedorform ofexpression. Conversation aboutprovidedmaterial difficult or impossible but
examiner can identify itemsfrom patient's response.
Severe dysphasia - all communication is throughfragmentary expression; great needfor inference,
questioning, andguessing by the listener who carries burden ofcommunication. Examiner cannot
identify items providedfrom patient response.




Mild to moderate dysarthria -patient slurs some words, can be understood with some difficulty.
Unintelligible or worse - speech is so slurred as to be unintelligible (absence ofor out ofproportion to
dysphasia) or is mute/anarthric
Untestable (intubation or other physical barrier to producing speech — please state)
13. Neglect
No neglect
Partial neglect - Visual, tactile, auditory, spatial, orpersonal inattention or extinction to bilateral
simultaneous stimulation in one ofthe sensory modalities
Complete neglect - Profoundhemi-inattention (e.g. does not recognise own handor orients to only one
side ofspace) or hemi-inattention to more than one sensorymodality (e.g. visual + tactile).








- Somnolent, can be awaked to full consciousness





- No gaze palsy
- Gaze palsy present





- Raises arm with normal strength
- Raises arm with reduced strength
- Raises arm with flexion in elbow









- Reduced strength in full range








- Raises straight leg with reduced strength
- Raises leg with flexion of knee








- Correct for time, place, person
- Two of these








- Limited vocabulary or incoherent speech
- More than yes/no, but no longer sentences











- Walks 5 m without aids
- Walks with aids
- Walks with help of another person







Maximal Score 22 48
* Motor power is assessed only on the affected side.
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Appendix 5: The modified Rankin scale (mRS)
Clinical status Score
No symptoms 0
Minor symptoms which do not interfere with lifestyle 1
Some restriction to lifestyle, but look after themselves 2
Significant restriction to lifestyle, preventing total independence 3
Severe handicap preventing independent existence, but not 4
requiring constant attention
Severe handicap, totally dependent, requiring attention day and night 5
Dead 6
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5 = independent (or in shower)
GROOMING
0 = needs help with personal care
5 = independent face/hair/teeth/shaving (implements provided)
DRESSING
0 = dependent
5 = needs help but can do about half unaided
10 = independent (including buttons, zips, laces etc)
BOWELS
0 = incontinent (or needs to be given enema)
5 = occasional accident
10 = continent
BLADDER
0 = incontinent, or catheterised and unable to manage alone




5 = needs some help, but can do something alone
10 = independent (on and off, dressing, wiping)
TRANSFERS (BED TO CHAIR AND BACK)
0 = unable, no sitting balance
5 = major help (one or two people, physical), can sit
10 = minor help (verbal or physical)
15 =independent
MOBILITY (ON LEVEL SURFACES)
0 = immobile or < 50 yards
5 = wheelchair independent, including corners > 50 yards
10 = walks with help of one person (physical or verbal) > 50 yards
15 = independent (but may use any aid; eg stick) > 50 yards
STAIRS
0 = unable




Appendix 7: CSO Application




Please complete this form in 12 point font size
Project title (not more than 25 words):
Practical, streamlined and optimal use of imaging in acute stroke.





















Name and title Position Institution
Dr 1 A Kane Stroke Research Fellow University of Edinburgh
Project summary (not more than 150 words):
The most promising treatment for acute ischaemic stroke, in those who present early, is
thrombolysis with recombinant tissue plasminogen activator (rt-PA). Currently rt-PA is
licensed for use in patients with acute ischaemic stroke who meet strict eligibility criteria. It is
not known which brain imaging method best identifies the patients that are most likely to
benefit from (or be harmed by) thrombolysis. CT scanning is widely available and quick to
perform, but may be insensitive. Magnetic resonance (MR) diffusion weighted imaging
(DWI) is sensitive to early ischaemic damage. MR perfusion imaging (PWI) demonstrates
blood flow in and around the infarct. The difference between these two may represent the
'salvageable' brain. Under the umbrella of the Third International Stroke Trial, our aim is to
test the methodology for a simple and efficient MR DWI/PWI protocol that yields sufficient
information to improve patient selection, yet is not unduly time consuming or hazardous.
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1. Application for a research grant in: (please tick)
Full grant Small grant
Biomedical & Therapeutic Research ✓
Health Services Research




_3. Keywords (please see suggested list Appendix H):
Stroke Neuroradiology Imaging Emergency Geriatric
medicine medicine
4. Dates:
Proposed start date May 2004
Proposed finish date May 2005
5. Applicants' details:
Title and full name
(Principal applicant) Dr IA Kane
Full address University of Edinburgh




















Title and full name
(Co- applicant) Professor JM Wardlaw
Full address University of Edinburgh





















Title and full name
(Co-applicant) Professor PAG Sandercock






















Title and full name
(Co- applicant)
Full address
Telephone no./ext. Fax no. E-mail Hours per week
Organisation Department Position
7. Ethica approval:
Attached ✓ Not required Requested
Anima s:
Attached Not required ✓ Requested
Confidentiality and data protection are the responsibility of the investigators.
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8. Support:
This project has been submitted within the past year to:
No previous submission
This project is currently being submitted to:
No current submission
Other research grants currently held (organisation, project title, funding andperiod of
support):
None by the PI. The co-applicants hold several grants which provide supporting
infrastructure for the present proposal, as follows:
The Health Foundation. The Third International Stroke Trial: Thrombolysis for acute
ischaemic stroke. Dr RI Lindley (PI), Professor PAG Sandercock, Professor JM Wardlaw,
Professor MS Dennis, Professor CP Warlow. £656.977 1st Dec 2002 - 31st Nov 2005.
Is there any overlap between this application and the other grants that you hold or are
applying for? (organisation, project title, funding andperiod ofsupport):
No.
9. Commercial exploitation:
Is the proposed research likely to lead to patentable or other commercially exploitable
results? (please give details)
No
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10. Financial support requested:
Chief Scientis Office
Financial year (1 April - 31 March)
Year 1 Year 2 Year 3 Year 4 Total
Staff
- - - -
Indirect costs
- - - -
Equipment






- - - -
Other
- - - -
Total
£14450
NHS support costs Financial year (1 April - 31 March)




- - - -
In-patient stays
- - - -
Extra nursing
- - - -
Other (please specify)




- - - -
Allocation of clinician
time to R&D
- - - -
Purchase/hire of
equipment
- - - -
Employment of
additional staff




11. Declaration and authorisation:
Applicants:
I have read the standard conditions ofgrant set out in Appendix B of "Allyou need to
know about grantsfor research and training from the ChiefScientist Office" and agree to
abide by them and any amendments which may subsequently be issued. To my knowledge
the project described here represents the ideas, concepts and writings ofmyselfand co-
investigators and is not a modification ofprojects submitted by others elsewhere.
Signature of applicants Name (Capitals) Date
This application should be submitted by/through (i) the Head of Department and (ii) the
officer who will be responsible for administering any grant that may be awarded.
I confirm that I have read this application and that, ifsuccessful, the work will be
accommodated and administered in this Department/Institution. The staffgradings and
salaries proposed are correct and in accordance with the normal practice ofthis
Institution. I accept responsibility for the conduct of this project andfunds awardedfor it
and shall immediately inform the ChiefScientist Office if there is any indication of
scientific misconduct or misuse ofgrantfunds.
Head of Department:
Signature Date






Finance Office of Administering Institution:
Signature Date
Title and full name (block capitals) Position held
Address
Postcode
Telephone no./ext. Fax no.
When NHSScotland support costs are requested, the R&D Officer must sign the
following:
This project application has been discussed with me and I note the NHS Scotland
support costs associated with the application.
Signature Date
Title and full name (block capitals) Position held
Address
Postcode
Telephone no./ext. Fax no.
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Section 1 (not more than 6 pages)
1. Title:
Practical, streamlined and optimal use of imaging in acute stroke.
2. Introduction:
In the UK, about 150,000 people have a stroke each year. About 30% die within 6 months and
another 30% need help thereafter for everyday activities.1 Eighty percent of strokes are ischaemic
and most ischaemic strokes are due to a blocked (thrombosed) artery.
Recombinant tissue plasminogen activator (rt-PA) is licenced for use in patients with acute
ischaemic stroke who meet highly specific clinical criteria and who can be treated within three
hours of symptom onset.
There is debate about which brain imaging technique best identifies which patients are most likely
to benefit from (or be harmed by) thrombolysis. CT scanning, a widely available imaging method,
has been used as the standard in previous trials, but may be insensitive.2 Magnetic resonance (MR)
diffusion weighted imaging (DWI) is very sensitive to early ischaemic damage. MR perfusion
imaging (PWI) demonstrates blood flow in and around the infarct.4 The difference between these
two ('mismatch') may be the 'salvageable' brain (i.e. the 'penumbra' or potential benefit),5'6 but the
degree of abnormality on DWI7 8 or PWI9 indicating thrombolysis-salvageable tissue is unclear.
Indeed DWI/PWI 'mismatch' did not predict outcome after rt-PA in one observational study.10
Perhaps other features of the DWI lesion need to be considered, e.g. degree of hyperintensity
(whiteness) and 'haziness' of the lesion edge, might be important determinants of tissue injury.
Magnetic resonance angiography (MRA) may also help - perhaps patients with a still-occluded
major artery without much DWI lesion will benefit most from rt-PA. MR imaging might help
identify potential hazards in other ways. Microhaemorrhages (tiny areas of old asymptomatic
haemorrhage) increase with age, are associated with periventricular white matter hyperintensities on
T2 MR and may" or may not12 be associated with a higher risk of bleeding with rt-PA.
Unfortunately, MR takes longer and is more difficult and may be less safe to use in acutely ill
patients than CT (11% become significantly hypoxic while in the MR scanner).13 It is not clear that
the extra information from MR ('benefit') outweighs the 'hazards' of delay to treatment (further
tissue loss, performing plain X-rays to exclude metallic foreign bodies in aphasic patients), potential
risk to patients (hypoxia), or the organisational implications for provision of imaging services.
Despite numerous studies, issues remain controversial as to which imaging techniques are best in
acute stroke (see abstracts, AHA 29th International Stroke meeting, February 2004, several of which
directly contradict each other as to practicality and benefits ofMR).
The Third International Stroke Trial (1ST-3) is evaluating the safety and efficacy of rt-PA in a
wider variety of patients than is covered by the current licence. To enable as many centres as
possible to randomise patients as quickly as possible, CT scanning is the specified pre-
randomisation imaging technique. However many sites are interested in performing MR DWI/PWI
imaging to try to improve patient selection, but the Steering Committee are concerned that this
could delay the start of treatment unduly.
Thus, we need to develop and test the methodology for a simple and efficient MR DWI/PWI
protocol that yields sufficient information to improve patient selection yet is not unduly time
consuming or hazardous.
3. Results of any pilot studies:
To date, 198 patients have been randomised into IST-3 (42 from the Western General Hospital).
Our observational study of the pathophysiological changes following acute ischaemic stroke on
DWI/PWI imaging at the Western General Hospital is nearing completion (CSO ref CZB/4/14).
Interim analysis at 60 patients with baseline DWI/PWI imaging showed no association between the
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presence of a DWI/PWI mismatch (mean transit time - MTT or cerebral blood flow - CBF) and 3
month clinical outcome in patients not receiving rt-PA (Figure 1); patients with early spontaneous
Figure 1: relationship between PWI/DWI mismatch and clinical outcome at 3 months according to
whether the PWI lesion is measured as CBF or MTT.
poor good poor good
Outcome Outcome
CBF maps: P=0.33 MTT maps: P=0.25
improvement in perfusion parameters had more rapid "normalization" of DWI changes.14 Our, and
others previous work showed that spontaneous reperfusion of the infarct is associated with
improved clinical outcome.15 Whilst the influence these imaging features have on prognosis is of
interest, the key question is whether there is a significant interaction with the treatment effect of rt-
PA. This can only be studied in a randomised controlled trial, where the relevant MR parameters
are measured before randomisation.
Some such thrombolysis trials using DWI/PWI are ongoing: DIAS/DEDAS is using very restrictive
MR features including DWI/PWI mismatch to select patients for desmoteplase therapy; EPIPHET
in Australasia (29 patients recruited to date - S Davis personal communication) is recording MR
DWI/PWI in up to 120 patients randomised to rt-PA or placebo three to six hours after stroke, but
selecting patients on clinical/CT criteria; ROSIE, in the USA, is selecting patients with a perfusion
deficit on MR and radiologically measuring reperfusion after ReoPro and Retevase treatment.
None of these studies will be able to assess reliably whether or not there is an interaction with
treatment effect and, to our knowledge, these studies are not examining the role of
microhaemorrhages or white matter lesions. To address issues such as practicality and safety, as
well as prognostic value, larger studies are needed.
To date there has been little comparative work on CT and CT perfusion versus MR. However, new
CT technology makes these sorts of studies more feasible, therefore ultimately there will need to be
some comparisons between the various imaging techniques.
4. Aims:
1. To develop, test and streamline an MR imaging protocol in Edinburgh (n=20) and devise
methods for making large acute MR imaging studies conducted within a randomised
controlled trial of thrombolysis possible.
2. To survey all acute stroke centres in the UK to identify those that could do MR imaging in
acute stroke. This will determine available technology, estimate recruitment within a centre,
the number of centres needed to complete a definitive study, and implications for healthcare
of routine MR prior to thrombolysis.
3. To establish a network of interested IST-3 centres in and outside the UK, pilot the local
image analysis methods and transfer of raw MR DWI/PWI data for archiving and analysis to
the Neurosciences Trials Unit in Edinburgh.
4. To determine if a study large enough to be informative is practicable under the umbrella of
IST-3.
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5. Research questions to be asked and hypotheses to be tested:
The key hypothesis for a large-scale study is that MR imaging will help select those patients with
acute ischaemic stroke who will benefit most from rt-PA. The ultimate aim is to address the
following questions, but before this can be done a pilot study is needed to gain information on
safety and feasibility. The questions are:
• Can routine MR be made more rapid, practical and safe in acute stroke?
• Does ischaemic lesion appearance on DWI (extent, intensity, or clarity) predict the amount
of non-salvageable tissue?
• Is the benefit of rt-PA confined to those with a PWI lesion larger than the DWI lesion
(DWI/PWI mismatch) or do those without mismatch benefit as well?
• Are patients with white matter hyperintensities or microhaemorrhages at greater risk of
intracranial haemorrhage after rt-PA than those without?
• How do CT scan 'early infarct signs' and white matter hypodensities relate to MR 'early
infarct signs' and white matter hyperintensities?
To answer these questions a multicentre study is required in order to attain a large enough
sample. Therefore the research question concerning this application is:
• In the context of IST-3, is it feasible to run an MR imaging substudy aiming to improve the
safety of thrombolysis?
6. Plan of investigation:
Study at the Western General Hospital
Subject selection
All patients potentially eligible for IST-3 who present at the Western General Hospital, between
9am and 5pm, Monday to Friday, are assessed and recorded. Those fitting the trial eligibility
criteria (full protocol available at www.ist3.com), consenting to IST-3 and safe to MR, will then be
examined with the following protocol (see appendix). Several patients have already been
randomised at the Western General Hospital into IST-3 following MR rather than CT, but we need
to obtain more systematic experience in a standardised fashion.
MRIprotocol
It is proposed that patients will have a CT followed by MR as outlined in the pathway (Appx 2). As
part of the protocol, coordination, times and any delays will be recorded as part of the planning for a
larger study in order to find the optimum way of organising a comparative imaging study. Patients
will have DWI/PWI, T2, gradient echo and 3D time-of-flight MRA (TOF MRA). The DWI (three
gradient echo planar technique TR 10000ms, TE 98.8ms, 34 phases), PWI (intravenous gadolinium
bolus tracking using various simple methods of analysis of the signal time curve and more
complicated methods such as the modified Ostergaard technique to produce mean transit time
(MTT), cerebral blood flow (CBF) and cerebral blood volume);4,9 T2 weighted imaging (fast spin
echo TR 6300ms, TE 102ms), gradient echo imaging (TR 625ms, TE 15ms), and 3D time of flight
MRA are all standard techniques, total acquisition time 12-15 minutes maximum. The MR protocol
will be repeated at 24-48 hours to identify haemorrhage, infarct expansion and perfusion changes in
place of the routine IST-3 follow-up CT at 24-48 hours.
There are no clearly defined, validated guidelines equivalent to the "1/3 MCA rule for CT", on
whether the appearance of the infarct on DWI/PWI should alter treatment decisions. It is therefore
not our intention to specify what DWI/PWI appearances (on the basis of very limited information)
should lead to inclusion or exclusion of the patient from the study. The only major and absolute
exclusion is the presence of fresh intracranial haemorrhage. The justification for the approach is that
DWI lesions may resolve, that animal studies show severely ischaemic tissue beyond the boundaries
of the DWI-visible lesion, and that some patients with severe strokes and poor outcome do not have
a DWI visible lesion at presentation. Even less is known about the PWI lesion.
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The CT scans will be read centrally for lesion site and extent and degree of hypodensity according
to well-validated scoring methods by an expert panel as already established for the main trial (see
16 17www.neuroimage.co.uk). ' The MR image analysis for a main study needs to be established and
streamlined, but will include several methods, including comparing the MR read locally (i.e by the
attending physician) with a reading centrally, blinded to treatment allocation. Central analysis will
be blinded to clinical details and will include simple subjective inspection of the DWI/PWI
mismatch (for example, by the same coding template as for CT,16 and whether the DWI lesion
involves more than 1/3 of the MCA territory),18 measurement of the volume of the DWI and PWI
lesions and mismatch, and voxel by voxel analysis of subregions of the lesion on a workstation
using co-registered images. The characteristics of the DWI lesion appearance will be recorded (e.g.
signal intensity - bright/pale and edge clarity - sharply defined/fuzzy edge) as these features may
be the "DWI equivalent" of CT early infarct signs. PWI processing will include CBF, cerebral
blood volume (CBV) and MTT.9 The DWI/PWI 'mismatch' will be defined as a difference in the
volume of the lesion ofmore than 20% between DWI and PWI (CBF and MTT). We will compare
estimation by visual inspection with measured lesion volume analysis. On MRA, we will compare
presence of major artery occlusion with DWI/PWI appearance, degree of reperfiision, and clinical
outcome. Microhaemorrhages are round dots of low signal on gradient echo imaging usually less
than 2mm in diameter. Small asymmetric dots of low signal where the lenticulostriate arteries
perforate the brain substance in the inferior part of the basal ganglia are not microhaemorrhages.
MRA will be coded for vessel occlusion using the modified TIMI classification.19
Detailed baseline clinical assessments of neurological deficit (National Institutes of Health Scale -
NIHSS), blind to imaging will be obtained at baseline by the stroke physician. Further clinical
information will be obtained at 7 days as per the IST-3 in hospital follow-up form including the
NIHSS. Six month final follow-up in IST-3 is by detailed postal questionnaire, mailed directly to
the patient and conducted independently of the treating physician.
Ultimately, statistical analysis will include univariate and multivariate modelling to test for a)
independent associations between DWI/PWI lesion volumes, other aspects of their appearance, the
mismatch, time to treatment, final infarct size and clinical outcome and the interaction with rt-PA;
b) risk of intracerebral haemorrhage with improved perfusion, and microhaemorrhages and the
interaction with rt-PA; and c) correlation between the CT appearance and DWI/PWI. We will
evaluate how each PWI parameter maps to infarct extent at 24-48 hours8 and how initial DWI lesion
extent, perfusion changes, and rt-PA relate to infarct swelling. In the pilot study we will apply
simple statistics to the survey results and analyse the DWI/PWI data obtained as proposed, but the
sample size is not large enough to answer the primary questions posed in the first part of section 5.
Survey of UK stroke centres
All UK stroke centres will be contacted to see what advanced stroke imaging they have available
and, if there are no on-site facilities, where the nearest available MR scanner is located in relation to
their hospital. We have contact details from the 1999 Stroke Association survey, coupled with
details from the Scottish Stroke Care Audit and the British Association of Stroke Physicians to
ensure complete coverage. The proposed questionnaire (developed from previous experience of a
survey of radiologists in Scotland which achieved 100% response rate) is in Appendix 1, but
requires piloting prior to posting to all stroke centres. By collating the information obtained from
the study at the Western General with the UK survey, an estimate of the percentage of all UK stroke
patients who could potentially undergo MR DWI/PWI imaging will be made.
7. Timetable ofwork
The MR imaging sequences are well established. Pilot then circulate the questionnaire, collate
responses and chase non-responders. IST-3 is currently in its expansion phase. Months 1-12 -
patient recruitment, baseline and repeat imaging and collection of clinical details. Throughout the
proposed study period data will be entered and images analysed as patients accrue.
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8. Existing facilities
IST-3 has secure funding from the Health Foundation until December 2005, providing costs of trial
co-ordination, patient randomization and a clinical research fellow. We have a research dedicated
MR scanner with stroke research as a major remit, a PhD student working on methods of DW1/PWI
image analysis in stroke, a post-doctoral research fellow working on MR perfusion analysis, and a
well-developed CT imaging substudy already in progress for IST-3 (www.neuroimage.co.uk).
9. Justification of requirements
The project requires funding to cover the cost of the MR scans for the patients. The cost per scan
(£300 not including contrast) is required to cover the running of the scanner (maintenance, essential
core staffing, consumables, archiving, data processing and analysis). Contrast for PWI costs £50 per
scan. However, this is cost effective as it is a heavily discounted rate (normal cost £350 per scan),
considerable infrastructure for analysis is already in place, and it would be much more expensive to
initiate such a study with no dedicated research scanner and the cost of the research fellow is
already covered. Additional costs are for stationery and postage for the UK survey (£450).
10. Research outcomes and implementation
The outcomes of the proposed study will provide guidance on how to streamline MR imaging in
acute ischaemic stroke and whether a larger study is feasible. If feasibility is confirmed then the
aim will be to expand this study out to other IST-3 centres as a well validated protocol, to answer
the further research questions proposed regarding MR imaging. Together with the survey of UK
stroke centres, we can determine the feasibility of using MR in ischaemic stroke pre thrombolysis in
the UK. If we can better determine the likelihood of salvageable tissue using MR techniques then it
may be that a broader range of patients could be considered for thrombolysis, for example the large
group who wake with stroke and in whom exact time of symptom onset is not known. This has
important implications for the provision of imaging services in Scotland. Scotland has, on average,
better MR provision than the rest of the UK so increasing demand for MR in acute stroke is likely
to impact here first. Scotland is also ahead of the rest of the UK for CT provisions and access for
stroke, so is well placed to address the use ofMR.
11. Dissemination
Information from this pilot study will be disseminated through the IST-3 collaboration with the aim
of developing a protocol that can be used in an international multi centre study. Findings will be
published in peer-reviewed journals, presented at national and international stroke meetings, and
incorporated into guidelines where appropriate.
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13. Relevant additional material
1. Appendix 1: proposed pathway for patients involved in the practical advanced imaging brain
study.
2. Appendix 2: Questionnaire for the UK survey of stroke centres.
3. The IST-3 protocol can be viewed at http://www.ist3.com
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Appendix 1
Name of your hospital
Do you have an acute stroke unit/ stroke rehab unit / combined stroke unit?
(please circle most appropriate answer)
Do you have a CT scanner on site YES / NO
The following questions relate to on site MRI scanning facilities. If you have no MRI at
your hospital please move directly to question 6.
1. Do you have an on site MRI scan YES / NO
2. If yes, is there 24-hour access to the MRI scanner YES / NO
3. Is the scanner available for acute stroke patients YES / NO
4. Can you MR scan acute stroke patients within 5 hrs of symptom onset? YES / NO
If yes, go to question 5
5. How many patients filling the criteria in Q4 are scanned per month? I I
6. If you do not have a scanner on site - where is the nearest available MRI?
• Location
• Approximate distance from your hospital
If you have any other information, which you feel may be useful, please note it here
Many thanks for taking the time to answer this questionnaire.
Dr Ingrid Kane
IST-3 Stroke Research Fellow
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Curriculum vitae of applicant(s)/proposed staff (if known): maximum 1 page per applicant.
(This form can be copied as necessary. DO NOTATTACH SEPARATE CV.)
Surname
Initials Age Title
KANE I A 33 DR
Degrees, etc.
BSc in Physiology and Basic Medical Sciences (2.1) 1993
MBBS (Lond) 1996
MRCP (UK) 2000
Posts held (with dates)
May 2003 Stroke Research Fellow, Edinburgh University
Oct 2001 -May 2003 SpR in Geriatrics and General Medicine (SW Thames)
Feb 2000-Aug 2000 Staff grade General Medicine, St Richards Hospital
Feb 1998-Aug 2000 SHO General Medicine, St Richards Hospital
Aug 1997-Feb 1998 SHO Accident and Emergency, West Middlesex University Hosp
Feb 1997-Aug 1997 HO General Surgery, Worthing Hospital
Aug 1996-Feb 1997 HO General Medicine, West Middlesex University Hospital
Relevant recent publications (with title and reference)
Kane I, Sandercock P. Thrombolysis for acute ischaemic stroke. Stroke Review 2003; 7(4):
95-99
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Curriculum vitae of applicant(s)/proposed staff (if known)
(this form can be copied as necessary)
Surname Initials Age Title
WARDLAW JM 45 PROFESSOR
Degrees, etc.
BSc(Hons), Physiology First Class University of Edinburgh 1979






Posts held (with dates)
2002 - present Professor and Honorary Consultant Neuroradiologist, Edinburgh
1998 - 2002 Reader and Honorary Consultant Neuroradiologist, Edinburgh
April '94 - Sept '98 Senior Lecturer and Elonourary Consultant Neuroradiologist, Edin
Feb '92 - Mar '94 Consultant Neuroradiologist, INS, Glasgow
Oct '90 - Jan '92 MRC Research Fellow (Senior Registrar) in Neuroradiology, Edin.
1988 - 90 Senior Registrar Radiology, Edinburgh
1985 - 88 Registrar Radiology, Edinburgh
1983 - 85 SHO General Medicine, Edinburgh
1982 - 83 Pre Registration FIO, Edinburgh
Relevant recentpublications (with title and reference)
Wardlaw JM, Keir SK, Bastin ME, Armitage PA, Rana AK. Is diffusion imaging appearance an
independent predictor of outcome after ischemic stroke? Neurology 2002;59:1381-1387.
Rana AK, Wardlaw JM, Armitage PA, Bastin ME: Apparent diffusion coefficient (ADC)
measurements may be more reliable and reproducible than lesion volume on diffusion-weighted
images from patients with acute ischaemic stroke - implications for study design. Magn. Reson.
Imag 2003;21:617-624.
Wardlaw JM, West TM, Sandercock PAG, Lewis SC, Mielke O, The International Stroke Trials
Collaborative Group: Visible infarction on computed tomography is an independent predictor of
poor functional outcome after stroke, and not of haemorrhagic transformation. JNNP
2003:74:452
Wardlaw JM, Sandercock PAG, Berge E. Thrombolytic therapy with recombinant tissue
plasminogen activator for acute ischaemic stroke. Where do we go from here? A cumulative
meta-analysis. Stroke 2003;34:1437-1442.
Wardlaw JM, del Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke
(Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
CD000213
Keir SL, Wardlaw JM: Systematic review of diffusion and perfusion imaging in acute ischaemic
stroke. Stroke 2000:31:2723-2731.
Wardlaw JM, Keir SL, Seymour J, Lewis S, Sandercock PAG, Dennis MS, Cairns J. What is the
best imaging strategy for acute stroke? Health Techno! Assess 2004;8(1).
Keir SL, Wardlaw JM, Bastin ME, Dennis MS: In which patients is diffusion-weighted MR
imaging most useful in routine stroke care? Journal ofNeuroimaging 2004
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Surname Initials Age Title
SANDERCOCK PAG 52 PROFESSOR
Degrees, etc.
BA University of Oxford (1st Class) 1972
BM, BCh University of Oxford 1975
DM University of Oxford 1985
FRCPE Royal College of Physicians, Edinburgh 1991
FmedSci Fellow Academy of Medical Sciences 2002
Posts held (with dates)
Professor ofNeurology University of Edinburgh 1999 -
Reader in Neurology University ofEdinburgh 1992-1999
Senior Lecturer in Neurology University of Edinburgh 1987-1992
Lecturer and Hon Senior Registrar Liverpool University 1985-1987
Registrar in Neurology Manchester Royal Infirmary 1979-1981
Registrar in General Medicine North Staffordshire Hospital 1978-1979
Rotating Senior House Officer North Staffordshire Hospital 1977-1978
Relevant recentpublications (with title and reference)
Collaborative meta-analysis of randomised trials of antiplatelet for prevention of death, myocardial
infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration. BMJ 2002;
324:71-86.
International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular
coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Molyneux A,
Kerr R, Stratton I, Sandercock PAG, Clarke M, Shrimpton J, Holman R. The Lancet 2002;
360:1267-1272.
A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of
thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS. Sandercock
PAG, Berge E, Dennis M, Lorbes J, Hand P, Kwan J, Lewis S, Lindley R, Neilson A, Thomas B,
Wardlaw J. Health Technology Assessment 2002; Vol 6: No.26.
Visible infarction on computed tomography is an independent predictor of poor functional outcome
after stroke, and not ofhaemorrhagic transformation. Wardlaw JM, West TM, Sandercock PAG,
Lewis SC, Mielke O for the International stroke Trials Collaborative Group. J Neurol Neurosurg
Psychiatry 2003; 74:452-458.
Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke:
where do we go from here? A cumulative meta-analysis. Wardlaw J, Sandercock PAG, Berge E.
Stroke 2003; 34(6): 1437-42.
Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia?
Wardlaw J, Sandercock PAG, Dennis M, Starr J. Stroke 1003; 4(3):806-12.
What is the best imaging strategy for acute stroke? Wardlaw JM, Keir SL, Seymour J, Lewis S,
Sandercock P, Dennis MS, Cairns J. Health Technol Assess 2004;8(1):1-192.
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Section 4
Report on previous CSO grant(s)
For each and every CSO grant which you or any of your co-applicants have held as principal
applicant and which has begun or terminated over the past five academic years, please give the
information requested below (this form should be copied for each grant).
Project title










Dr JMWardlaw, Dr MS Dennis
Current perception ofsignificance
The purpose of this work was to improve identification of patients at greatest risk of stroke after
a TIA, amaurosis fugax or minor stroke, so that preventive measures like carotid endarterectomy may be
targetted more effectively. We also examined the prediction of vascular death and myocardial infarction.
We collected clinical and radiological data on over 4000 TIA/stroke patients. Our statistical models can identify
the 75% of patients who are very unlikely to have a stroke, MI or vascular death, and the small proportion of
patients at 40-50% risk of stroke, MI or vascular death in the two years after presentation, although they, like
others,are not so specific. Compared with previously described models in the literature, ours performed better
predicted MI and vascular death as well as stroke, and was derived in a realistic, modern cohort of patients
typical of vascular clinics (as opposed to those from highly selected trial data). We therefore believe that it will
make a significant contribution to the body of knowledge on targeting stroke prevention and impact on
neurovascular clinics and daily patient management, as well as in new research to identify other risk factors.
Scientific papers directly resultingfrom this grant
Wardlaw JM, Lewis SC, Dennis MS, Counsell C, McDowall M: Is Visible Infarction ofComputed Tomography
Associated With an Adverse Prognosis in Acute Ischaemic Stroke? Stroke 1998;29:1315-1319.
- Mead G, Lewis SC, Wardlaw JM, Dennis MS: Should computed tomography appearance of lacunar stroke influence
patient management? JNNP 1999;67:682-4.
- Mead GE, Wardlaw JM, Lewis SC, McDowall M, Dennis MS: The influence of randomised trials on the use of
anticoagulation for atrial fibrillation. Age Ageing 1999;28:441-446.
- Oliver TB, Lammie GA, Wright AR, Wardlaw J, Patel SG, Peek R, Ruckley CV, Collie DA: Atherosclerotic Plaque at the
Carotid Bifurcation: CT Angiographic Appearance with Histopathologic Correlation. AJNR May 1999;20:897-901.
- Mead GM, Wardlaw JM, Lewis SC, McDowall M, Dennis MS: Can simple clinical features be used to identify patients
with severe carotid stenosis on Doppler ultrasound? JNNP 1999;66:16-19.
- Lammie GA, Wardlaw JM, Allan PA, Ruckley CV, Peek R: What simple markers of atheromatous plaque activity can be
reliably detected using ultrasound? Eur J Ultrasound 2000; 11:77-86.
- Mead GE, Lewis SC, Wardlaw JM: Interobserver variability in Doppler ultrasound influences referral of patients for
carotid surgery. Eur J Ultrasound 2000; 12:137-143.
- Mead GE, Wardlaw JM, Lewis SC, McDowall M, Dennis MS: The influence of randomised trials on the use of
anticoagulation for atrial fibrillation. Age Ageing 1999;28:441-446.
- Mead G, Lewis SC, Wardlaw JM, Dennis MS: Should computed tomography appearance of lacunar stroke influence
patient management? JNNP 1999;67:682-4.
- Mead GE, Wardlaw JM, Dennis MS, Lewis SC, Warlow CP: Relationship between pattern of intracranial artery abnormalities
on transcranial Doppler and Oxfordshire Community Stroke Project clinical classification of ischaemic stroke. Stroke
2000;31:714-719.
- Mead GM, Lewis SC, Wardlaw JM, Dennis MS, Warlow CP: Severe ipsilateral carotid stenosis and middle cerebral artery
disease in lacunar ischaemic stroke: innocent bystanders? J Neurol 2002;249:266-271.
- Lewis SC, Wardlaw JM: Which Doppler velocity is best for assessing suitability for carotid endarterectomy? European
Journal ofUltrasound 2002;15:9-20.
- Mead G. Lewis S, Wardlaw JM, Dennis MS: Comparison of risk factors in patients with transient and prolonged eye and
brain ischemic syndromes. Stroke 2002;33:2383-2390.
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Section 4
Report on previous CSO grant(s)
For each and every CSO grant which you or any of your co-applicants have held as principal
applicant and which has begun or terminated over the past five academic years, please give the
information requested below (this form should be copied for each grant).
Project title




Start date Finish date Date report due
1st Feb 2001 31st Jan 2004 March 2004
Grantholders
Dr JM Wardlaw, Dr MS Dennis, Dr ME Bastin
Current perception ofsignificance
We aim to improve understanding of the relationship between the appearance of the brain on
advanced MR imaging and brain perfusion and clinical features and outcome to improve identification
of penumbral tissue after acute ischaemic stroke.
There is great interest in applying advanced imaging in acute ischaemic stroke but most of the
previous work has not been very critically performed. We are collecting a series of patients who will
have sequential MR imaging to follow the pattern of change in imaging appearance and symptoms to
identify salvageable/ unsalvageable tissue. We aim to recmit 60 with complete imaging and have
already recruited 35 of whom 10 have completed imaging.
57 patients had been recruited. 46 patients have undergone serial scanning. 11 have not had
further scanning because of refusal (5), the stroke was actually due to a haemorrhage (3), or
death (3). 30 patients have reached the 3 month follow-up point so far.
Scientific papers directly resultingfrom this grant
So far only abstracts have been produced:
- Hand PJ, Rivers CS, Rowat AM, Bastin ME, Dennis MS, Wardlaw JM. Does DWI lesion volume predict
outcome after stroke? 11th European Stroke Conference, Geneva, Switzerland, May 29th - June 1st 2002 (Oral
Session - Neuroimaging I), Cerebrovasc Dis 2002; 13(suppl 3):57.
- Hand PJ, Kwan J, Sandercock PAG, Wardlaw JM, Dennis MS. Improving the clinical assessment of patients
eligible for thrombolysis. 7th International Symposium on Thrombolysis in Acute Ischaemic Stroke, Lyon, May
2002.
- P.A. Armitage, C.S. Rivers, T.K. Carpenter, M.E. Bastin, P.J. Hand, J.M. Wardlaw. MR perfusion imaging:
problems resulting from a lack of contrast agent in infarcted regions. 12th European Stroke Conference, May
2003, Valencia, Cerebrovascular Dis in press.
- O'Brien P, Stratton S, Seller RS, Wardlaw JM. Fogging" on MR after ischaemic stroke - how often does it
occur and does it matter? 12lh European Stroke Conference, May 2003, Valencia, Cerebrovascular Dis in press.
- Rivers CS, Armitage PA, Carpenter T, Hand PJ, Dennis MS, Bastin ME, Wardlaw JM. MR diffusion and
perfusion abnormalities in ischaemic stroke - patterns of sub-regional change and tissue recovery. 12th European
Stroke Conference, May 2003, Valencia, CerebrovascularDis in press.
- Rivers CS, Armitage PA, Carpenter T, Bastin ME, Hand PJ, Dennis MS, Wardlaw JM The effect of ischaemic
lesion swelling on serial MR diffusion and perfusion measurements in stroke. 12th European Stroke Conference,
May 2003, Valencia, Cerebrovascular Dis in press.
- Carpenter TK, Armitage PA, Bastin ME, Wardlaw JM. Artefacts in MR Perfusion parametric images in
ischaemic stroke - effects of variation in bolus arrival time. 12th European Stroke Conference, May 2003,
Valencia, Cerebrovascular Dis in press.
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Report on previous CSO grant(s)
For each and every CSO grant which you or any of your co-applicants have held as principal
applicant and which has begun or terminated over the past five academic years, please give the









Final report date and CSO Committee Grade (excellent, good, satisfactory, unsatisfactory)




Scientific papers directly resultingfrom this grant:
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Section 5
R&D Project Details Pro forma - Information for the National Research Register
1. Methodology:
(please tick)
Full grant Small grant
Clinical trial
Randomised trial
Other (please specify in free text)
2. Sample group description (the notional population from which the sample is drawnfor
the purposes ofyour study)
The population is drawn from those presenting within 6 hours of developing the
symptoms of acute ischaemic stroke, who fit the eligibility criteria for thrombolysis
under the Third International Stroke Trial (see www.ist3.com). They must have no
contraindications to MR imaging.
3. Outcome measure description (endpoints orfactors used to evaluate health status, such as
survival discharge status or quality of life. Can also be a symptom e.g. reduction in blood
pressure.)
The outcomes of the proposed study will provide guidance on how to streamline MR
imaging in acute ischaemic stroke and whether a larger study is feasible. If feasibility is
confirmed then the aim will be to expand this study out to other IST-3 centres as a well
validated protocol, to answer the further research questions proposed regarding MR
imaging. Together with the survey ofUK stroke centres, we can determine the
feasibility of using MR in ischaemic stroke pre thrombolysis in the UK.
4. Project related web site (the address for a web site which contains further related
informationfor an individual project)
www.ist3.com
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• ANY patient with a mild, moderate, or severe deficit, due to acute stroke, in whom:
1. There is a clear time of onset of < 6 hours since symptoms first noticed.
2. CT or MRI brain scan has excluded intracranial haemorrhage.
3. In the doctor's opinion, there is no clear indication for treatment, or clear
contraindication to rt-PA (recombinant tissue plasminogen activator).
• Reasons for not entering patients in the trial may include:
1. small likelihood of worthwhile benefit, such as:
□ symptoms considered likely to resolve completely within the next few hours
(i.e. a TIA)
□ patient already dependent on others prior to the onset of the present stroke
□ prognosis likely to be very poor no matter what treatment(s) are given (e.g.
coma)
□ patient has another serious life-threatening illness which is likely to lead to death
within the next few months,
□ patient is female and has childbearing potential (unless it can be assured that
pregnancy is not possible), or is currently breast feeding.
2. high risk of adverse effects of treatment, such as:
□ persistent, severe elevation of blood pressure.
□ known abnormal coagulation or platelet dysfunction.
□ trauma (e.g. collapse at time of stroke) or major surgery, or gastrointestinal or
urinary tract haemorrhage within the previous 21 days.
□ arterial puncture at a non-compressible site within the previous 7 days.
• Patients who have been taking aspirin or other anti-platelet agents before the trial are
eligible.
• The final decision for trial eligibility rests with the responsible doctor, if unsure phone the
trial's 24-hour helpline (details below).
BEFORE YOU MAKE THE RANDOMISATION PHONECALL
• Measure NIHSS
• Check blood glucose (must be 3.0 - 20 mmol/L)
• Obtain patient consent, or relative assent, for entry into IST-3 using patient or relative
information provided
• Complete the Randomisation Notepad
• Telephone the 24 hour randomisation service +44 (0) 131 537 2797
• At the end of the call you will be allocated either rt-PA (the calculated dose for the bolus and
one-hour infusion will be provided) or conventional treatment.
Give bolus immediately over 1-2 minutes by hand,
randomisation
followed by the remainder infusion over the next 60
of the
minutes
Complete the treatment record form as you give the
trial treatment
record,
Do not give antiplatelet or anticoagulant therapy in
first 24 hours after the infusion
All other management is at the discretion of the
responsible clinician
Repeat brain scan 24-48 hours after randomisation
Repeat brain scan 24-48 hours after
Management of the patient is at the discretion
responsible clinician
Aspirin can be given
Fill in the patient treatment and monitoring
including the blood pressure readings
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Appendix 11
MAGNETIC RESONANCE IMAGING STUDY IN ACUTE STROKE
PATIENT'S CONSENT FORM
The Magnetic Resonance Imaging Study in Acute Stroke has been
explained to me and I have read the information leaflet about it.
I have had time to consider the study and have had all my questions
about it answered.
I understand that I am free to withdraw at any time from any part of the
study, without giving a reason, and without it adversely affecting my future
medical care.




Signed: (signature of the investigator)
Name: (name of the investigator)
Date:




Practical, streamlined and optimal
use of imaging in acute stroke.
Time of symptom onset: :
Time of arrival at ARU: :
_
Time of assessment: :
Time of CT: :
Total time in CT:
_____
Time of MRI: :
Total time in MRI:
Time of randomisation: :
Treatment: control / rt-PA / rt-PA (licensed)
Date:
Patient details:






Drug treatment on admission:




Any other details e.g. delays prior to MR; skull or CXR required
Total scan acquisition time in MR (mins):
Observer with patient in MR: Y / N
Scan completed: Y / N If N, main reason:
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Appendix 14
UK survey of availability of MR scanning for patients with acute stroke
Name of your hospital:
1. Do you have a CT scanner on site? YES / NO
2. Do you have an MRI scanner on site? YES / NO
The following questions relate to the on site MRI scanning facilities at your hospital. If you
do NOT have an MRI scanner at your hospital please move directly to question 6.
3. Is it possible to obtain an MR scan on an acute stroke patient within 6 hours of symptom
onset in normal working hours?
Please indicate using scale below, by marking on the line e.g. I j I
Very easy Impossible5r^i
4. Is it possible to get out of hours access to the MR scanner for stroke
patients?
Please indicate using scale below, by marking on the line e.g. ]__| [
Very easy Impossible
5. If you know the details of your MR scanner, please circle relevant options.
Make: GE Phillips Siemens Not known
Magnet strength: <1.5T 1.5T 3.0T Not known
Approx. year installed: Before 2000 2000-2005 Not known
6. If you do NOT have a scanner on site - where is the nearest available
MRI?
• Location
Approximate distance from your hospital
7. In the last 6 months, how often (approx) have you obtained an MR scan
for stroke within 6 hrs of symptom onset , within 12hrs ,
after any time .
If you have any other information about access to imaging for acute stroke, which you feel
may be useful, please note it here
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Availability of CT and MR for Assessing Patients
with Acute Stroke
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Background
Brain imaging is essential for the selection of stroke patients
for thrombolysis. The imaging method must be available rapidly
at all times, quick to perform, and able to exclude intracerebral
haemorrhage and mimics of stroke [1]. Computerised tomogra¬
phy (CT) scanning is already widely available [2-4] and cost-ef¬
fective [5]. However, signs on CT indicating ischaemic stroke are
subtle within the first few hours of symptom onset and can be
hard to see in people with leukoaraiosis or previous stroke [6].
Magnetic resonance imaging (MRI) may provide more infor¬
mation than CT in patients with acute stroke. For example, diffu¬
sion-weighted imaging (DWI) MRmay bemore sensitive than CT
at detecting ischaemic stroke in patients with mild symptoms [7],
and gradient echo more sensitive for showing old haemorrhages
in patients who present several days after their stroke [8]. There
is increasing pressure that MR should be the method of choice to
select patientswith acute stroke for thrombolysis [9] and the first-
line imaging method for all stroke [10] (though there are practi¬
cal difficulties in performing MR in about 20% ofstroke patients)
[11,12].
At least 2 acute stroke trials in progress are assessing the use
ofMRI DWI to select patients [13, 14], If it is established that MR
improves selection for thrombolysis, we sought to identify wheth¬
er the UK would be in a position to provide this imaging modal¬
ity for patients with acute stroke. We therefore surveyed all acute
hospitals in the UK admitting patients with acute stroke to assess
their access to MRI.
Methods
We assembled a database of the 268 hospitals in the UK that
admitted acute stroke patients, from the National Sentinel Stroke
Audit [2] and the Scottish Stroke Audit [4]. We sent a short ques¬
tionnaire to the lead stroke clinicians at each hospital, with a cov¬
ering letter and stamped addressed envelope in February 2005.
For centres with access to MRI, we sought further details on the
capacity of their MRI machines both in and out of normal work¬
ing hours. The questionnaire included visual analogue scales to
assess the ease ofaccess toMRI, whichwere measured with a scale
from 0 for 'impossible' to 12 for 'very easy'. We arbitrarily defined
'difficult' as a score between 0 and 5. We sent a reminder to those
who failed to respond on the first occasion.
Results
The total number of replies was 248/268 (93% of the total num¬
ber of admitting hospitals). The survey was complete by the end
of 2005.
Access to CT
Ofthe hospitals admitting acute stroke patients, 240 (97%) had
a CT scanner on site. Only 8 had neither CT nor MRI, ofwhich 3
were in rural areas (174-402 km to their nearest scanner). The
remaining 5 hospitals with no CT or MRI were very small units
about 32 km from their nearest scanner.
Access to MRI
Most hospitals that admitted patients with acute stroke had
MRI facilities on site (192/245; 78%). Of the 192 hospitals with
MR, 3 used mobile units which were not available 24 h a day. All
the hospitals that had MR also had CT (fig. 1).
Forty-eight hospitals had on-site CT but no MRI. Of the 46
respondents, the average distance to an MRI machine was 37 km
(range 0.8-129).
Although more than three quarters of hospitals had MRI in
their hospital, access for stroke patients was difficult. Seventy-
three percent of hospitals found MRI access difficult during
working hours and 95% out of hours.
■ CT only (n = 48)
I I CT and MRI (n = 192)
~2 No on-site scanning (n = 8)
Fig. 1. UK availability of scanning facilities for
acute stroke.
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Table 1. Number of hospitals carrying out MRI scans on acute
stroke patients within the previous 6 months
Estimated num¬ <6 h after <12 h after At any time after
ber of patients stroke (num¬ stroke (num¬ stroke onset (num¬
scanned ber of hospitals) ber of hospitals) ber of hospitals)
None 137 117 8
1-5 17 29 34
6-10 3 3 40
>10 1 5 59
Totals 158 154 141
Few patients hadMRI within 6 h ofstroke (table 1).Within the
6 months preceding the survey, only 21/192 (11%) hospitals with
MR on site had performedMR on any patientswithin 6 h of stroke
onset and 58/192 (30%) had scanned any patients within 12 h of
stroke.
Discussion
CT scanning was available in almost all UK hospitals admit¬
ting patients with acute stroke. Although 78% of such hospitals
had access to MRI, it was rarely available sufficiently quickly to
be ofvalue in the management ofpatients with acute stroke. Mak¬
ing a number of assumptions about patterns of acute stroke care,
we estimated that for the year 2005 in the whole of the UK about
300 patients with acute stroke hadMRI within 6 h of stroke; about
0.2% ofall new strokes in the UK. This may be an underestimate,
but even ifwe have erred by a factor of 10 (which would not accord
with our experience), the total would still only be 2%. We believe
this estimate ofMRI service provision to be realistic in view of the
excellent response rate (93%). The Royal College of Physicians
Sentinel Stroke Audit [2] tends to confirm this and found that al¬
though 88% of stroke units had access to MRI scanning, it was
only available urgently in 53%. This contrasts with 91% of units
having access to emergency CT scanning.
Does this survey indicate that stroke patients in the UK are
disadvantaged? For routine use of thrombolysis, perhaps not. Im¬
mediate CT scanning for acute stroke is a highly cost-effective CT
strategy [15]. In patients who are candidates for thrombolysis, CT
within the first few hours of stroke with a structured interpreta¬
tion is as good as MR with DWI in identifying early ischaemic
change [12], though in milder stroke, MRI may be more sensitive
[16]. Both CT and MR can assess cerebral perfusion in the acute
phase, and it remains unclear which will be the best test for select¬
ing patients for thrombolytic therapy.
Although this survey demonstrates that there is wide provi¬
sion ofMRI equipment in the UK, the proportion ofscanners per
head of population is still less than in the best resourced areas of
Europe orNorth America [17]. Many UK centres now have access
toMRI and at least 1 UK centre has audited the use ofMR as first-
line imaging for suspected stroke [18]. We have not found any
comparable nationwide surveys of access to MR for patients with
acute stroke in other countries, although MR is reported to be dif¬
ficult to access in some countries [19]. However, access to imaging
for stroke patients depends on more than the mere presence of an
MR scanner. Stroke competes with many other diseases, which
often affect a younger population who are perceived to be needier.
Demands on CT and MR are substantial, with radiology depart¬
ments dealing with many competing priorities. Better access to
MRI (and CT) for stroke patients requires not only more ma¬
chines but also extended operating hours and increased funding
for support by clinical radiologists (currently a shortage special¬
ty). If the UK, one of the most prosperous countries in Europe
(ranked fourth in the world by GDP), has yet to provide rapid ac¬
cess to MR for all patientswith acute stroke, how can less wealthy
countries be expected to provide MR for all?
Therefore, in many countries, CT may well continue to be the
'workhorse' imaging modality in acute stroke, since it is univer¬
sally available - without delay - to patients with acute stroke; for
a trained reader, it is as sensitive as DWI MR; and perfusion CT
imagingmay prove to be as effective asMR perfusion for selecting
patients for thrombolysis. On the other hand, for milder strokes,
strokes presenting late and other areas ofcerebrovascular disease,
MR still has advantages over CT and does not involve ionizing
radiation, so the drive to increase the availability ofMR around
the world for patients with stroke should continue.
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Introduction
Posterior reversible encephalopathy syndrome (PRES) is a rare
complication of preeclampsia-eclampsia [1]. The characteristic
neuroradiological findings are multifocal and often symmetric,
increased T2 or diffusion-weighted signal intensity lesions in the
posterior dominant white and gray matter [2], Diffusion tensor
imaging (DWI) changes support the hypothesis that vasogenic
edema is the pathophysiological mechanism underlying this syn¬
drome [2]. Several reports, however, associate PRES with cyto¬
toxic edema, ischemic stroke, and angiographic vasospasm [3-6].
These findings suggest an interrelationship between PRES and
cerebral vasospasm. We report two preeclamptic-eclamptic pa¬
tients with clinical and neuroradiological features of PRES. In
these patients, MR angiography (MRA) showed reversible vaso¬
spasm of large- and medium-sized cerebral arteries. The vaso¬
spasm was not present initially, and was preceded by the develop¬
ment of vasogenic edema.
Case Reports
Patient 1
A 28-year-old Japanese woman, gravida 2, para 0, with a twin
pregnancy, suddenly developed a severe headache and vomiting
at 35 weeks and 5 days of gestation. She had no evidence of car¬
diac, pulmonary, renal or cerebrovascular disease. Her blood
pressure was 178/80 mm Hg, with proteinuria of 7.8 g/24 h. Neu¬
rological examination was normal. Hematological, renal and liv¬
er function tests were also normal. A diagnosis of preeclampsia
was made. She was started on intravenous magnesium sulfate for
seizure prophylaxis, and an emergent cesarean delivery was per¬
formed for breech presentation. Two male infants weighting 2,302
and 1,948 g were delivered, and both did well.
Four hours postoperatively, the patient grew disoriented and
became obtunded. Her blood pressure was 170/110 mm Hg. A
complete blood count showed no major abnormalities with a
platelet count of 160,000/p.l. Her electrolytes and renal function
tests were normal. Brain magnetic resonance imaging (MRI)
showed multifocal areas of edema with hyperintense signals on
T2-weighted and fluid-attenuated inversion recovery (FLAIR)
images in the bilateral frontal, parietal, and occipital gray and
white matters, basal ganglia, brainstem and bilateral cerebellum
(fig. la). These areas showed predominantly high signals on DWI
that corresponded to high signal intensities on an ADC map.
These findings represented vasogenic edema. However, some of
the diffusion-hyperintense lesions in the bilateral basal ganglia
and left cerebellum showed low-signal intensities on the ADC
map. This was consistent with cytotoxic edema. An MRA at this
time did not show any significant abnormalities except for an an¬
eurysm at the right internal carotid-ophthalmic artery (fig. lb).
The patient was treated with sodium nitroprusside, nicardipine,
magnesium sulfate, glycerol, and the free radical scavenger edara-
bone. The next day, she recovered consciousness without neuro¬
logical sequelae. On postpartum day 4, her headache had resolved
and her blood pressure stabilized at 120/70 mm Hg.
A follow-up MRI on postpartum day 4 showed resolution of
the high signal areas on FLAIR and T2-weighted images (fig. lc);
however, MRA revealed multifocal irregular narrowing of the bi¬
lateral anterior cerebral arteries (ACAs), middle cerebral arteries
(MCAs), and posterior cerebral arteries (PCAs). This was consis¬
tent with vasoconstriction (fig. Id). An extensive workup for ce¬
rebral vasculitis was negative. Additionally, microbiological, au¬
toimmune and thrombophilia studies showed no abnormalities.
On postpartum day 13, the patient's blood pressure had returned
to normal without any medications, and she had no proteinuria.
All neuroradiological abnormalities had resolved on a repeat
brain MRI and MRA preformed on postpartum day 13. The pa¬
tient had recovered completely with no neurological deficits on
postpartum day 22, and was discharged.
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Comparison of 10 Different Magnetic Resonance Perfusion
Imaging Processing Methods in Acute Ischemic Stroke
Effect on Lesion Size, Proportion of Patients With Diffusion/Perfusion
Mismatch, Clinical Scores, and Radiologic Outcomes
Ingrid Kane, MRCP; Trevor Carpenter, PhD; Francesca Chappell, MSc; Carly Rivers, PhD;
Paul Armitage, PhD; Peter Sandercock, FRCPE, FMedSci; Joanna Wardlaw, FRCR, FRCP, FMedSci
Background and Purpose—Several methods are available to assess the magnetic resonance perfusion lesion in acute
ischemic stroke. We tested 10 of these to compare perfusion lesion sizes and to assess the relation to clinical scores and
final infarct extent.
Methods—We recruited patients with acute ischemic stroke, performed diffusion- and perfusion-weighted imaging, and
recorded stroke severity at baseline, final infarct size on T2-weighted imaging at ^1 month, and Rankin Scale score at
3 months. We calculated 10 perfusion parameters (6 of mean transit time, MTT; 3 of cerebral blood flow; 1 of cerebral
blood volume; 7 relative and 3 quantitative), measured the perfusion-weighted imaging lesion and diffusion/perfusion
mismatch volumes, and compared each with clinical and radiologic outcomes.
Results—Among 32 patients, the median perfusion lesion volume varied from 0 to 14 882 voxels (/><0.0001); the
proportion of patients with mismatch varied from 9% to 72% (P<0.05), depending on the perfusion parameter. Five
measures of relative MTT were associated with baseline National Institutes of Health Stroke Scale score; 1 (arrival time
fitted) was also associated with clinical outcome. Final infarct size was most strongly associated with MTT measures,
including arrival time fitted. There was no advantage of quantitative perfusion measures and no relation between
mismatch presence/absence and infarct expansion with any of the 10 perfusion measures.
Conclusions—Perfusion lesion size differs markedly depending on the parameter calculated. Relative perfusion parameters
performed as well as quantitative ones. Some parameters (mainly representing MTT measures) were correlated with
clinical scores; others were correlated with final infarct size; and arrival time fitted was correlated with both. These
findings should be validated in other datasets. A consensus is required on which perfusion measurement and processing
methods should be used. (Stroke. 2007;38:3158-3164.)
Key Words: cerebral perfusion ■ diffusion imaging ■ magnetic resonance ■ stroke
Magnetic resonance (MR) perfusion-weighted imaging(PWI) in combination with diffusion-weighted imag¬
ing (DWI) is thought to identify ischemic, potentially sal¬
vageable tissue in acute ischemic stroke. Therefore, PWI and
DWI are used increasingly in clinical trials1 and to guide
clinical decision making in patients with acute ischemic
stroke.2'3
The most commonly used method for acquiring the PWI
data, dynamic susceptibility contrast imaging, is per¬
formed by rapid imaging immediately before and then for
up to 1.5 minutes after an intravenous injection of a
gadolinium-based MR contrast agent.4 PWI data so ac¬
quired may then be analyzed in several different ways to
yield relative or quantitative values (Figure 1 and Table l).5-6
Relative values require less complex data processing and
are often immediately accessible from the scanner console
(eg, time to peak, TTP; full-width, half-maximum,
FWHM). However, relative measurements do not usually
account for the arterial input function (AIF) and thus may
introduce large errors.7-9 Quantitative perfusion parame¬
ters (eg, quantitative cerebral blood flow, qCBF, or cere¬
bral blood volume, CBV)4 overcome some but not all10-11
of the limitations of relative parameters but require off-line
processing including deconvolution; therefore, they take
longer to produce the perfusion image.10 A recent literature
summary of a stroke imaging center survey indicated that
different PWI parameters were used in different centers.3
Does this variation matter?
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Figure 1. Contrast-time curve showing the different parameters
used to estimate perfusion (concentration in arbitrary units, All).
FWHM first moment="balancing point" of curve along the time
axis; Cmax (also known as peak height), TTP (also known as
Tmax after deconvolution), and BAT=bolus arrival time. AUC
indicates area under the curve.
PWI lesions that reflect CBF are generally smaller than
those that reflect mean transit time (MTT).12"16 Different
ways of estimating a single PWI parameter like MTT may
yield differently sized PWI lesions.'7 Comparisons of how
well different relative and/or quantitative PWI lesions predict
infarct growth yield differing results,17"19 possibly due to
differences in patient case mix or the timing of scanning, as
well as to variations in the combinations of PWI processing
methods used.
What effect does this PWI lesion variability have on any
relation between the presence or size of the PWI lesion or
DWI/PWI mismatch and the neurologic severity of the stroke
at baseline? Of previous studies reporting correlations be¬
tween perfusion parameters and stroke severity at presenta¬
tion, 220-21 reported that TTP, a relative measure of MTT, was
correlated with baseline National Institutes of Health Stroke
Scale (NIHSS) score; 215-22 suggested a correlation between
qMTT and baseline NIHSS; and l22 suggested a correlation
between qMTT and the Scandinavian Stroke Scale score.
If imaging is to guide clinical trials or routine practice, then
it is important to know which baseline PWI lesion(s) best
relates to the final infarct extent and clinical outcome. These
2 outcomes may have different baseline predictors, which
may differ from PWI lesions that are correlated with baseline
neurologic deficit. Several studies that compared acute PWI
lesions and radiologic outcomes used outcome time points
that were too early to determine the "final" infarct extent (24
hours to «»1 week after stroke).1824 Three studies that
examined later time points only compared perfusion values,
not lesion extent, but found associations between measures of
MTT and 60- or 90-day T2 findings.20-21-25 A correlation
between the acute PWI lesion and functional clinical outcome
was found between TTP and modified Rankin Scale (mRS)
score,21 relative (r) MTT and mRS,26 and qMTT and the
Barthel Index.22
In view of these differences, we compared 10 different
ways of processing the PWI data to quantify variation in PWI
lesion size and DWI/PWI mismatch and to explore the
association between each PWI parameter and the NIHSS
score on admission, the ntRS score at 3 months, the final
infarct size on T2-weighted imaging at least 1 month after




We recruited patients presenting with their first-ever acute ischemic
stroke who were able to undergo MRI as soon after stroke onset as
possible and within an absolute maximum of 24 hours (the scanner
was only available during normal working hours). A trained stroke
physician assessed all patients as soon as possible, assigned a stroke
subtype according to the Oxfordshire Community Stroke Project
classification,27 and determined the stroke severity according to the
NIHSS. Blinded to baseline features and imaging, we measured
functional outcome at 3 months by the mRS. We included all
ischemic stroke subtypes.
Image Acquisition
We performed all imaging on a GE Signa LX 1.5-T MRI scanner
(General Electric, Milwaukee, Wis) with a birdcage quadrature coil
and a standardized protocol for acute stroke (described previously).14
The spin-echo echoplanar imaging diffusion-tensor axial sequences
and dynamic susceptibility contrast echoplanar imaging PWI had 15
axial slices each of 5-mm thickness with an interslice gap of 1 mm
and an imaging matrix 128X 128 encompassing a 240X 240 mm field
of view. Additionally for PWI, a gadolinium-based contrast agent
(10 mL of 1 mol/L Gadovist or 20 mL of 0.5 mol/L Omniscan) was
injected, with imaging starting 10 seconds after the start of contrast
injection, continuing for 85 seconds, and collecting 34 volumes of 15
axial slices with an echo time of 30 ms and a repetition time of 2.5
seconds. Final follow-up T2-weighted imaging was performed at a 1
month.
Image Processing
We performed all image processing blinded to clinical and any other
imaging data. We coregistered the individual DWI and PWI data by
using the open-access software FLIRT (www.fmrib.ox.ac.uk/fsl).
We obtained the DWI lesion volumes by manually tracing around
the edge of the hyperintense lesion on a workstation (previously
described).14
To produce the PWI images, we discarded the first acquisition
volume (as is standard) and converted the remaining signal time
course in each voxel to a concentration-time curve. We fitted a y
variate function to the concentration data in every voxel that showed
enhancement >3 times the SD of the precontrast points. Voxels not
meeting the >3 times SD criterion were given a negative value in the
perfusion maps, can represent either cerebrospinal fluid or other
tissue not accessible to contrast (eg, center of the infarct), and were
excluded unless a lesion volume completely encircled negative
voxels, in which case these voxels were included in the calculation
of the lesion volume.
We defined the AIF from the fitted data by averaging the
concentration-time data from voxels corresponding to the lumina of
both internal carotid arteries on the first volume of the registered data
(to limit effects of any carotid stenosis). We chose this approach for
several reasons: to be more relevant to an acute situation, wherein the
only knowledge of infarct location (before DWI/PWI data process¬
ing) may come from the symptoms; to characterize brain blood
supply as a global "normalizing" factor (the internal carotid arteries
being before the circle of Willis represent the available blood supply
minus the contribution from the basilar artery); and last because the
internal carotid arteries are aligned perpendicular to the plane of
imaging and hence avoid problems associated with partial volume.
Care was taken to ensure that the regions drawn within the internal
carotid arteries corresponded to the lumen (2 or 3 voxels per vessel).
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Table 1. Volumes of PWI Lesions and Mismatch Tissue and No. of Patients With a PWI Lesion and PWI/DWI Mismatch












ATF Estimated delay in arrival of
contrast in a voxel obtained
from the curve fitting
procedure; p. rMTT
15 106 (5747) 11 18(56) 715





21 185 (12478) 7 21 (66) 7690
HP Peak time fitted minus arrival
time fitted; p rMTT
22 802 (14882) 9 20 (63) 8213
FWHM Width of the
concentration-time curve at
the point halfway to the peak
concentration; p rMTT
32 260 (13405) 7 23 (72) 8748
First moment (ie, rMTT) First moment of the
concentration-time curve;
p rMTT
23 177 (13996) 7 23 (72) 9684
Cmax Maximum value of the fitted
concentration-time curve;
p rCBF and MTT
5993 (0) 17 7(22) -1224
rCBF rCBV/rMTT 4162 (0) 17 5(16) -1278
qMTT qCBF/qCBV 22 167 (8620) 13 18(56) 3853
qCBF Maximum value of the scaled
estimate of the voxel residue
response
12 783(0) 17 13(41) -492
CBV Area under the
concentration-time curve;
p rCBV or qCBV
2446 (0) 19 3(9) -1849
Mean and median PWI volumes are shown to overcome the "0" medians. Lesion volumes are expressed in voxels, p indicates proportional to.
'Negative values indicate that the median DWI lesion is larger than the median acute PWI lesion.
We calculated maps of rCBV, rMTT, rCBF, arrival time fitted
(ATF), peak time fitted (PTF), TTP, and FWHM of the
concentration-time curve and the maximum value of the fitted
concentration-time curve (Cmax). We normalized the parameter
value in each voxel by the sample mean of the parameter value in the
voxels used to define the A1F. Normalizing the rCBV value by the
rCBV sample mean of the voxels used to define the AIF results in
qCBV; hence, this parameter is not mentioned later. We produced
maps of qCBF and qMTT by deconvolving the peak voxel
concentration-time curves with the concentration-time curve of the
AIF to obtain a scaled estimate of the voxel residue response.4-28 The
deconvolution was performed by singular value decomposition 4 :28
with the addition of a block-circulant discretization scheme to
remove the dependency on arrival time in the calculated qMTT
maps. The value of qCBF was estimated by using the peak height of
the residue function.24 We did not cross-calibrate the PWI data with
an assumed value for CBF for normal white matter or use data for the
patient's white matter to provide an assumed normal value, because
in this older patient population, white matter is unlikely to be
standard. We then scaled the individual perfusion maps at a constant
level chosen to encompass the range of parameter values across all
subjects to yield a consistent image presentation per parameter across
all subjects. The thresholded maps were then converted to Analyze
format.
An experienced stroke neuroradiologist outlined any PWI lesions
visible on printed color maps (Figure 2) by identifying areas of signal
that indicated reduced cerebral perfusion (reduced CBF, abnormal
CBV, or increased MTT) compared with the normal perfusion
distribution, taking account particularly of any differences between
the 2 hemispheres or in the anteroposterior distribution and gray/
white matter differences. We did not include areas of increased CBF
or CBV in the "perfusion deficit." Each PWI parameter was outlined
separately, blinded to all clinical, other imaging, and other PWI data.
We then traced the lesion outline onto the Analyze format images by
using Analyze version 7.8 and derived PWI lesion volumes by
counting the number of voxels within the lesion on all slices on
which it was visible. All PWI lesions for a single patient were traced
in Analyze in the same session but while blinded to all other
information. We defined the DWI/PWI mismatch as the acute PWI
lesion volume minus the acute DWI lesion volume and infarct
expansion as any increase in size from the acute DWI lesion to the
final T2 lesion.
Statistical Analysis
The data were not normally distributed (Kolmogorov-Smirnov test).
We compared the median PWI lesion and the PWI/DWI mismatch
volumes with the Friedman test (multiple nonparametric related
measurements). We compared the proportion of patients with or
without DWI/PWI mismatch by PWI processing method by the x1
test. We compared the different PWI volumes to DWI lesion
volumes and NIHSS score at baseline and T2-weighted imaging final
infarct volume and functional outcome (mRS score) at 3 months by
linear regression. We used each PWI parameter in turn as the
dependent variable, with DWI lesion volume, NIHSS score. T2-
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Figure 2. Admission DWI and PWI (10
different perfusion maps generated by
the 10 different perfusion processing
methods) and 1-month T2-weighted
image for the same brain slice from 1
patient. See Table 2 for abbreviations
and definitions.
weighted final infarct volume, and mRS score as the independent
variables. We transformed the PWI lesion volume data by taking the
cube root to minimize the effect of outliers. We used Fisher's exact
test to investigate any correlation between the presence or absence of
mismatch at baseline and the presence or absence of infarct expan¬
sion on the final T2 image. All analyses were performed in SPSS
version 13 for Windows.
Results
We recruited 32 patients (13 female, 19 male), whose mean
age was 70 years (range, 36 to 93 years). The median time to
MRI was 7.3 hours (range, 1.4 to 24 hours). The time to
imaging was <6 hours from symptom onset in 12 of 32
(38%), 6 to 12 hours in 8 (25%), and between 12 and 24 hours
in 12 (37%). According to the Oxfordshire Community
Stroke Project classification,27 there were 3 lacunar stroke
(LACS), 19 partial anterior circulation stroke (PACS), and 10
total anterior circulation stroke (TACS). The median baseline
NIHSS score was 7 (range, 1 to 25).
The PWI lesion size varied markedly with the method of
calculating the PWI lesion (Table 1 and Figure 2). The
median PWI lesion volume varied from 0 voxels (Cmax,
rCBF, CBV) to 14 882 voxels (TTP) (Friedman test 121.5,
P<0.0001). Overall, measurements reflecting MTT (eg, TTP
and PTF) produced larger PWI lesions, and measures of CBF
gave smaller lesion volumes, with CBV giving the smallest
PWI lesions (Table 1). The number of patients with no PWI
lesion by at least 1 method (Table 1) varied from 7 of 32
(22%; rMTT, FWHM, PTF) to 19 of 32 (59%; CBV) (/,
P<0.001). As a consequence of variation in PWI lesion size,
the median volume of tissue mismatch varied from 0 (actu¬
ally, — 1849 voxels, CBV) to the smallest positive value of
715 voxels (ATF) to the largest of 9684 voxels (rMTT)
(Friedman test 123.8, P<0.0001). Four of the perfusion
parameters (CBV, rCBF, qCBF, and Cmax) had negative
median mismatch values because the median DWI lesion was
larger than the PWI lesion. The proportion of patients with
mismatch varied considerably (Table 1) from 3 of 32 (9%,
CBV) to 23 of 32 (72%; rMTT, FWHM) Or=48, P<0.0001).
Only 1 PWI measure, ATF (Table 2), was associated with
both baseline clinical severity (NIHSS) and clinical outcome
(mRS at 3 months), with a regression slope of 0.209
(P=0.006) and 0.049 (P=0.035), respectively. No other PWI
measures were associated with clinical outcome. Four other
PWI measures (Table 2) were associated with baseline
NIHSS; PTF, TTP, FWHM, and rMTT. All were relative
measures of MTT. Eight PWI measures (Table 2) were
associated with radiologic outcome (final T2 infarct size); 5
of MTT (ATF, PTF. TTP. rMTT, and FWHM in order of
strength of association), 2 of CBF (rCBF and qCBF), and 1 of
CBV (CBV).
Figure 3 shows the variation in the median PWI volumes
and the median acute DWI and final T2 lesion volumes.
There was no significant relation between the presence or
absence of mismatch at baseline and infarct expansion at S:1
month for any of the PWI parameters by Fisher's exact test
(all probability values were >0.183).
Discussion
Different PWI parameters produce very different estimates of
abnormal perfusion in the same data from the same patient
and hence, very different estimates of the volume of "tissue at
risk." If patients with DWI/PWI mismatch only were to
receive thrombolysis, then selection based on TTP would
result in 20 of 32 (63%) patients receiving treatment, whereas
selection on the basis of Cmax would result in only 7 of 32
Table 2. Association Between PWI Lesion Size (in Voxels) and
Baseline Clinical Score (NIHSS), Functional Outcome at 3
Months (mRS), and Final Infarct Extent on T2-Weighted MRI
Imaging (>1 Month After Symptom Onset)
Slope of Linear Regression Line With
T2 Final
Baseline 3-Month Infarct Size
Perfusion Method NIHSS mRS at >1 Month
ATF 0.209 (0.006) 0.049 (0.035) 0.330 (0.002)
PTF 0.210(0.005) 0.042 (0.068) 0.292 (0.007)
HP 0.193 (0.006) 0.040 (0.066) 0.286 (0.004)
FWHM 0.180 (0.006) 0.021 (0.313) 0.214 (0.025)
First moment (ie, rMTT) 0.206 (0.005) 0.042 (0.067) 0.303 (0.004)
Cmax 0.147 (0.133) 0.018(0.549) 0.263 (0.059)
rCBF 0.206 (0.057) 0.035 (0.285) 0.324 (0.036)
qMTT 0.050 (0.456) 0.017(0.407) 0.162(0.089)
qCBF 0.098 (0.195) 0.029 (0.202) 0.236 (0.025)
CBV 0.236 (0.066) 0.042 (0.278) 0.392 (0.032)
Significant associations are highlighted in boldface type; P values are in
parentheses.
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Figure 3. Variation in median perfusion lesion size (voxels) for
the 10 different PWI processing methods. The median baseline
DWI (DWI acute) and final infarct extent (T2 final) lesion volumes
are also indicated. Note the median lesion volumes for Cmax,
rCBF, qCBF, and CBV were 0 due to the large proportion of
patients with no visible PWI lesion.
(22%) patients being so treated. Such a variation is not
acceptable if PWI is to be used to guide treatment in routine
clinical practice. However, both of these parameters are
commonly quoted in the literature. In this dataset, ATF was
the only parameter that was correlated with both clinical
(baseline and follow-up) and radiologic parameters, but this
finding should be replicated in other datasets. This work also
highlights the need to standardize PWI, including the PWI
parameter measured, the analysis approach, and the software
used.
Nonquantitative PWI parameters have the advantage that
they are quick to measure on the scanner console but may
introduce unacceptable variability between patients. Quanti¬
tative PWI parameters reduce the difference in lesion volume
between the PWI parameters but would still result in discrep¬
ancies in the number of patients treated: 18 of 32 (56%) with
qMTT. 13 of 32 (41%) with qCBF, and 3 of 32 (9%) with
qCBV, and require complex off-line processing to produce
perfusion parameter maps. There were even differences
between relative and quantitative parameters purporting to
reflect only MTT or only CBF: with rCBF, 5 of 32 (16%) of
patients had mismatch, and with qCBF, 13 of 32 (41%)
patients had mismatch; with any of the rMTT measures, 18 of
32 to 23 of 32 (56% to 72%) had mismatch, and with qMTT,
18 of 32 (56%) had mismatch. However, relative measures
were better correlated with clinically relevant outcomes.
Our overall important finding was that 5 MR perfusion
parameters reflecting MTT (ATF. PTF, FWHM, rMTT, and
rCBF) were associated with clinical scores of acute stroke
severity, of which 1, also reflecting MTT (though on average
producing smaller lesions than noted earlier, ATF), was
associated with functional outcome. The correlation of large
MTT lesions with baseline NIHSS score presumably means
that these PWI lesions are a better indicator of the extent of
neurologically "shut-down" tissue (viable and nonviable) at
the time of imaging, although they overestimate functional
outcome because they include both oligemic but not shut¬
down tissue as well as "tissue at risk," which recovers.
A wider range of PWI parameters was correlated with final
T2 lesion extent, but how useful is this? ATF, PTF, TTP, and
rMTT were most closely associated with final T2 lesion
extent and FWHM, rCBF, qCBF and CBV less so. However,
the final T2 lesion extent may not reflect the total damage
within the brain. Histologic evidence of damage may occur
outside the T2-visible lesion.3031 Functional outcome is more
relevant to stroke services and patients. The true final damage
being greater than just the T2-visible lesion might explain
why, in this study, the correlations between baseline PWI
lesion and functional outcome were strongest for rMTT
measures.
Our results confirm previous observations that TTP and
qMTT are correlated with baseline NIHSS score,'3-20_22 but
previous studies compared fewer PWI lesions than in the
present study. The maximum PWI parameters compared in
previous studies were 9,18 6,12 4,1719 and 3,1316 but these
studies did not quantify the difference in visible lesion
volume or the impact of that difference on DWI/PWI mis¬
match. Thus, in general, relative measures of MTT were
correlated with both baseline stroke severity and clinical
functional outcome. These are relatively quick to perform and
easy to obtain (no deconvolution required) and therefore are
practical in the acute setting.
The fact that we were unable to demonstrate a correlation
between the presence/absence of mismatch and the presence/
absence of infarct expansion suggests that the presence of
mismatch per se is not an ideal criterion to use when selecting
patients for acute stroke treatments. About half of the patients
without mismatch (either on rMTT or rCBF) may develop
infarct growth,14-32 so the mismatch concept may not identify
all "tissue at risk"—DWI-abnormal tissue may recover, and
most PWI parameters probably overestimate tissue at risk.
We used visual assessment of the PWI lesions because
visual assessment is the fastest method for detecting the acute
lesion in the clinical setting. We did not use thresholding/
automated lesion edge detection because no consistent thresh¬
old has yet been identified.33 Furthermore, it was unclear how
a threshold with NIHSS score or 3-month functional outcome
should be derived. The threshold that matches the boundary
of the final T2 lesion is relatively straightforward to deter¬
mine but may not represent the final tissue damage and is of
less clinical relevance. However, manual outlining introduces
observer variation. Some might disagree on where the bound¬
aries should be drawn. For example, in Figure 2, it would
appear that the ATF has produced a large lesion compared
with other MTT lesions, whereas Figure 3 indicates that, on
average, the ATF produced the smallest of the MTT-like
lesions. Similarly. Figure 2 suggests that the CBF lesions are
quite large, whereas Figure 3 indicates that, on average, the
CBF, CBV, and Cmax lesions were very small or nonexistent.
Figure 2 is only intended to illustrate the variation in lesion
appearance among the 10 parameters and was chosen because
the CBF and CBV lesions were visible, so these may not be
truly representative of the average in this cohort. This is a
■■ Median
- - - - DWI Acute
T2 Final
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further reason for validation of these findings in other
datasets.
We did not use cross-calibration (scaling to a fixed value of
presumed normal white matter) so as to preserve information
in the perfusion maps about the underlying perfusion status of
all tissue. Although scaling to presumed normal white matter
may allow the different PWI parameter images to be scaled
directly into the same windowing, in the typical elderly stroke
population, the background white matter is often abnormal,
so applying an arbitrary scaling factor might not improve
image accuracy or interpretability. It might also skew the
scaling of some parameters so as to actually reduce the
visibility of some lesions. Instead, we normalized the indi¬
vidual perfusion parameter maps to the average value of that
parameter in the region used to define the AIF because AIF
(eg, maximum contrast value, area under the curve) is linearly
associated with the corresponding tissue parameters Cmax,
rCBV, etc. Thus, normalization by the average parameter
value within the AIF region of interest attempts to counteract
variation in the calculated relative perfusion parameters due
to the differing arrival rate of contrast in the brain between
patients, thereby more effectively achieving standardization,
as would scaling to presumed normal white matter.
We included data for all patients in the statistical analysis,
whether there was a PWI lesion present or not, to be able to
determine the relative predictive values of the different PWI
processing methods, including those that less frequently
produce a PWI lesion. Choosing a PWI parameter that has a
high probability of not producing a visible lesion, while not
knowing what the absence of a lesion means, is unlikely to be
helpful. We did not use an explicit correction for multiple
comparisons, but the effect of doing so can be seen by
ignoring probability values >0.01 in Table 2. Other publica¬
tions did not make clear whether all patients, or just those
with visible PWI lesions, were included, which may explain
previous discrepancies. Excluding patients without PWI le¬
sions would result in a very skewed comparison; eg, in our
series, some PWI parameters (eg, TTP) might contribute 23
of 32 patients, whereas others like rCBF or CBV might only
contribute 13 of 32. Excluding patients without PWI lesions
would provide no information on the relevance of a PWI-
negative examination. In the acute situation, with limited time
for multiple postprocessing attempts, one needs to use the
PWI parameter that is most likely to inform decision making.
There is an urgent need to standardize methods for pro¬
cessing perfusion data. This includes deciding on not only
which PWI lesion to measure but also how to measure it and
which software should be used. Manufacturer processing
algorithms may differ and could produce variations in lesion
size between scanners, even when each center is producing
maps of the same PWI lesion. Therefore, there is a need to
standardize software also. Perhaps there is a need for a
standard PWI test dataset that could be used to calibrate
different software. This might at least reduce some of the
variation between PWI lesions. Relative measures of MTT,
which are quick to perform and are associated with stroke
severity and functional outcome, may be more useful than
PWI parameters that are related closely to radiologic surro¬
gates. Similar variation may arise if computed tomography
perfusion data are processed in different ways with different
manufacturer's software. Similar studies should be performed
with computed tomography perfusion as a matter of urgency,
as computed tomography perfusion is rapidly increasing in
popularity and is much more accessible than MRI.
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Background: The mismatch between perfusion and diffusion lesions on magnetic resonance perfusion-
weighted imaging (PWI)/diffusion-weighted imaging (DWI) may help identify patients for thrombolysis.
Evidence underlying this hypothesis was assessed.
Methods: All papers describing magnetic resonance PWI/DWI findings in patients with acute ischaemic
stroke, and their functional and/or radiological outcome at 1 month, with or without thrombolysis were
systematically reviewed.
Results: 1 1 papers fulfilled the inclusion criteria. Among these, there were 5 different mismatch definitions
and at least 7 different PWI methods. Only 3 papers including 61 patients with and 18 without mismatch
provided data on mismatch, outcome and influence of thrombolysis. Mismatch (v no mismatch) without
thrombolysis was associated with a non-significant twofold increase in the odds of infarct expansion (odds
ratio (OR) 2.2, 95% confidence interval (CI) 0.34 to 14.1), which did not change with thrombolysis (OR 2.0,
95%. CI 0.37 to 10.9). Half of the patients without mismatch also had infarct growth (with or without
thrombolysis). No data were available on functional outcome.
Conclusions: Standardised definitions of mismatch and perfusion are needed. Infarct growth may occur even
in the absence of mismatch. Currently, data available on mismatch are too limited to guide thrombolysis in
routine practice. More data are needed from studies including patients with and without mismatch, and
randomised treatment allocation, to determine the role of mismatch.
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schaemic stroke is a global problem, for which few acute
treatments are available. Thrombolysis has to be given rapidly
and, when guided by plain computed tomography scan of the
brain, carries a risk of intracranial haemorrhage. Imaging the
mismatch between diffusion-weighted imaging (DWI) and
perfusion-weighted imaging (PWI) on magnetic resonance
imaging (MRI) (or presumed reversible ischaemia on computed
tomography perfusion') might help identify patients with tissue
at risk of infarction (even beyond the current 3 h time
window), thereby avoiding thrombolysis in those with little
chance of benefit.2 5 These techniques are used increasingly
where technology is available, and in acute-stroke trials (http://
www.strokecenter.org/trials).41
The increasing use of this approach in trials and routine
practice suggests that there are clear definitions of what
constitutes mismatch and substantial evidence to justify its use.
However, it is now known that the DWI lesion is not irreversible
(initial DWI lesions may disappear spontaneously or after
thrombolysis5), and that the appearance of PWI lesion depends
on which of the manymethods were used to calculate it. Different
perfusion parameters (eg, mean transit time (MTT), regional
cerebral blood flow" and arterial input function7) give different
perfusion lesion volumes in the same patient. Thus, it is unclear
whether the presence (v absence) of mismatch affects prognosis.
If mismatch is to be used to select patients for treatment, then the
key point is to determine whether thrombolysis has a greater
effect in the presence than in the absence of mismatch. This
requires a randomised controlled trial in which patients with and
without mismatch are randomly selected to receive thrombolysis
or control treatment, an expensive and difficult undertaking
given the large sample size needed.8
As there is already a considerable body of literature available
on the magnetic resonance mismatch concept, we undertook
this systematic review to assess all current evidence on the
effect of magnetic resonance PWI/DWI mismatch in patients
with acute ischaemic stroke on outcome (clinical and radi¬
ological) and whether this is modified by thrombolysis. We set
rigorous prespecified inclusion and exclusion criteria based on
scientific principles for observational studies and randomised
trials to minimise bias.
METHODS
Design
We sought papers describing PWI/DWI mismatch and outcome
in the presence or absence of thrombolysis. We included papers
published in full to obtain detailed methodological data and
results.
Search strategy
We developed a search strategy with the Cochrane Stroke
Group for articles published between January 1996 and May
2005. We searched Medline and EMBASE (using the terms
"diffusion weighted", "perfusion weighted", "thrombolysis"
and "magnetic resonance imaging", exploded to maximise
findings) and reference lists in the identified articles for further
relevant papers.
Inclusion criteria
We included prospective studies of human acute stroke, of at
least 20 patients, imaged at presentation with acute stroke
using magnetic resonance, DWI and PWI, with clinical
Abbreviations: DWI, diffusion-weighted imaging; MRI, magnetic
resonance imaging; mRS, modified Rankin Score; MTT, mean transit time;
NIHSS, National Institutes of Health Score; PWI, perfusion-weighted
imaging; rt-PA, recombinant tissue-type plasminogen activator
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Figure 1 Selection of papers for systematic review. MRA, magnetic
resonance angiography; PET, positron emission tomography; PWI,
perfusion-weighted imaging.
assessment at baseline and follow-up at least 1 month after
stroke using a recognised assessment scale, and where possible
radiological follow-up, in which patients did or did not receive
thrombolysis.
Exclusion criteria
We excluded articles published before 1996 (before that neither
magnetic resonance PWI/DWI nor thrombolysis was widely
used in acute stroke), retrospective studies (because of the
potential for bias), with <20 patients (very small sample sizes
are prone to bias and provide little robust data to inform clinical
practice), and with functional and/or radiological outcome
assessed at less than a month after stroke (before that would be
too early to assess functional outcome; radiologically, ischaemic
lesions may still be evolving,'' "fogging" may cause under¬
estimation,"' and oedema may cause overestintation of the final
lesion volume").
Data extraction
Data were collected on a standardised assessment form by one
reviewer. Queries were independently checked by another
reviewer. We collected the sample size, patients' clinical
characteristics, clinical scores (eg, National Institutes of Health
Score (NIHSS)), time from onset of symptom to imaging,
details of the magnetic resonance sequences performed and
post-processing techniques, definition of PWI/DWI mismatch,
evidence of infarct expansion (increase in the lesion volume from
the acute baseline DWI to final T2), whether interpretation of the
magnetic resonance images was blinded to clinical details or
imaging, details of patients excluded from analysis, whether
administration of thrombolysis was randomised or not, and any
information on functional or radiological outcome in those who
received or did not receive thrombolysis with or without PWI/
DWI mismatch. We compared imaging at presentation with final
follow-up performed at 1 month or more. We did not examine
scan data from intermediary time points (if available) because
they are unreliable for estimation of functional outcome or final
infarct extent (see above). We were careful to avoid including
duplicate publications of the same patients. We defined poor
functional outcome as modified Rankin Score (mRS) SI or
Barthel Index<90.
Analysis
We summarised study population demographics, proportions
with or without mismatch, number treated with thrombolysis,
with poor functional outcome or infarct expansion. Odds ratios
(ORs) and 95% confidence intervals (CIs) were used to
determine associations between mismatch, infarct expansion,
functional outcome and any influence of thrombolysis. We
aimed at comparing functional and radiological outcomes in
patients with mismatch with those without mismatch, and to
determine whether thrombolysis changed the relationship
between mismatch and functional or radiological outcome.
RESULTS
The search identified 1652 papers on any aspect of DWI and
PWI, of which 85 were potentially relevant to DWI/PWI
mismatch and outcome with or without thrombolysis. Eleven
papers (641 patients) fulfilled all prespecified inclusion criteria
(for reasons for rejection, often more than one reason, see fig 1).
Ten included reports"-20 were prospective observational
studies, and one4 was a placebo-controlled, double-blind,
randomised, dose-finding phase II trial of desmoteplase.
These papers derive from six research groups. Median time to
baseline magnetic resonance imaging ranged from 1.5 to 6 h
after stroke. Seven papers had radiological follow-up at
1 month or more"-'" in most patients (table 1).
The most common baseline clinical score was the NIHSS,
used in all but two papers,19 20 by an individual explicitly stated
to be trained in its use. In all but one paper," other scores (eg,
Barthel Index and mRS) were recorded at follow-up. Eight
papers gave incomplete details of blinding of clinical and
radiological assessors. Three papers (27%)17 18 20 did not men¬
tion blinding at all.
Measurement of perfusion lesion
All groups used gadolinium-based dynamic susceptibility
contrast imaging to assess perfusion, the dose varying from
0.1 to 0.2 mmol/kg. The method for perfusion lesion assess¬
ment varied: four papers calculated time to peak" 1618 2"; the
others used some form of MTT measurement, quantitative in
three cases (table 2).12 14 18
Assessment of perfusion/diffusion mismatch
There was no consistent definition of mismatch. Among the 11
papers from 6 research groups, there were 5 different
definitions of mismatch. Mismatch was determined by "visual
inspection" in two studies,4 20 and by measuring lesion volumes
on a workstation in the rest, using various lesion boundary
definitions (eg, MTT >4 s compared with the contralateral
side) (table 2).
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Table 1 Methodological details of included studies
Other
outcome
Publication Sample Incomplete Clinical scores ot - Time to Time to final
Author date size imagingYdied score 1 month acute MRI MRI (days)
Beaulieu C 1999 21 6 NIHSS None Mean (SD) 5.2 (1.2) h Mean (SD) 42 (22)
Barber P'2 2004 49 4 NIHSS Bl and mRS Median 4 h (IQR 3.3-5) Median 84 (IQR 70-89)
Rohl L'4 2001 22 1 SSS Bl Mean 5 h Range 22-42 (1@102)
Parsons M' 2002 40 4 NIHSS mRS Treatment group mean (SD) Treatment group mean
3.8 (1.2) h Controls 3.7(1.2) (SD) 77.9 (17.1) Controls
81.4(12)
Barber P13 1999 26 5 CNS Bl and mRS Mean (SD) 12.1 (7.6) h Mean (SD) 90.1 (30.3)
Hacke W4t 2005 104 18 NIHSS Bl and mRS Median 325 min Due at 30
Derex L16 2004 49 5 NIHSS mRS Mean (SD) 3 h 37 (52) mins Due at 60
Schellinger P'7 2001 51 1 NIHSS and SSS Bl and mRS Mean (SD) 3.33 (1.29) h Due at 5
Chalela J'9 2004 42 5 NIHSS COacE Median to: DWI 84 min, Median to: DWI 253 mins,
PWI 92 min PWI 269 mins
Rother J18 2002 139 10 NIHSS mRS Median 180 min (75-360) Due at 7
Ribo M20 2005 122 Not specified NIHSS mRS Median group A: 136 min CT 24-48 h
(60-180); group B: 223 min
(185-360)
Bl, Barthel Index; CNS, central nervous system; mRS, modified Rankin Score; NIHSS, National Institutes of Health Score; SSS, Scandinavian Stroke Scale.
Overall assessment of PWI/DWI mismatch on outcome
and effect of thrombolysis
Among the 11 studies initially included in the review, we were
able to extract data regarding mismatch and outcome (without
or with thrombolysis) only front three." 14 15 Although all of
these studies recruited at least 20 patients, not all of the original
sample contributed to the data, mainly due to incomplete
imaging (table 1). In the rest, it was not possible to separate the
results for thrombolysis for patients with and those without
thrombolysis from those of patients without mismatch," 16 18
although some did have outcome data. Some papers only
reported recanalisation and outcome, not mismatch." " All
three papers with usable data included patients with and
without mismatch, and two" 15 examined the effects of
thrombolysis. In total, there were 61 patients with, and 18
without mismatch. Final follow-up scans were not available
(patient died or scan was not performed) for 7 of 61 patients,
some with mismatch at baseline and some without. Only two
papers reported functional outcome.14 15
PWI/DWI mismatch and outcome: no thrombolysis
Two papers'4 15 provided data on mismatch and functional
outcome, and three" 14 15 on infarct expansion at 1 month or
more (total n = 50 patients) in patients who did not receive
thrombolysis: 41 of 50 patients had mismatch (by any
definition), of whom 33 (80%) had any infarct expansion and
6 (20%) did not (follow-up scans were missing for two
patients); 9 of 50 patients had no mismatch, of whom 5
(56%) developed infarct expansion. Therefore, mismatch was
associated with a non-significant twofold increase in the odds
of infarct expansion (OR 2.2, 95% CI 0.34 to 14.1). Note that the
wide CIs include the possibility of both a reduction and an
increase in the risk. Data on functional outcome were not
presented in a way that allowed calculation of ORs. However,
the mean Barthel Index or mRS at final follow-up was non-
significantly worse in those with mismatch at baseline than in
those without mismatch (table 3, fig 2).
PWI/DWI mismatch and outcome: with thrombolysis
Two studies provided data on mismatch, radiological outcome
(but only one on functional outcome") and thrombolysis (total
n = 29)." 15 Note that in one," thrombolysis was actually given
immediately before the first MRI, meaning that the baseline
scans may have already been affected by thrombolysis, thus
making interpretations about the effects of recombinant tissue-
type plasminogen activator (rt-PA) in these patients difficult.
Table 2 Definition and frequency of PWI/DWI mismatch in studies meeting methodological inclusion criteria
Workstation/ Dose of Number
visual Number with gadolinium Perfusion treated with
Author Definition of PWI/DWI mismatch measurement mismatch (mmol/kg)* measure thrombolysis
Beaulieu C" Differences of at least ± 10% Workstation 11 (52%) PWI>DWI 7
(33%) PWI < DWI
0.2 TTP* 11 (52%)
Barber P12 PWI >acute DWI Workstation 77% 0.1 MTT 12 (24%)
Rohl L'4 > 10% difference between acute DWI Workstation 18 (82%) 0.1 MTT1 None
lesion and MTT map lesion
Parsons M'5 Acute MTT (delay >4 s) lesion volume
20%>DWI lesion
Workstation 16 (84%) treatment group
16 (76%) control group
0.2 MTT 19(48%)
Barber P13 PWI >acute DWI Workstation 14(56%) 0.1 rMTT* None
Hacke W4 >20% PWI/DWI mismatch Visual initially then
workstation
104(100%) 0.1 MTT* 75 (72%)
Derex L16 PWI/DWI volume ratio of >1.2 Workstation 42 (85%) 0.1 TTP* All (100%)
Schellinger P17 PWI/DWI volume ratio of >1.2 Workstation 40/51 (78%) 25 ml MTT* 24 (47%)
Chalela J'9 MTT lesion minus DWI lesion at each
time point.
Workstation Not specified 0.1 MTT* All (100%)
Rother J'8 PWI/DWI volume ratio of >1.2 Workstation 120/139 (86.3%) 25 ml HP* 76 (55%)
Ribo M20 Group B: DWI/PWI mismatch >50% Visual Group B:43/l 22 (35%) Bolus HP* All (100%)
DWI, diffusion-weighted imaging; MTT, mean transit time; PWI, perfusion-weighted imaging; TIP, time to peak.
'Semiquantitative measure.
www.jnnp.com
Downloaded from jnnp.bmj.com on 5 May 2007





□ Infarct expansion □ No infarct expansion □ Not known
81% 15% i°/<
1








Figure 2 Fate of the acute magnetic resonance diffusion-weighted imaging lesion in patients with or without mismatch and/or thrombolysis.
However, we included these data on the basis that the effects of
rt-PA are not instantaneous. With this in mind, we can
conclude that 12 of 20 (60%) patients with mismatch had
infarct growth (data missing for two patients) after thrombo¬
lysis, whereas 8 of 20 (40%) did not; 4 of 9 (44%) patients
without mismatch had infarct expansion (data missing for one
patient) with thrombolysis, 5 of 9 (50%) did not. Thus, there
was a similar OR for the risk of infarct expansion in the
presence of mismatch with thrombolysis (OR 2, 95% CI 0.37 to
10.9) as that without thrombolysis. The wide CIs include the
possibility of either reduction or increase in the risk. The one
paper with clinical outcome data" compared patients with
mismatch who received thrombolysis with 16 historical
controls with mismatch who did not receive thrombolysis
(table 2), but such historical comparisons are prone to bias and
are unreliable. Hence, there are no meaningful data on clinical
outcomes in patients with or without mismatch in the presence
of thrombolysis (table 4, fig 2).
To account for missing follow-up scans, we calculated "best"
(assuming that all the patients with missing data did not have
infarct expansion) and "worst" (assuming that all the patients
with missing data did have infarct expansion) case scenarios
(tables 3 and 4). In the best case scenario, mismatch without
thrombolysis was associated with a 14-fold increase in the risk
of infarct expansion (OR 14.4, 95% CI 2.5 to 83.2), and
mismatch with thrombolysis was associated with a twofold
increase in the risk of infarct expansion (OR 2.5, 95% CI 0.48 to
12.9). In the worst case scenario, mismatch without thrombo¬
lysis was associated with a sevenfold increase in the risk of
infarct expansion (OR 7.3, 95% CI 1.5 to 35.2) and mismatch
with thrombolysis was associated with a twofold increase in the
risk of infarct expansion (OR 1.86, 95% CI 0.37 to 9.49).
However, note that the marked change in OR when outcome
changed for only a few patients, combined with the wide CIs,
indicates that these data, although promising, are unreliable
and highly unstable, and require confirmation in large,
methodologically sound studies.
DISCUSSION
This review highlights the urgent need for more data to confirm
and refine or refute the mismatch concept, and for standardisa¬
tion of methods to assess mismatch and PWI lesions. Despite
more than 1500 papers reporting some aspect of PWI/DWI
mismatch, many advocating its use to identify "tissue at risk",
there is very limited evidence even to say whether patients with
mismatch have a different outcome from those without
mismatch, or crucially, what the effect of rt-PA might be.
These data were very fragmented and difficult to manage
systematically, and there was little that was ultimately usable.
Indeed, some might argue that we should have excluded even
more, such as the study that performed magnetic resonance
DWI/PWI just after rt-PA. However, we reasoned that others
may have adopted the same approach without explicitly
mentioning it, and that this was a relatively minor flaw among
many more fundamental ones. We did not seek additional
unpublished information from authors because personal com¬
munications are not peer-reviewed and may be misleading, and
the published literature is the accessible knowledge base.
Therefore, current opinion should not be based on information
that is absent from the published literature, because unpub¬
lished information is not accessible to all to evaluate and form
their own opinion.
The inclusion criteria for the review included studies with
>20 patients because of the well-known problem of bias in
smaller studies. Other criteria such as type and site of arterial
occlusion were outside the scope of this systematic review and
were therefore not included.
The lack of standardisation of the DWI and PWI imaging is a
major problem. Perfusion imaging used different doses of
contrast and different processing techniques, and measured
different parameters in different ways. It is unclear whether
one should use complex and time-consuming methods of
analysis of PWI data incorporating the arterial input function
(and if so which7) or, as suggested recently, use simpler
semiquantitative methods such as Tmax, which may be just as
good.2' There was no consistency in the definition or measure¬
ment of mismatch either. The 5 definitions from the 6 research
groups ranged from a PWI lesion >acute DWI lesion12 " 19 to a
PWI lesion 50% >acute DWI lesion.2" Two papers specified
visual inspection, but the others measured lesion volume on a
workstation. Few studies'2 13 16 commented on the observer
reliability of any of these PWI/DWI assessments.
Nonetheless, the pattern suggested by fig 2 does indeed,
rather tantalisingly, suggest that patients with mismatch are
www.jnnp.com






















































































scenario1 Bl,artfielIndex;mRS,odifiedRank nSc r ;NIHS ,tionalI s tut sfHealthre;SSca dinaviantr kcale. 'Assumesnoinfarctgrowthoccurredpatienwithmis ings a . 1Assumesinfarctgrowthoccurrednpatien sw tm s ings a . Table4Detailsofpatientswithandithoutmismatchtre t dtthrombo y is AuthorNumber with mismatchNumber without mismatchBaselineNIHSS: mismatchMean (range)Baseline NIHSS:no mismatch Mean(range)
Outcome score: mismatch
Outcome score:n mismatch
Mismatch andnoinf rct expansion
Mismatch andinf rct expansion
Nomismatch andnoinfarct expansion















































mRS,odifiedRankinSc r ;NIHSti nalInstitut sfHeal hS r . 'Assumesnoinfarctgrowthoccurredpatien sw tmis ings a . *Assumesinfarctgrowthoccurredpatientw thm ssings a .
CO
*•0
Downloaded from jnnp.bmj.com on 5 May 2007
490
more likely than patients without mismatch to have infarct
growth, and that the proportion of patients with mismatch who
had infarct growth may be reduced by thrombolysis. However,
there are no data on functional outcome (more relevant than
radiological outcomes), and these data are not from rando
mised comparisons, but from rather small observational studies
of different patients with widely differing definitions, some¬
times with historical controls. Clearly, some patients without
mismatch definitely get infarct growth, so the absence of
mismatch does not mean that there is no "tissue at risk" of
infarct growth. This suggests little justification for excluding
patients without mismatch either from routine acute stroke
treatments or possibly from trials. If the mismatch theory is
correct, then there is an urgent need to gather more robust
evidence to support its use.
To move forward, common standards and definitions for
mismatch are needed. A large randomised trial of thrombolysis
against control in patients with and without mismatch is
needed to reliably determine whether the degree of mismatch
really does influence response to thrombolytic treatment. The
EPITHET (http://www.strokecenter.org/trials) study has this
design, although patients are recruited on the basis of their
computed tomography results and not on the basis of magnetic
resonance mismatch, which may lead to an imbalance of
patients with and without mismatch in the treatment and
control groups. Certainly, until there is better evidence, patients
without mismatch should probably not be denied any routine
acute treatments, because about 50% will get infarct expansion
that might be prevented by acute treatments such as
thrombolysis. The lack of data underpinning the mismatch
theory should also be acknowledged in the design of any future
trials of novel therapeutic agents (eg, new thrombolytic or
neuroprotective agents) planning to use mismatch as an
inclusion criterion. These problems also apply to computed
tomography perfusion. It certainly should not be assumed that
presumed reversible ischaemia on computed tomography
perfusion identifies "tissue at risk" without adequate data,
and standards should be agreed urgently.
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Abstract
Background: Obtaining informed consent for a patient's
participation in a randomized trial of treatment for use
in a medical emergency may be achieved in a variety of
ways. We sought to assess the process of consent and
to evaluate the influence of the patient's neurological
deficit on the method used to obtain consent in the first
300 patients recruited into the Third International Stroke
Trial (IST-3). Methods: IST-3 is the first large-scale ran¬
domized controlled trial of intravenous thrombolysis in
acute ischaemic stroke. The clinician could use one of
four procedures to recruit the patient: written consent,
witnessed consent, assent, or a waiver of consent. The
patient's neurological deficits were recorded at baseline.
We analysed the relationship between the neurological
deficits at baseline and the consent procedure. Results:
The method of consent used was written consent in 71
subjects (24%), witnessed verbal consent in 30 subjects
(10%), assent by a relative in 197 subjects (66%), and
waiver of consent in 2 subjects (1%). Patients with severe
neurological deficits (as measured either by their stroke
syndrome or their lower predicted probability of being
alive and independent at 6 months) were more likely to
be recruited by assent. Patients able to give written con¬
sent had less severe strokes. Conclusions: Patients with
non-lacunar hemispheric stroke syndromes or with a
more severe neurological deficit were less likely to give
written consent. Excluding such patients from acute
stroke treatment trials would eliminate many otherwise
eligible subjects, who have a poor predicted outcome
without treatment and yet might benefit from acutetreat-
ments such as thrombolysis. Flexible consent proce¬
dures developed for IST-3 have made it feasible to recruit
the target population.
Copyright© 2006 S. Karger AG, Basel
Introduction
It is important to evaluate new interventions for the
treatment of medical emergencies (such as acute stroke)
by means of randomized controlled trials. The standard
approach to recruitment in a randomized trial of a non¬
emergency treatment is to require fully informed written
consent after giving the patient sufficient time to consid¬
er the matter. This is clearly not practicable in the emer¬
gency treatment of acute stroke, where patients may have
a variety of neurological deficits which either impair ef-
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fective spoken or written communication and/or writing
(e.g., coma, confusion, paralysis, aphasia) [1,2]. There is
substantial variation between countries in the legal and
regulatory requirements for consent procedures for trials
being conducted in such patients. In Europe and the USA,
such research can only be conducted if several stringent
conditions are met, which may render some types of re¬
search impractical.
Although stroke is a significant cause of death and dis¬
ability, and the care of stroke patients places a huge bur¬
den on health services and families throughout the world,
there are few effective emergency medical treatments for
use in the acute phase of the illness. For patients with
acute ischaemic stroke, thrombolysis with recombinant
tissue plasminogen activator (rt-PA) can reduce disabil¬
ity in survivors and is of net benefit, despite a 3% risk of
fatal intracranial bleeding [3], In the USA and Europe,
rt-PA is approved for use in acute ischaemic stroke in
highly selected patients who present very early and can
be assessed and treated within 3 h of symptom onset. The
American Heart Association guidelines state that, when
considering treatment in routine clinical practice with in¬
travenous rt-PA, written consent is not a necessity, but
patients and their relatives should be informed about the
potential risks and benefits [4], Ciccone [5] has proposed
a practical approach to consent in this setting. A recent
study by Rosenbaum et al. [6] highlighted that while such
consent was often not documented, patients with dimin¬
ished capacity seemed to have given consent. A system¬
atic review also highlighted difficulties in obtaining in¬
formed consent as a barrier to effective delivery of throm¬
bolytic treatment [7],
The Third International Stroke Trial (IST-3) is a large-
scale trial (6,000 patients) which seeks to determine wheth¬
er a wider variety of patients might benefit from thrombo¬
lytic therapy, beyond the very restricted group defined by
the current approval. In order to achieve this sample size,
the trial methods had to be simple, flexible, yet ethically
acceptable. Therefore, the trial team developed [8] and ob¬
tained ethical approval for a set of flexible consent proce¬
dures that allow patients with different types of stroke and
different degrees of neurological impairment to be includ¬
ed. In this analysis, we aimed to examine which method of
consent was employed and to explore the impact of the
patient's initial neurological deficit on the method of con¬
sent that was employed in the first 300 patients recruited.
This would, in turn, help assess the feasibility of recruiting
patients into the trial, and also to inform future research
and clinical practice in acute stroke care.
Methods
IST-3 is a multicentre randomized controlled trial of intrave¬
nous rt-PA in patients with acute ischacmic stroke. Patients, aged
over 18, who can be assessed and have treatment started within
6 h of symptom onset, arc eligible for the trial. Consent or assent
must be obtained before randomization. The full trial protocol can
be found at www.ist3.com.
We developed draft patient information leaflets and consent
forms. To improve the quality of the informed consent process, we
then subjected the draft forms to an iterative process of testing and
further development that closely involved patients and potential
patients [8]. The trial information leaflets include approximate per¬
centage benefits and risks derived from the latest Cochrane review
[3]. There arc three methods of consent/assent which may be em¬
ployed to recruit patients into the trial. The UK multicentre re¬
search ethics committee has approved these. The first, and the ide¬
al, is written consent from the patients themselves. However, if
patients arc unable to write, for example if the dominant hand is
affected, they arc able to give witnessed consent if they have no
problems with communication. If the patients are unable to give
informed consent as a consequence of their stroke (e.g., due to apha¬
sia), assent can be sought from patients' relatives (in North Amer¬
ica, this is known as surrogate consent). In some countries, under
exceptional circumstances, a fourth method, i.e. waiver ofconsent,
is also permitted, usually on condition that an independent physi¬
cian agrees that recruitment of that individual into the trial is ap¬
propriate and that if the patient recovers, the option to withdraw
consent may be offered (this is not exactly comparable with what
is referred to as 'deferred consent'). When obtaining consent to en¬
ter a patient into the trial, the randomizing clinician has a discus¬
sion with the patient and the family and the trial information leaf¬
lets arc used as a guide to the conversation, employing simple lan¬
guage that is easy to understand. The method of consent is
recorded in the hospital records and on the trial 7-day follow-up
form. The presence or absence of the key neurological deficits is
recorded at randomization. A computer algorithm uses these data
to assign a stroke syndrome to each patient: total anterior circula¬
tion, partial anterior circulation, lacunar or posterior stroke syn¬
drome. A separate algorithm, based on a validated prognostic mod¬
el [9], uses the baseline clinical data to calculate a predicted prob¬
ability that the patient will be alive and independent at 6 months
after the stroke.
Results
We analysed data for the first 300 patients randomized
into the trial. The method of consent employed was writ¬
ten consent in 71 patients (24%), witnessed verbal con¬
sent in 30 patients (10%), assent by a relative in 197 pa¬
tients (66%), and waiver of consent in 2 patients (1%).
Table 1 shows the impact of individual neurological
deficits on the method of consent. In patients with dys¬
phasia, 92% were randomized into the trial with assent
of a relative or by witnessed verbal consent. In patients
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6 (23) 0 (0)
145 (83) 2 (1)
145 (76) 1 (1)
Lesion location (final diagnosis)2
Right hemisphere 45 (36) 13(10) 66 (54) 0(0)
Left hemisphere 23(14) 15(9) 128 (76) 2(1)
Cerebellar or brainstem 2(67) 1(33) 0(0) 0(0)
Not localizable3 1 (20) 1(20) 3(60) 0(0)
Total 71 (24) 30(10) 197 (66) 2(1)
Figures indicate number of patients, with percentages in parentheses.
1 Percentages are of row totals.
2 Final diagnosis is determined at 7 days on the basis of all the ncuroimaging data, an¬
cillary investigations and the patient's clinical course.
Some patients had a clinical syndrome consistent with localization in either hemi¬
sphere or the posterior fossa, but had no relevant visible lesion on brain imaging.
with visuospatial disorders, most commonly due to a non-
dominant hemisphere stroke, the majority were recruited
by assent of a relative (76%) or by witnessed verbal con¬
sent (10%). Those without such a deficit were more likely
to be able to give written consent. As expected, the hemi¬
sphere affected by the stroke has a clear influence: pa¬
tients with left hemisphere lesions were less likely to be
able to give written consent than patients with right hemi¬
sphere lesions, i.e. 14 versus 36%, respectively (difference
22%; 95% confidence interval 13-32).
As demonstrated in figure 1, consent of those patients
with most severe strokes (i.e. total anterior circulation
stroke) was given by either assent of a relative or by wit¬
nessed verbal consent in the majority of cases. In patients
with the milder partial anterior circulation stroke syn¬
drome, about a third of patients were able to give written
consent. The numbers in the lacunar stroke and posterior
circulation stroke subtypes were small, but written con¬
sent in these groups was common.
Figure 2 confirms the observations from figure 1, dem¬
onstrating a trend that patients randomized into the trial
with written consent have less severe strokes, and those
consented with assent or waiver of consent had, on aver¬
age, more severe strokes.
Discussion
These analyses confirm that the consent procedureswe
have developed were feasible and permitted patients with
a range ofneurological deficits to be recruited. In general,
the severer the stroke (either determined by clinical stroke
syndrome or predicted outcome), the less likely was writ¬
ten informed consent to be employed, as one would ex¬
pect. The proportion of patients with total anterior circu¬
lation stroke syndrome was greater in the assent group
compared with the written consent group (fig. 1). When
stroke severity was assessed by the predicted probability
of outcome, patients giving written consent were judged
to have milder strokes (fig. 2).
The data also suggest that the severer the stroke deficit,
the more likely that assent will be needed as the method
ofconsent (table 1). In particular, the data show that those
with any type ofhigher cerebral dysfunction, e.g., dyspha¬
sia or a visuospatial disorder, could not take part in a
trial such as IST-3 without the option of a flexible consent
procedure. If the left hemisphere is affected by the stroke,
then assent is more likely since patients are more likely
to be dysphasic or - even if they do not have such a high¬
er cerebral dysfunction - their dominant (writing) arm
is likely to be affected making writing difficult or impos¬
sible.
If only the patients who are able to provide written
informed consent were included in acute stroke trials,
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Fig. 1. Effect of stroke syndrome on method of consent. The per¬
centage of patients within each stroke subtype and the type of con¬
sent used to recruit them into the trial depending on their stroke
subtype: total anterior circulation stroke (TACS), partial anterior
circulation stroke (PACS), lacunar stroke (LACS) and posterior cir¬
culation stroke (PACS). Note: only 2 cases had waiver of consent,
both ofwhich have been omitted from this figure. Both had TACS-
typc strokes.
they would generate estimates of treatment effect appli¬
cable to a group with a good prognosis (irrespective of
treatment allocation). The IST-3 consent procedures con¬
form to legal requirements and allow a wider variety of
patients to be included in the trial. These patients may
have as much benefit from thrombolysis treatment as pa¬
tients with milder strokes. Indeed, previously fit and ac¬
tive elderly people who are affected by a severe stroke
should surely have the opportunity to participate in re¬
search. According to theWorld Medical Association Dec¬
laration of Helsinki policy on the ethics of medical re¬
search involving human subjects, it is stated 'for a re¬
search subject who is legally incompetent, physically or
mentally incapable of giving consent, or is a legally in¬
competent minor, the investigator must obtain informed
consent from the legally authorized representative in ac¬
cordance with applicable law. These groups should not be
included in research unless the research is necessary to
promote the health of the population represented and this
research cannot instead be performed on legally compe¬
tent persons' [ 10]. Research on emergency medical treat¬
ments is necessary in stroke patients who are unable to
Fig. 2. Effect of stroke severity on the method of consent. Stroke
severity is assessed by the predicted probability of the patient being
alive and independent 6 months after their stroke. The predicted
probability is calculated from their pre-trcatmcnt neurological def¬
icit with a validated prognostic model. Hence, a probability of zero
represents a very severe stroke with a low probability of good out¬
come and 1.0 a very mild stroke with a very high probability of a
good outcome. The patients have been grouped according to the
method ofconsent used to recruit them into IST-3. It docs not take
into account the effect of post-randomization treatment. In this
plot, the box represents the interquartile range. The whiskers ex¬
tend from the box to the highest and lowest values. The line across
each box indicates the median. If it is assumed that the method of
consent is an ordered categorical variable and a Jonckhccre test is
performed, then the trend is significant (p < 0.001), with those giv¬
ing written consent having a less severe stroke, as assessed by this
measure.
give consent due to the nature of their stroke. Without
studying them, we would be unable to move forward and
provide an evidence base for giving these groups ofpeople
such acute treatments in emergency settings when time is
limited and decisions have to be made very quickly.
When considering treatments whose benefits decline
with increasing time from onset of symptoms, the need
to avoid delay reduces the time available to the patient,
the family and the doctor for discussion and weighing up
risks and benefits. Data from the recent MRC CRASH
trial showed there were significant reductions in time to
randomization when waiver of consent was used com¬
pared with assent by relatives [11]. This reduction in time
delaymay be crucial to maximizing the benefit from treat¬
ment and hence the likelihood of the trial producing a
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clear and positive result, if treatment is clearly effective.
One way to do this may be to increase public understand¬
ing and awareness of conditions like acute stroke by im¬
proving public education in groups at risk of stroke. At
least, in this case, people have a chance to think about
potential situations that may arise in the future and what
sort of risks of treatment they may find acceptable.
The EU directive on clinical trials makes waiver of
consent for trials in emergency situations difficult, if not
impossible. This will be a major obstacle to evaluating
interventions that could have substantial impact on mor¬
tality and disability.
These data confirm that the consent procedures devel¬
oped for IST-3 have proved feasible and have enabled the
balance of risk and benefit of thrombolytic therapy to be
assessed in a randomized trial in a wider variety of pa¬
tients than previously. This is an area where there is scope
to develop still better tools to improve the process of in¬
formed consent in acutely ill people.
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